Lars Farde

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2025;45(8):1606-1616
In vivo quantification of [¹¹C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase
Bolin M; Nag S; Arakawa R; Varrone A; Farde L; Martarello L; Kaliszczak MA; Halldin C; Moren AF
Journal article: ACS PHARMACOLOGY AND TRANSLATIONAL SCIENCE. 2025;8(7):1986-1995
Radiosynthesis and Evaluation of ¹¹C-Labeled Imidazolyl Pyrimidine Derivatives for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3
Li Y; Dahl K; Elmore CS; Sandell J; Takano A; Halldin C; Farde L; Ahlgren C; Cochrane A; Rong J; Chen J; Zhao C; Zhou X; Patel JS; Song Z; Chaudhary A; Gao Y; Sun Z; Zhang Z; Feng S; Haider A; Liang SH; Schou M
Journal article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2025;392(9):103638
Brain exposure of the mesenchymal-epithelial transition inhibitor savolitinib in nonhuman primates: A positron emission tomography study
Johnstrom P; Cselenyi Z; Miah K; Jucaite A; Scarfe G; Gonzalez MAC; Farde L; Halldin C; Vishwanathan K; Schou M
Journal article: IMAGING NEUROSCIENCE. 2025;3:imag_a_00464
Putative mapping of α-subunits in the human brain: A PET study of GABA_A receptor binding
Cselenyi Z; Jucaite A; Farde L
Article: PHARMACEUTICALS. 2025;18(2):135
Radiolabeling and Preliminary In Vivo Evaluation of the Candidate CCR2 Targeting PET Radioligand [¹¹C]AZD2423
Dahl K; Johnstrom P; Toth M; Bolin M; Varnas K; Nakao R; Takano A; Khani Meynaq Y; Bayrakdarian M; Cselenyi Z; Halldin C; Farde L; Schou M
Article: ACS PHARMACOLOGY AND TRANSLATIONAL SCIENCE. 2024;7(8):2414-2423
Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2
Li Y; Dahl K; Johnstrom P; Varnas K; Farde L; Halldin C; Medd A; Maier D; Powell ME; Chen J; Van R; Patel J; Chaudhary A; Gao Y; Song Z; Haider A; Shao Y; Elmore CS; Liang S; Schou M
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2024;27(5):pyae021
Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect
Garde M; Matheson GJ; Varnaes K; Svenningsson P; Hedman-Lagerloef E; Lundberg J; Farde L; Tiger M
Article: JOURNAL OF ALZHEIMERS DISEASE. 2024;98(4):1391-1401
High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [¹¹C]AZD2184
Mattsson P; Cselenyi Z; Moren AF; Freund-Levi Y; Wahlund L-O; Halldin C; Farde L
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108465
O-69 Discovery, preclinical validation and early human imaging with [11C]AZ14193391 – the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand
Gonzalez MAC; Jucaite A; Cselenyi Z; Johnstrom P; Pike A; Högnäsbacka A; Dahl K; Balazs A; Degorce S; Ghosh A; Hande S; Johannes J; Staniewska A; Leo E; Hammerlik P; Davies B; Cosulich S; Swales J; Lawrence R; Stenkrona P; Farde L; Halldin C; Schou M
Article: ACS CHEMICAL NEUROSCIENCE. 2023;14(17):3206-3211
PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [¹⁸F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain
Varnas K; Nag S; Halldin C; Farde L
Article: SCHIZOPHRENIA RESEARCH. 2023;257:34-40
CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance
Orhan F; Goiny M; Becklen M; Mathe L; Piehl F; Schwieler L; Fatouros-Bergman H; Farde L; Cervenka S; Sellgren CM; Engberg G; Erhardt S
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2023;77(4):e22269
[¹¹C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome
Cselenyi Z; Wallin J; Tjerkoski J; Bloth B; Svensson S; Nennesmo I; Sunnemark D; Jelic V; Farde L; Svenningsson P
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(6):955-965
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Article: ADDICTION. 2023;118(6):1053-1061
Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers
Jangard S; Jayaram-Lindstrom N; Isacsson NH; Matheson GJ; Plaven-Sigray P; Franck J; Borg J; Farde L; Cervenka S
Article: FRONTIERS IN NUCLEAR MEDICINE. 2023;2:1080005
Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans
Cselenyi Z; Jucaite A; Ewing P; Stenkrona P; Kristensson C; Johnstrom P; Schou M; Bolin M; Halldin C; Larsson B; Grime K; Eriksson UG; Farde L
Journal article: NEUROSCIENCE APPLIED. 2023;2:101035
Glutamate 5 receptor availability differences in twins discordant for autism and controls, do shared genetics matter
Griffioen G; Andersson M; Tangen Ä; Bolin M; Farde L; Halldin C; Bölte S; Lundberg J; Borg J
Article: ACS CHEMICAL NEUROSCIENCE. 2022;13(14):2078-2083
Synthesis and Preclinical Evaluation of [¹¹C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor
Dahl K; Johnstrom P; Forsberg-Moren A; Gustafsson B; Miranda-Azpiazu P; Khani Y; Halldin C; Farde L; Elmore CS; Schou M
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2022;76(7-8):e22235
Decreased 5-HT_1A binding in mild Alzheimer's disease-A positron emission tomography study
Mattsson P; Cselenyi Z; Andree B; Borg J; Nag S; Halldin C; Farde L
Article: MOLECULAR PSYCHIATRY. 2022;27(2):1233-1240
Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis
Plaven-Sigray P; Ikonen Victorsson P; Santillo A; Matheson GJ; Lee M; Collste K; Fatouros-Bergman H; Sellgren CM; Erhardt S; Agartz I; Halldin C; Farde L; Cervenka S
Article: MOVEMENT DISORDERS. 2022;37(1):119-129
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹C]PBR28 and Machine Learning Analysis
Jucaite A; Cselenyi Z; Kreisl WC; Rabiner EA; Varrone A; Carson RE; Rinne JO; Savage A; Schou M; Johnstrom P; Svenningsson P; Rascol O; Meissner WG; Barone P; Seppi K; Kaufmann H; Wenning GK; Poewe W; Farde L
Article: NPJ SCHIZOPHRENIA. 2021;7(1):46
No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis
Lee M; Fatouros-Bergman H; Plaven-Sigray P; Victorsson PI; Sellgren CM; Erhardt S; Flyckt L; Farde L; Cervenka S
Article: MOLECULAR PSYCHIATRY. 2021;26(5):1647-1658
Serotonin transporter availability in adults with autism-a positron emission tomography study
Andersson M; Tangen A; Farde L; Bolte S; Halldin C; Borg J; Lundberg J
Article: NEURO-ONCOLOGY. 2021;23(4):687-696
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Jucaite A; Stenkrona P; Cselenyi Z; De Vita S; Buil-Bruna N; Varnas K; Savage A; Varrone A; Johnstrom P; Schou M; Davison C; Sykes A; Reddy VP; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
Journal article: JOURNAL OF THORACIC ONCOLOGY. 2021;16(3):s620
P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
Ekman S; Cselényi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnström P; Laus G; Lewensohn R; Brown A; Van Der Aart J; Vishwanathan K; Farde L
Article: NEUROIMAGE. 2021;226:117523
Low convergent validity of [¹¹C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [¹¹C]FLB 457
Freiburghaus T; Svensson JE; Matheson GJ; Plaven-Sigray P; Lundberg J; Farde L; Cervenka S
Article: BRITISH JOURNAL OF ANAESTHESIA. 2021;126(1):238-244
Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo
Varnas K; Finnema SJ; Johnstrom P; Arakawa R; Halldin C; Eriksson LI; Farde L
Article: CLINICAL CANCER RESEARCH. 2021;27(1):189-201
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Colclough N; Chen K; Johnstrom P; Strittmatter N; Yan Y; Wrigley GL; Schou M; Goodwin R; Varnas K; Adua SJ; Zhao M; Nguyen DX; Maglennon G; Barton P; Atkinson J; Zhang L; Janefeldt A; Wilson J; Smith A; Takano A; Arakawa R; Kondrashov M; Malmquist J; Revunov E; Vazquez-Romero A; Moein MM; Windhorst AD; Karp NA; Finlay MRV; Ward RA; Yates JWT; Smith PD; Farde L; Cheng Z; Cross DAE
Article: ACS CHEMICAL NEUROSCIENCE. 2020;11(24):4398-4404
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B
Nag S; Jia Z; Svedberg M; Jackson A; Ahmad R; Luthra S; Varnas K; Farde L; Halldin C
Article: BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING. 2020;5(12):1095-1103
Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study
Tonnesen S; Kaufmann T; de Lange A-MG; Richard G; Nhat TD; Alnaes D; van der Meer D; Rokicki J; Moberget T; Maximov II; Agartz I; Aminoff SR; Beck D; Barch DM; Beresniewicz J; Cervenka S; Fatouros-Bergman H; Craven AR; Flyckt L; Gurholt TP; Haukvik UK; Hugdahl K; Johnsen E; Jonsson EG; Kolskar KK; Kroken RA; Lagerberg TV; Loberg E-M; Nordvik JE; Sanders A-M; Ulrichsen K; Andreassen OA; Westlye LT
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2020;47(10):2407-2416
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort
Fazio P; Ferreira D; Svenningsson P; Halldin C; Farde L; Westman E; Varrone A
Article: NATURE COMMUNICATIONS. 2020;11(1):4016
The genetic architecture of human brainstem structures and their involvement in common brain disorders
Elvsashagen T; Bahrami S; van der Meer D; Agartz I; Alnaes D; Barch DM; Baur-Streubel R; Bertolino A; Beyer MK; Blasi G; Borgwardt S; Boye B; Buitelaar J; Boen E; Celius EG; Cervenka S; Conzelmann A; Coynel D; Di Carlo P; Djurovic S; Eisenacher S; Espeseth T; Fatouros-Bergman H; Flyckt L; Franke B; Frei O; Gelao B; Harbo HF; Hartman CA; Haberg A; Heslenfeld D; Hoekstra PJ; Hogestol EA; Jonassen R; Jonsson EG; Kirsch P; Kloszewska I; Lagerberg TV; Landro NI; Le Hellard S; Lesch K-P; Maglanoc LA; Malt UF; Mecocci P; Melle I; Meyer-Lindenberg A; Moberget T; Nordvik JE; Nyberg L; O'Connell KS; Oosterlaan J; Papalino M; Papassotiropoulos A; Pauli P; Pergola G; Persson K; de Quervain D; Reif A; Rokicki J; van Rooij D; Shadrin AA; Schmidt A; Schwarz E; Selbaek G; Soininen H; Sowa P; Steen VM; Tsolaki M; Vellas B; Wang L; Westman E; Ziegler GC; Zink M; Andreassen OA; Westlye LT; Kaufmann T; Farde L; Flyckt L; Engberg G; Erhardt SS; Fatouros-Bergman H; Cervenka S; Schwieler L; Piehl F; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F; Sellgren CM
Article: SCHIZOPHRENIA RESEARCH. 2020;222:175-184
Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness
Matheson GJ; Plaven-Sigray P; Louzolo A; Borg J; Farde L; Petrovic P; Cervenka S
Article: EJNMMI RESEARCH. 2020;10(1):77
Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability
Tjerkaski J; Cervenka S; Farde L; Matheson GJ
Article: EJNMMI RESEARCH. 2020;10(1):59
Quantification and reliability of [¹¹C]VC-002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects
Cselenyi Z; Jucaite A; Kristensson C; Stenkrona P; Ewing P; Varrone A; Johnstrom P; Schou M; Vazquez-Romero A; Moein MM; Bolin M; Siikanen J; Gryback P; Larsson B; Halldin C; Grime K; Eriksson UG; Farde L
Journal article: SCHIZOPHRENIA BULLETIN. 2020;46(Supplement_1):s135-s136
M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
Victorsson P; Plavén-Sigray P; Matheson G; Santillo A; Lee M; Collste K; Fatouros-Bergman H; Agartz I; Halldin C; Farde L; Cervenka S
Article: PSYCHIATRY AND CLINICAL NEUROSCIENCES. 2020;74(4):263-269
[¹¹C]raclopride positron emission tomography study of dopamine-D_2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects
Tiger M; Svensson J; Liberg B; Saijo T; Schain M; Halldin C; Farde L; Lundberg J
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2020;40(4):799-807
A PET study in healthy subjects of brain exposure of ¹¹C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer
Varrone A; Varnas K; Jucaite A; Cselenyi Z; Johnstrom P; Schou M; Vazquez-Romero A; Moein MM; Halldin C; Brown AP; Vishwanathan K; Farde L
Article: ACS CHEMICAL NEUROSCIENCE. 2020;11(7):1048-1057
Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: ¹⁸F-AZD9272
Nag S; Varnas K; Arakawa R; Jahan M; Schou M; Farde L; Halldin C
Article: NEUROPHARMACOLOGY. 2020;162:107809
The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans
Varnas K; Cselenyi Z; Arakawa R; Nag S; Stepanov V; Moein MM; Johnstrom P; Kingston L; Elmore CS; Halldin C; Farde L
Article: EJNMMI RESEARCH. 2019;9(1):100
Potential for imaging the high-affinity state of the 5-HT_1B receptor: a comparison of three PET radioligands with differing intrinsic activity
Lindberg A; Arakawa R; Nogami T; Nag S; Schou M; Elmore CS; Farde L; Pike VW; Halldin C
Article: NEUROIMAGE. 2019;202:116143
Validity and reliability of extrastriatal [¹¹C]raclopride binding quantification in the living human brain
Svensson JE; Schain M; Plaven-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Article: NATURE NEUROSCIENCE. 2019;22(10):1617-1623
Common brain disorders are associated with heritable patterns of apparent aging of the brain
Kaufmann T; van der Meer D; Nhat TD; Schwarz E; Lund MJ; Agartz I; Alnaes D; Barch DM; Baur-Streubel R; Bertolino A; Bettella F; Beyer MK; Boen E; Borgwardt S; Brandt CL; Buitelaar J; Celius EG; Cervenka S; Conzelmann A; Cordova-Palomera A; Dale AM; de Quervain DJF; Carlo P; Djurovic S; Dorum ES; Eisenacher S; Elvsashagen T; Espeseth T; Fatouros-Bergman H; Flyckt L; Franke B; Frei O; Haatveit B; Haberg AK; Harbo HF; Hartman CA; Heslenfeld D; Hoekstra PJ; Hogestol EA; Jernigan TL; Jonassen R; Jonsson EG; Kirsch P; Ktoszewska I; Kolskar KK; Landro NI; Hellard S; Lesch K-P; Lovestone S; Lundervold A; Lundervold AJ; Maglanoc LA; Malt UF; Mecocci P; Melle I; Meyer-Lindenberg A; Moberget T; Norbom LB; Nordvik JE; Nyberg L; Oosterlaan J; Papalino M; Papassotiropoulos A; Pauli P; Pergola G; Persson K; Richard G; Rokicki J; Sanders A-M; Selbaek G; Shadrin AA; Smeland OB; Soininen H; Sowa P; Steen VM; Tsolaki M; Ulrichsen KM; Vellas B; Wang L; Westman E; Ziegler GC; Zink M; Andreassen OA; Westlye LT; Farde L; Flyckts L; Engberg G; Erhardt S; Fatouros-Bergmann H; Schwieler L; Piehl F; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(11):2329-2338
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [¹¹C]PBR28 HRRT PET study
Tuisku J; Plaven-Sigray P; Gaiser EC; Airas L; Al-Abdulrasul H; Bruck A; Carson RE; Chen M-K; Cosgrove KP; Ekblad L; Esterlis I; Farde L; Forsberg A; Halldin C; Helin S; Kosek E; Lekander M; Lindgren N; Marjamaki P; Rissanen E; Sucksdorff M; Varrone A; Collste K; Gallezot J-D; Hillmer A; Huang Y; Hoglund CO; Johansson J; Jucaite A; Lampa J; Nabulsi N; Pittman B; Sandiego CM; Stenkrona P; Rinne J; Matuskey D; Cervenka S
Article: JOURNAL OF NEUROIMMUNOLOGY. 2019;334:577000
Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [¹¹C]PBR28 positron emission tomography
Forsberg A; Lampa J; Estelius J; Cervenka S; Farde L; Halldin C; Lekander M; Hoglund OC; Kosek E
Article: NEUROPSYCHOPHARMACOLOGY. 2019;44(10):1706-1713
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain
Yang K-C; Stepanov V; Amini N; Martinsson S; Takano A; Bundgaard C; Bang-Andersen B; Sanchez C; Halldin C; Farde L; Finnema SJ
Article: SCHIZOPHRENIA RESEARCH. 2019;210:221-227
Increased peripheral levels of TARC/CCL17 in first episode psychosis patients
Malmqvist A; Schwieler L; Orhan F; Fatouros-Bergman H; Bauer M; Flyckt L; Cervenka S; Engberg G; Piehl F; Erhardt S; Farde L; Flyckt L; Engberg G; Erhardt S; Fatouros-Bergman H; Cervenka S; Schwieler L; Piehl F; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: JAMA PSYCHIATRY. 2019;76(7):739-748
Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk
Alnaes D; Kaufmann T; van der Meer D; Cordova-Palomera A; Rokicki J; Moberget T; Bettella F; Agartz I; Barch DM; Bertolino A; Brandt CL; Cervenka S; Djurovic S; Nhat TD; Eisenacher S; Fatouros-Bergman H; Flyckt L; Di Giorgio A; Haatveit B; Jonsson EG; Kirsch P; Lund MJ; Meyer-Lindenberg A; Pergola G; Schwarz E; Smeland OB; Quarto T; Zink M; Andreassen OA; Westlye LT; Farde L; Collste K; Victorsson P; Engberg G; Erhardt S; Malmqvist A; Hedberg M; Orhan F; Sellgren CM; Schwieler L; Piehl F
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2019;22(7):415-425
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
Stenkrona P; Matheson GJ; Halldin C; Cervenka S; Farde L
Article: NEUROIMAGE. 2019;188:102-110
Accuracy and reliability of [¹¹C]PBR28 specific binding estimated without the use of a reference region
Plaven-Sigray P; Schain M; Zanderigo F; Farde L; Halldin C; Forsberg A; Varrone A; Jucaite A; Cervenka S; Stenkrona P; Collste K; Kander M; Kosek E; Lampa J; Hoglund CO; Rabiner EA; Gunn RN; Ogden RT; Cervenk S
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(2):367-375
PET imaging of [¹¹C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
Varnas K; Cselenyi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
Article: EJNMMI RESEARCH. 2019;9(1):9
Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator
Schou M; Ewing P; Cselenyi Z; Friden M; Takano A; Halldin C; Farde L
Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):12
Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder
Schwarz E; Nhat TD; Pergola G; Westlye LT; Kaufmann T; Wolfers T; Brecheisen R; Quarto T; Ing AJ; Di Carlo P; Gurholt TP; Harms RL; Noirhomme Q; Moberget T; Agartz I; Andreassen OA; Bellani M; Bertolino A; Blasi G; Brambilla P; Buitelaar JK; Cervenka S; Flyckt L; Frangou S; Franke B; Hall J; Heslenfeld DJ; Kirsch P; McIntosh AM; Noethen MM; Papassotiropoulos A; de Quervain DJ-F; Rietschel M; Schumann G; Tost H; Witt SH; Zink M; Meyer-Lindenberg A; Bettella F; Brandt CL; Clarke T-K; Coynel D; Degenhardt F; Djurovic S; Eisenacher S; Fastenrath M; Fatouros-Bergman H; Forstner AJ; Frank J; Gambi F; Gelao B; Geschwind L; Di Giannantonio M; Di Giorgio A; Hartman CA; Heilmann-Heimbach S; Herms S; Hoekstra PJ; Hoffmann P; Hoogman M; Jonsson EG; Loos E; Maggioni E; Oosterlaan J; Papalino M; Rampino A; Romaniuk L; Selvaggi P; Sepede G; Sonderby IE; Spalek K; Sussmann JE; Thompson PM; Vasquez AA; Vogler C; Whalley H; Farde L; Flyckt L; Engberg G; Erhardt S; Fatouros-Bergman H; Cervenka S; Schwieler L; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: EJNMMI RESEARCH. 2018;8(1):113
The development of a GPR44 targeting radioligand [¹¹C]AZ12204657 for in vivo assessment of beta cell mass
Jahan M; Johnstrom P; Selvaraju RK; Svedberg M; Winzell MS; Bernstrom J; Kingston L; Schou M; Jia Z; Skrtic S; Johansson L; Korsgren O; Farde L; Halldin C; Eriksson O
Article: EJNMMI RESEARCH. 2018;8(1):102
Test-retest reliability and convergent validity of (R)-[¹¹C]PK11195 outcome measures without arterial input function
Plaven-Sigray P; Matheson GJ; Cselenyi Z; Jucaite A; Farde L; Cervenka S
Article: PEERJ. 2018;6:e5790
Serotonin 5-HT₁_A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing
Griffioen G; Matheson GJ; Cervenka S; Farde L; Borg J
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2018;138(5):432-440
Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis
Orhan F; Schwieler L; Fatouros-Bergman H; Malmqvist A; Cervenka S; Collste K; Flyckt L; Farde L; Sellgren CM; Piehl F; Engberg G; Erhardt S
Article: BIOLOGICAL PSYCHIATRY. 2018;84(9):644-654
Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
van Erp TGM; Walton E; Hibar DP; Schmaal L; Jiang W; Glahn DC; Pearlson GD; Yao N; Fukunaga M; Hashimoto R; Okada N; Yamamori H; Bustillo JR; Clark VP; Agartz I; Mueller BA; Cahn W; de Zwarte SMC; Pol HEH; Kahn RS; Ophoff RA; van Haren NEM; Andreassen OA; Dale AM; Nhat TD; Gurholt TP; Hartberg CB; Haukvik UK; Jorgensen KN; Lagerberg TV; Melle I; Westlye LT; Gruber O; Kraemer B; Richter A; Zilles D; Calhoun VD; Crespo-Facorro B; Roiz-Santianez R; Tordesillas-Gutierrez D; Loughland C; Carr VJ; Catts S; Cropley VL; Fullerton JM; Green MJ; Henskens FA; Jablensky A; Lenroot RK; Mowry BJ; Michie PT; Pantelis C; Quide Y; Schall U; Scott RJ; Cairns MJ; Seal M; Tooney PA; Rasser PE; Cooper G; Weickert CS; Weickert TW; Morris DW; Hong E; Kochunov P; Beard LM; Gur RE; Gur RC; Satterthwaite TD; Wolf DH; Belger A; Brown GG; Ford JM; Macciardi F; Mathalon DH; O'Leary DS; Potkin SG; Preda A; Voyvodic J; Lim KO; McEwen S; Yang F; Tan Y; Tan S; Wang Z; Fan F; Chen J; Xiang H; Tang S; Guo H; Wan P; Wei D; Bockholt HJ; Ehrlich S; Wolthusen RPF; King MD; Shoemaker JM; Sponheim SR; De Haan L; Koenders L; Machielsen MW; van Amelsvoort T; Veltman DJ; Assogna F; Banaj N; de Rossi P; Iorio M; Piras F; Spalletta G; McKenna PJ; Pomarol-Clotet E; Salvador R; Corvin A; Donohoe G; Kelly S; Whelan CD; Dickie EW; Rotenberg D; Voineskos AN; Ciufolini S; Radua J; Dazzan P; Murray R; Marques TR; Simmons A; Borgwardt S; Egloff L; Harrisberger F; Riecher-Roessler A; Smieskova R; Alpert KI; Wang L; Jonsson EG; Koops S; Sommer IEC; Bertolino A; Bonvino A; Di Giorgio A; Neilson E; Mayer AR; Stephen JM; Kwon JS; Yun J-Y; Cannon DM; McDonald C; Lebedeva I; Tomyshev AS; Akhadov T; Kaleda V; Fatouros-Bergman H; Flyckt L; Busatto GF; Rosa PGP; Serpa MH; Zanetti MV; Hoschl C; Skoch A; Spaniel F; Tomecek D; Hagenaars SP; McIntosh AM; Whalley HC; Lawrie SM; Knoechel C; Oertel-Knoechel V; Staeblein M; Howells FM; Stein DJ; Temmingh HS; Uhlmann A; Lopez-Jaramillo C; Dima D; McMahon A; Faskowitz JI; Gutman BA; Jahanshad N; Thompson PM; Turner JA
Article: SCIENCE TRANSLATIONAL MEDICINE. 2018;10(461):eaam8434
GABA_A receptor availability is not altered in adults with autism spectrum disorder or in mouse models
Horder J; Andersson M; Mendez MA; Singh N; Tangen A; Lundberg J; Gee A; Halldin C; Veronese M; Bolte S; Farde L; Sementa T; Cash D; Higgins K; Spain D; Turkheimer F; Mick I; Selvaraj S; Nutt DJ; Lingford-Hughes A; Howes OD; Murphy DG; Borg J
Article: EJNMMI RESEARCH. 2018;8(1):74
[¹¹C]SCH23390 binding to the D₁-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis
Stenkrona P; Matheson GJ; Cervenka S; Sigray PP; Halldin C; Farde L
Article: TRANSLATIONAL PSYCHIATRY. 2018;8(1):132
Serotonin concentration enhancers at clinically relevant doses reduce [¹¹C] AZ10419369 binding to the 5-HT_1B receptors in the nonhuman primate brain
Yang K-C; Takano A; Halldin C; Farde L; Finnema SJ
Article: NEUROPHARMACOLOGY. 2018;135:455-463
The metabotropic glutamate receptor 5 radioligand [¹¹C]AZD9272 identifies unique binding sites in primate brain
Varnas K; Jureus A; Finnema SJ; Johnstrom P; Raboisson P; Amini N; Takano A; Stepanov V; Halldin C; Farde L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018;115(22):E5154-E5163
Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium
Kong X-Z; Mathias SR; Guadalupe T; Glahn DC; Franke B; Crivello F; Tzourio-Mazoyer N; Fisher SE; Thompson PM; Francks C
Article: MOLECULAR IMAGING AND BIOLOGY. 2018;20(2):183-187
Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [¹¹C]Raclopride in Non-human Primates
Arakawa R; Farde L; Matsumoto J; Kanegawa N; Yakushev I; Yang K-C; Takano A
Article: MOVEMENT DISORDERS. 2018;33(4):592-599
Nigrostriatal dopamine transporter availability in early Parkinson's disease
Fazio P; Svenningsson P; Cselenyi Z; Halldin C; Farde L; Varrone A
Article: EUROPEAN PSYCHIATRY. 2018;50:21-27
The MINDVIEW project: First results
Benlloch JM; Gonzalez AJ; Pani R; Preziosi E; Jackson C; Murphy J; Barbera J; Correcher C; Aussenhofer S; Gareis D; Visvikis D; Bert J; Langstrom B; Farde L; Toth M; Haggkvist J; Caixeta FV; Kullander K; Somlai-Schweiger I; Schwaiger M
Article: PLOS ONE. 2018;13(3):e0193770
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
Plaven-Sigray P; Matheson GJ; Gustavsson P; Stenkrona P; Halldin C; Farde L; Cervenka S
Article: JOURNAL OF ALZHEIMER'S DISEASE REPORTS. 2017;1(1):169-180
Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [¹⁸F]FDG-μPET Study
Venzi M; Toth M; Haggkvist J; Bogstedt A; Rachalski A; Mattsson A; Frumento P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2017;54:34-40
[¹¹C]AZ10419096-a full antagonist PET radioligand for imaging brain 5-HT_1B receptors
Lindberg A; Nag S; Schou M; Takano A; Matsumoto J; Amini N; Elmore CS; Farde L; Pike VW; Haildin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2017;20(9):683-691
Fenfluramine Reduces [¹¹C] Cimbi-36 Binding to the 5-HT_2A Receptor in the Nonhuman Primate Brain
Yang K-C; Stepanov V; Martinsson S; Ettrup A; Takano A; Knudsen GM; Halldin C; Farde L; Finnema SJ
Article: EJNMMI RESEARCH. 2017;7(1):58
Assessment of simplified ratio-based approaches for quantification of PET [¹¹C] PBR28 data
Matheson GJ; Plaven-Sigray P; Forsberg A; Varrone A; Farde L; Cervenka S
Article: NEUROIMAGE. 2017;155:344-353
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [¹¹C] SCH-23390
Matheson GJ; Stenkrona P; Cselenyi Z; Plaven-Sigray P; Halldin C; Farde L; Cervenka S
Journal article: CANCER RESEARCH. 2017;77(13_Supplement):2641
Abstract 2641: AZD4635 A2A receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program
Johnström P; Gutierrez PM; Varnäs K; Schou M; Takano A; Jones L; Mugundu G; McCoon P; Lyne P; Infante J; Falchook G; Patel M; Karlix J; Merchant M; Clarke J; Cross A; Seneca N; Farde L; Congreve M; Mason JS; Marshall FH
Article: MOLECULAR PSYCHIATRY. 2017;22(6):850-856
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [¹¹C]PBR28
Collste K; Plaven-Sigray P; Fatouros-Bergman H; Victorsson P; Schain M; Forsberg A; Amini N; Aeinehband S; Erhardt S; Halldin C; Flyckt L; Farde L; Cervenka S
Article: ANNALS OF NEUROLOGY. 2017;81(4):572-582
The Immune Response of the Human Brain to Abdominal Surgery
Forsberg A; Cervenka S; Fagerlund MJ; Rasmussen LS; Zetterberg H; Harris HE; Stridh P; Christensson E; Granstrom A; Schening A; Dymmel K; Knave N; Terrando N; Maze M; Borg J; Varrone A; Halldin C; Blennow K; Farde L; Eriksson LI
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2017;44(2):308-320
Characterization of [¹¹C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain
Yang K-C; Stepanov V; Amini N; Martinsson S; Takano A; Nielsen J; Bundgaard C; Bang-Andersen B; Grimwood S; Halldin C; Farde L; Finnema SJ
Article: PSYCHOPHARMACOLOGY. 2017;234(4):707-716
GABA_A receptor occupancy by subtype selective GABA_Aα2,3 modulators: PET studies in humans
Jucaite A; Cselenyi Z; Lappalainen J; McCarthy DJ; Lee C-M; Nyberg S; Varnas K; Stenkrona P; Halldin C; Cross A; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2016;57(10):1529-1534
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Sonni I; Fazio P; Sehain M; Halldin C; Svenningsson P; Farde L; Varrone A
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2016;358(3):464-471
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676
Varnas K; Jureus A; Johnstrom P; Ahlgren C; Schott P; Schou M; Gruber S; Jerning E; Malmborg J; Halldin C; Afzelius L; Farde L
Article: MOLECULAR PSYCHIATRY. 2016;21(8):1077-1084
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jonsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2016;19(8):pyw023
Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [¹⁸F]Lu AF10628
Varnas K; Finnema SJ; Stepanov V; Takano A; Toth M; Svedberg M; Nielsen SM; Khanzhin NA; Juhl K; Bang-Andersen B; Halldin C; Farde L
Article: PSYCHIATRY RESEARCH-NEUROIMAGING. 2016;253:36-42
Low serotonin_1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder
Tiger M; Farde L; Ruck C; Varrone A; Forsberg A; Lindefors N; Halldin C; Lundberg J
Article: NEUROIMAGE. 2016;133:313-320
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data
Fazio P; Schain M; Varnas K; Halldin C; Farde L; Varrone A
Article: BRAIN BEHAVIOR AND IMMUNITY. 2016;54:149-157
In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects
Kanegawa N; Collste K; Forsberg A; Schain M; Arakawa R; Jucaite A; Lekander M; Hoglund CO; Kosek E; Lampa J; Halldin C; Farde L; Varrone A; Cervenka S
Article: ACS CHEMICAL NEUROSCIENCE. 2016;7(2):177-184
Discovery and Preclinical Validation of [¹¹C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor
Schou M; Varnas K; Jureus A; Ahlgren C; Malmquist J; Haggkvist J; Tari L; Wesolowski SS; Throner SR; Brown DG; Nilsson M; Johnstrom P; Finnema SJ; Nakao R; Amini N; Takano A; Farde L
Article: NEUROPHARMACOLOGY. 2016;101:519-530
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates
Hjorth S; Karlsson C; Jucaite A; Varnas K; Hamren UW; Johnstrom P; Gulyas B; Donohue SR; Pike VW; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2016;43(1):173-183
Test-retest reproducibility of [¹¹C]PBR28 binding to TSPO in healthy control subjects
Collste K; Forsberg A; Varrone A; Amini N; Aeinehband S; Yakushev I; Halldin C; Farde L; Cervenka S
Journal article: CLINICAL AND TRANSLATIONAL IMAGING. 2015;3(6):491-492
TSPO binding may also represent 'resting' microglia
Farde L
Article: JOURNAL OF NEUROCHEMISTRY. 2015;135(5):859-866
Distinct binding of amyloid imaging ligands to unique amyloid-b deposited in the presubiculum of Alzheimer's disease
Ji B; Chen C-J; Bando K; Ashino H; Shiraishi H; Sano H; Kasahara H; Minamizawa T; Yamada K; Ono M; Zhang M-R; Seki C; Farde L; Suhara T; Higuchi M
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(11):893-898
Synthesis of ([¹¹C]carbonyl)raclopride and a comparison with ([¹¹C]methyl)raclopride in a monkey PET study
Rahman O; Takano A; Amini N; Dahl K; Kanegawa N; Langstrom B; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 2015;232(21-22):4159-4167
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [¹¹C]MADAM PET study
Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;42(10):1507-1511
β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹C]AZD2184
Mattsson P; Forsberg A; Persson J; Nyberg L; Nilsson L-G; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2015;35(9):1485-1493
Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio
Cselenyi Z; Farde L
Article: BRAIN. 2015;138(Pt 9):2687-2700
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease
Jucaite A; Svenningsson P; Rinne JO; Cselenyi Z; Varnas K; Johnstrom P; Amini N; Kirjavainen A; Helin S; Minkwitz M; Kugler AR; Posener JA; Budd S; Halldin C; Varrone A; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2015;69(7):365-374
5-HT_1B receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients
Varrone A; Svenningsson P; Marklund P; Fatouros-Bergman H; Forsberg A; Halldin C; Nilsson L-G; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(6):555-560
Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing
Johnstrom P; Bergman L; Varnas K; Malmquist J; Halldin C; Farde L
Article: NEUROIMAGE. 2015;112:225-231
Diurnal and seasonal variation of the brain serotonin system in healthy male subjects
Matheson GJ; Schain M; Almeida R; Lundberg J; Cselenyi Z; Borg J; Varrone A; Farde L; Cervenka S
Article: JOURNAL OF NUCLEAR MEDICINE. 2015;56(5):714-720
Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Fazio P; Svenningsson P; Forsberg A; Jonsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2015;18(10):pyv036
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates
Schou M; Varnas K; Lundquist S; Nakao R; Amini N; Takano A; Finnema SJ; Halldin C; Farde L
Article: RSC ADVANCES. 2015;5(108):88886-88889
¹¹C-carbonylation reactions using gas-liquid segmented microfluidics
Dahl K; Schou M; Ulin J; Sjoberg C-O; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2014;18(3):pyu081
Amphetamine Decreases α_2C-Adrenoceptor Binding of [¹¹C]ORM-13070: A PET Study in the Primate Brain
Finnema SJ; Hughes ZA; Haaparanta-Solin M; Stepanov V; Nakao R; Vamas K; Varrone A; Arponen E; Marjamaki P; Pohjanoksa K; Vuorilehto L; Babalola PA; Solin O; Grimwood S; Sallinen J; Farde L; Scheinin M; Halldin C
Article: NEUROIMAGE. 2014;103:303-308
Distinct regional age effects on [¹¹C]AZ10419369 binding to 5-HT_1B receptors in the human brain
Nord M; Cselenyi Z; Forsberg A; Rosenqvist G; Tiger M; Lundberg J; Varrone A; Farde L
Article: NEUROIMAGE. 2014;102:590-595
Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study
Plaven-Sigray P; Gustavsson P; Farde L; Borg J; Stenkrona P; Nyberg L; Backman L; Cervenka S
Article: NEUROINFORMATICS. 2014;12(4):551-562
Evaluation of Two Automated Methods for PET Region of Interest Analysis
Schain M; Varnas K; Cselenyi Z; Halldin C; Farde L; Varrone A
Article: EJNMMI RESEARCH. 2014;4(1):50-8
Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain
Friden M; Wennerberg M; Antonsson M; Sandberg-Stall M; Farde L; Schou M
Article: SCHIZOPHRENIA RESEARCH. 2014;158(1-3):156-162
Meta-analysis of cognitive performance in drug-naive patients with schizophrenia
Fatouros-Bergman H; Cervenka S; Flyckt L; Edman G; Farde L
Article: PSYCHIATRY RESEARCH. 2014;223(2):164-170
Reduced 5-HT_1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder
Tiger M; Ruck C; Forsberg A; Varrone A; Lindefors N; Halldin C; Farde L; Lundberg J
Article: JOURNAL OF NUCLEAR MEDICINE. 2014;55(7):1164-1170
¹⁸F-MCL-524, an ¹⁸F-Labeled Dopamine D₂ and D₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study
Finnema SJ; Stepanov V; Nakao R; Sromek AW; Zhang T; Neumeyer JL; George SR; Seeman P; Stabin MG; Jonsson C; Farde L; Halldin C
Article: JOURNAL OF NUCLEAR MEDICINE. 2014;55(6):932-938
Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer ¹¹C-AZD2184
Ito H; Shimada H; Shinotoh H; Takano H; Sasaki T; Nogami T; Suzuki M; Nagashima T; Takahata K; Seki C; Kodaka F; Eguchi Y; Fujiwara H; Kimura Y; Hirano S; Ikoma Y; Higuchi M; Kawamura K; Fukumura T; Boo EL; Farde L; Suhara T
Article: NEUROBIOLOGY OF AGING. 2014;35(4):867-875
Positron emission tomography imaging of 5-hydroxytryptamine_1B receptors in Parkinson's disease
Varrone A; Svenningsson P; Forsberg A; Varnas K; Tiger M; Nakao R; Halldin C; Nilsson L-G; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2014;16(2):173-179
Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [¹¹C]AZD4694 in Nonhuman Primates
Schou M; Varnas K; Sandell J; Johnstrom P; Cselenyi Z; Svensson S; Nakao R; Amini N; Bergman L; Sumic A; Gulyas B; Lindstrom-Boo E; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41(2):301-307
Test-retest reliability of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain
Nord M; Finnema SJ; Schain M; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(10):2235-2244
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
Nyberg S; Jucaite A; Takano A; Kagedal M; Cselenyi Z; Halldin C; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2013;54(10):1825-1832
Performance Evaluation of the Small-Animal nanoScan PET/MRI System
Nagy K; Toth M; Major P; Patay G; Egri G; Haggkvist J; Varrone A; Farde L; Halldin C; Gulyas B
Journal article: BRAIN BEHAVIOR AND IMMUNITY. 2013;32:e42
145. Translocator protein (TSPO) as a biomarker of microglia activation: PET imaging using [11C]PBR28 in Parkinson’s disease
Jucaite A; Cselényi Z; Varrone A; Varnäs K; Johnström P; Halldin C; Salter H; McLoughlin MJ; Rinne J; Svenningsson P; Alexander R; Kugler A; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2013;67(9):586-595
The dopamine D₁ receptor agonist (S)-[¹¹C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentrationa positron emission tomography examination in the monkey brain
Finnema SJ; Bang-Andersen B; Jorgensen M; Christoffersen CT; Gulyas B; Wikstrom HV; Farde L; Halldin C
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(6):747-754
Radiosynthesis and evaluation of new α₁-adrenoceptor antagonists as PET radioligands for brain imaging
Airaksinen AJ; Finnema SJ; Balle T; Varnas K; Bang-Andersen B; Gulyas B; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(7):1577-1586
Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain
Nord M; Finnema SJ; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2013;33(7):1058-1065
Arterial input function derived from pairwise correlations between PET-image voxels
Schain M; Benjaminsson S; Varnas K; Forsberg A; Halldin C; Lansner A; Farde L; Varrone A
Article: CEPHALALGIA. 2013;33(10):853-860
A PET study with [¹¹C]AZ10419369 to determine brain 5-HT_1B receptor occupancy of zolmitriptan in healthy male volunteers
Varnas K; Jucaite A; McCarthy DJ; Stenkrona P; Nord M; Halldin C; Farde L; Kanes S
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(4):763-769
Effects of amphetamine on the human brain opioid system - a positron emission tomography study
Guterstam J; Jayaram-Lindstrom N; Cervenka S; Frost JJ; Farde L; Halldin C; Franck J
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(4):547-553
Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272
Andersson JD; Seneca N; Truong P; Wensbo D; Raboisson P; Farde L; Halldin C
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(4):574-579
Test-retest reproducibility of dopamine D_2/3 receptor binding in human brain measured by PET with [¹¹C]MNPA and [¹¹C]raclopride
Kodaka F; Ito H; Kimura Y; Fujie S; Takano H; Fujiwara H; Sasaki T; Nakayama K; Halldin C; Farde L; Suhara T
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(3):410-414
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate
Schou M; Varnas K; Jucaite A; Gulyas B; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(4):580-593
Low background and high contrast PET imaging of amyloid-β with [¹¹C]AZD2995 and [¹¹C]AZD2184 in Alzheimer's disease patients
Forsberg A; Jureus A; Cselenyi Z; Eriksdotter M; Freund-Levi Y; Jeppsson F; Swahn B-M; Sandell J; Julin P; Schou M; Andersson J; Johnstrom P; Varnas K; Halldin C; Farde L; Svensson S
Article: PSYCHOPHARMACOLOGY. 2013;226(1):147-153
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study
Takano A; Halldin C; Farde L
Article: NEUROIMAGE. 2013;67:1-6
Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum
de Manzano O; Cervenka S; Jucaite A; Hellenas O; Farde L; Ullen F
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(2):228-237
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT
Schain M; Toth M; Cselenyi Z; Arakawa R; Halldin C; Farde L; Varrone A
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15(8):1167-1172
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
Lundberg J; Tiger M; Landen M; Halldin C; Farde L
Journal article: ALZHEIMERS & DEMENTIA. 2012;8(4S_Part_1):p14
IC‐P‐011: Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods
Chen K; Langbaum J; Fleisher A; Roontiva A; Liu X; Thiyyagura P; Bandy D; Richter N; Jakimovich L; Prouty A; Cselenyi Z; Farde L; Budd S; Reiman E
Journal article: ALZHEIMERS & DEMENTIA. 2012;8(4S_Part_1):p10
IC‐O3‐04: Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods
Chen K; Langbaum JB; Fleisher AS; Roontiva A; Liu X; Thiyyagura P; Bandy D; Richter N; Jakimovich L; Prouty A; Cselenyi Z; Farde L; Budd S; Reiman EM
Journal article: ALZHEIMERS & DEMENTIA. 2012;8(4S_Part_4):p162
P1‐155: Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods
Chen K; Langbaum J; Fleisher A; Roontiva A; Liu X; Thiyyagura P; Bandy D; Richter N; Jakimovich L; Prouty A; Cselenyi Z; Farde L; Budd S; Reiman E
Journal article: ALZHEIMERS & DEMENTIA. 2012;8(4S_Part_1):p30
IC‐P‐045: Comparison of beta‐amyloid imaging using congo red and thioflavin T derivatives
Svensson S; Jeppsson F; Juréus A; Johnström P; Sandell J; Swahn B; Mattsson A; Cselényi Z; Farde L; Cope F
Article: EJNMMI RESEARCH. 2012;2:15
Kinetic analysis and test-retest variability of the radioligand [¹¹C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
Jucaite A; Cselenyi Z; Arvidsson A; Ahlberg G; Julin P; Varnas K; Stenkrona P; Andersson J; Halldin C; Farde L
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2012;227(4):1663-1669
Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism
Sestini S; Halldin C; Mansi L; Castagnoli A; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32(4):685-695
Confirmation of fenfluramine effect on 5-HT_1B receptor binding of [¹¹C]AZ10419369 using an equilibrium approach
Finnema SJ; Varrone A; Hwang T-J; Halldin C; Farde L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2012;22:s55
P.3.004 Amphetamine-opioid interactions in the human brain reward system – a PET study using [11C]carfentanil
Guterstam J; Jayaram-Lindstrom N; Cervenka S; Halldin C; Farde L; Frost J; Franck J
Article: JOURNAL OF NUCLEAR MEDICINE. 2012;53(3):415-424
Clinical Validation of ¹⁸F-AZD4694, an Amyloid-β-Specific PET Radioligand
Cselenyi Z; Jonhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnstrom P; Varnas K; Svensson S; Farde L
Article: NEUROIMAGE. 2012;60(1):800-807
Quantification of serotonin transporter availability with [¹¹C]MADAM - A comparison between the ECAT HRRT and HR systems
Schain M; Toth M; Cselenyi Z; Stenkrona P; Halldin C; Farde L; Varrone A
Article: NEUROIMAGE. 2012;59(4):3582-3593
Quantitative PET analyses of regional [¹¹C]PE2I binding to the dopamine transporter - Application to juvenile myoclonic epilepsy
Odano I; Varrone A; Savic I; Ciumas C; Karlsson P; Jucaite A; Halldin C; Farde L
Article: JOURNAL OF NEUROIMAGING. 2012;22(1):28-32
A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry
Comley RA; Cervenka S; Palhagen SE; Panagiotidis G; Matthews JC; Lai RY; Halldin C; Farde L; Nichols TE; Whitcher BJ
Article: ANALYTICAL CHEMISTRY. 2011;83(24):9694-9701
Qualitative and Quantitative MALDI Imaging of the Positron Emission Tomography Ligands Raclopride (a D2 Dopamine Antagonist) and SCH 23390 (a D1 Dopamine Antagonist) in Rat Brain Tissue Sections Using a Solvent-Free Dry Matrix Application Method
Goodwin RJA; Mackay CL; Nilsson A; Harrison DJ; Farde L; Andren PE; Iverson SL
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2011;14(10):1357-1366
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
Nord M; Nyberg S; Brogren J; Jucaite A; Halldin C; Farde L
Article: HUMAN BRAIN MAPPING. 2011;32(10):1626-1636
Extrastriatal Dopamine D₂ Receptor Binding in Huntington's Disease
Esmaeilzadeh M; Farde L; Karlsson P; Varrone A; Halldin C; Waters S; Tedroff J
Article: NEUROBIOLOGY OF AGING. 2011;32(10):1849-1856
Dopamine D₁ receptors and age differences in brain activation during working memory
Backman L; Karlsson S; Fischer H; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Nyberg L
Article: CEREBRAL CORTEX. 2011;21(9):2023-2032
Dopamine D1 Receptor Associations within and between Dopaminergic Pathways in Younger and Elderly Adults: Links to Cognitive Performance
Rieckmann A; Karlsson S; Karlsson P; Brehmer Y; Fischer H; Farde L; Nyberg L; Backman L
Article: NEUROIMAGE. 2011;57(2):346-351
Relationship of dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in healthy humans
Karlsson S; Rieckmann A; Karlsson P; Farde L; Nyberg L; Backman L
Journal article: ALZHEIMERS & DEMENTIA. 2011;7(4S_Part_1):s42-s43
IC‐P‐083: Beta‐amyloid binding of [3]AZD4694 and [3H]AV45 in vitro
Jeppsson F; Juréus A; Sandell J; Swahn B; Cselényi Z; Farde L; Svensson S
Article: PSYCHOPHARMACOLOGY. 2011;216(2):279-286
NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo
Takano A; Nag S; Gulyas B; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2011;14(1):83-89
Effect of risperidone on high-affinity state of dopamine D₂ receptors: a PET study with agonist ligand [¹¹C](R)-2-CH₃O-N-n-propylnorapomorphine
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Article: NUCLEAR MEDICINE AND BIOLOGY. 2011;38(2):261-272
Development of a PET radioligand for the central 5-HT_1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds
Andersson JD; Pierson ME; Finnema SJ; Gulyas B; Heys R; Elmore CS; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 2011;213(2-3):533-545
Dose-dependent binding of AZD3783 to brain 5-HT_1B receptors in non-human primates and human subjects: a positron emission tomography study with [¹¹C]AZ10419369
Varnas K; Nyberg S; Karlsson P; Pierson ME; Kagedal M; Cselenyi Z; McCarthy D; Xiao A; Zhang M; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2011;31(1):113-123
Quantitative analysis of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain
Varnas K; Nyberg S; Halldin C; Varrone A; Takano A; Karlsson P; Andersson J; McCarthy D; Smith M; Pierson ME; Soderstrom J; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2010;64(10):733-741
Radiosynthesis of the Candidate β-Amyloid Radioligand [¹¹C]AZD2184: Positron Emission Tomography Examination and Metabolite Analysis in Cynomolgus Monkeys
Andersson JD; Varnas H; Cselenyi Z; Gulyas B; Wensbo D; Finnema SJ; Swahn B-M; Svensson S; Nyberg S; Farde L; Halldin C
Article: JOURNAL OF NEUROCHEMISTRY. 2010;114(3):784-794
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
Jureus A; Swahn B-M; Sandell J; Jeppsson F; Johnson AE; Johnstrom P; Neelissen JAM; Sunnemark D; Farde L; Svensson SPS
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2010;64(7):573-577
Fenfluramine-Induced Serotonin Release Decreases [¹¹C]AZ10419369 Binding to 5-HT_1B-Receptors in the Primate Brain
Finnema SJ; Varrone A; Hwang TJ; Gulyas B; Pierson ME; Halldin C; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2010;64(6):478-485
PET Studies of D2-Receptor Binding in Striatal and Extrastriatal Brain Regions: Biochemical Support In Vivo for Separate Dopaminergic Systems in Humans
Cervenka S; Varrone A; Fransen E; Halldin C; Farde L
Article: PLOS ONE. 2010;5(5):e10670
Thinking Outside a Less Intact Box: Thalamic Dopamine D2 Receptor Densities Are Negatively Related to Psychometric Creativity in Healthy Individuals
de Manzano O; Cervenka S; Karabanov A; Farde L; Ullen F
Article: NEUROSCIENCE. 2010;167(1):104-110
AGE-RELATED REDUCTION IN DOPAMINE D1 RECEPTORS IN THE HUMAN BRAIN: FROM LATE CHILDHOOD TO ADULTHOOD, A POSITRON EMISSION TOMOGRAPHY STUDY
Jucaite A; Forssberg H; Karlsson P; Halldin C; Farde L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2010;107(16):7574-7579
Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning
Karabanov A; Cervenka S; de Manzano O; Forssberg H; Farde L; Ullen F
Article: BIOLOGICAL PSYCHIATRY. 2010;67(6):575-580
Simulating Neurocognitive Aging: Effects of a Dopaminergic Antagonist on Brain Activity During Working Memory
Fischer H; Nyberg L; Karlsson S; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Backman L
Article: NEUROIMAGE. 2010;50(1):323-328
Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability
Cervenka S; Gustavsson JP; Halldin C; Farde L
Article: NEUROIMAGE. 2009;48(2):398-404
Modulation of striatal dopamine D1 binding by cognitive processing
Karlsson S; Nyberg L; Karlsson P; Fischer H; Thilers P; MacDonald S; Brehmer Y; Rieckmann A; Halldin C; Farde L; Backman L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(11):1859-1863
Detection of amyloid in Alzheimer's disease with positron emission tomography using [¹¹C]AZD2184
Nyberg S; Jonhagen ME; Cselenyi Z; Halldin C; Julin P; Olsson H; Freund-Levi Y; Andersson J; Varnas K; Svensson S; Farde L
Article: BIOLOGICAL PSYCHIATRY. 2009;66(5):477-485
Genetic Variation in Brain-Derived Neurotrophic Factor Is Associated with Serotonin Transporter but Not Serotonin-1A Receptor Availability in Men
Henningsson S; Borg J; Lundberg J; Bah J; Lindstrom M; Ryding E; Jovanovic H; Saijo T; Inoue M; Rosen I; Traskman-Bendz L; Farde L; Eriksson E
Journal article: ALZHEIMERS & DEMENTIA. 2009;5(4S_Part_2):p57
IC‐P‐141: AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β‐amyloid deposits
Sundgren‐Andersson AK; Svensson SPS; Swahn B; Juréus A; Sandell J; Johnson AE; Jeppsson F; Neelissen JAM; Halldin C; Johnström P; Schou M; Cselényi Z; Farde L
Journal article: ALZHEIMERS & DEMENTIA. 2009;5(4S_Part_9):p267-p268
P2‐023: AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β‐amyloid deposits
Sundgren‐Andersson AK; Svensson SPS; Swahn B; Juréus A; Sandell J; Johnson AE; Jeppsson F; Neelissen JAM; Halldin C; Johnström P; Schou M; Cselényi Z; Farde L
Journal article: NEUROIMAGE. 2009;47:s77
Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training
McNab F; Varrone A; Farde L; Jucaite A; Bystritsky P; Forssberg H; Klingberg T
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2009;12(6):783-792
Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT_1A receptor binding in humans
Borg J; Henningsson S; Saijo T; Inoue M; Bah J; Westberg L; Lundberg J; Jovanovic H; Andree B; Nordstrom A-L; Halldin C; Eriksson E; Farde L
Article: NEUROSCIENCE. 2009;161(2):422-426
AGE-RELATED LOSS OF OLFACTORY SENSITIVITY: ASSOCIATION TO DOPAMINE TRANSPORTER BINDING IN PUTAMEN
Larsson M; Farde L; Hummel T; Witt M; Lindroth NE; Backman L
Article: JOURNAL OF NUCLEAR MEDICINE. 2009;50(5):703-710
Quantitative PET Analysis of the Dopamine D₂ Receptor Agonist Radioligand ¹¹C-(R)-2-CH₃O-N-n-Propylnorapomorphine in the Human Brain
Otsuka T; Ito H; Halldin C; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Nakao R; Suzuki K; Finnema S; Hirayasu Y; Suhara T; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2009;63(5):378-389
Dopamine D_2/3 Receptor Occupancy of Apomorphine in the Nonhuman Primate Brain-A Comparative PET Study With [¹¹C]Raclopride and [¹¹C]MNPA
Finnema SJ; Halldin C; Bang-Andersen B; Gulyas B; Bundgaard C; Wikstrom HV; Farde L
Article: NEUROIMAGE. 2009;45(3):891-902
[¹⁸F]Flumazenil binding to central benzodiazepine receptor studies by PET - Quantitative analysis and comparisons with [¹¹C]flumazenil
Odano I; Halldin C; Karlsson P; Varrone A; Airaksinen AJ; Krasikova RN; Farde L
Article: JOURNAL OF NEUROCHEMISTRY. 2009;108(5):1177-1186
AZD2184: a radioligand for sensitive detection of β-amyloid deposits
Johnson AE; Jeppsson F; Sandell J; Wensbo D; Neelissen JAM; Jureus A; Strom P; Norman H; Farde L; Svensson SPS
Article: SCIENCE. 2009;323(5915):800-802
Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training
McNab F; Varrone A; Farde L; Jucaite A; Bystritsky P; Forssberg H; Klingberg T
Article: MOLECULAR IMAGING AND BIOLOGY. 2009;11(1):23-30
Investigation of the Metabolites of (S,S)-[¹¹C] MeNER in Humans, Monkeys and Rats
Schou M; Zoghbi SS; Shetty HU; Shchukin E; Liow J-S; Hong J; Andree BA; Gulyas B; Farde L; Innis RB; Pike VW; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11(5):671-678
Age-related diurnal effect on D₂ receptor binding: a preliminary PET study
Cervenka S; Halldin C; Farde L
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2008;16(13):6467-6473
[¹¹C]cyclopropyl-FLB 457:: A PET radioligand for low densities of dopamine D₂ receptors
Airaksinen AJ; Nag S; Finnema SJ; Mukherjee J; Chattopadhyay S; Gulyas B; Farde L; Halldin C
Article: NEUROIMAGE. 2008;41(3):1075-1085
[¹¹C]AZ10419369:: A selective 5-HT_1B receptor radioligand suitable for positron emission tomography (PET).: Characterization in the primate brain
Pierson ME; Andersson J; Nyberg S; McCarthy DJ; Finnema SJ; Varnas K; Takano A; Karlsson P; Gulyas B; Medd AM; Lee C-M; Powell ME; Heys JR; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2008;28(5):1059-1069
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [¹¹C]PE2I:: quantitative modeling and test-retest reproducibility
Hirvonen J; Johansson J; Teras M; Oikonen V; Lumme V; Virsu P; Roivainen A; Nagren K; Halldin C; Farde L; Hietala J
Article: NEUROIMAGE. 2008;40(3):1287-1295
Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum
Cervenka S; Backman L; Cselenyi Z; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11(2):163-171
PET analysis of the 5-HT_2A receptor inverse agonist ACP-103 in human brain
Nordstrom A-L; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2007;10(6):777-785
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Lundberg J; Christophersen JS; Petersen KB; Loft H; Halldin C; Farde L
Article: PSYCHOPHARMACOLOGY. 2007;195(3):425-433
A PET study on regional coexpression of 5-HT_1A receptors and 5-HTT in the human brain
Lundberg J; Borg J; Halldin C; Farde L
Journal article: PHARMACOPSYCHIATRY. 2007;40(05)
Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115)
Karlsson P; Hargarter L; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2007;27(2):369-377
Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [¹¹C]FLB 457 PET
Montgomery AJ; Asselin M-C; Farde L; Grasby PM
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2007;15(2):616-625
Synthesis of ¹¹C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET
Schou M; Pike VW; Sovago J; Gulyas B; Gallagher PT; Dobson DR; Walter MW; Rudyk H; Farde L; Halldin C
Article: PSYCHIATRY RESEARCH. 2006;148(2-3):165-173
Dopamine D₂ receptor binding in dirug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography
Talvik M; Nordstrom A-L; Okubo Y; Olsson H; Borg J; Halldin C; Farde L
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2006;49(11):1007-1019
Synthesis and PET evaluation of (R)-[S-methyl-¹¹C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters
Schou M; Pike VW; Varrone A; Gulyas B; Farde L; Halldin C
Article: NEUROIMAGE. 2006;32(4):1690-1708
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [¹¹C]FLB 457 and [¹¹C]WAY 100635
Cselenyi Z; Olsson H; Halldin C; Gulyas B; Farde L
Article: PSYCHOPHARMACOLOGY. 2006;188(1):119-127
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion:: a PET study in nonhuman primate brain using (S,S)-[¹⁸F]FMeNER-D₂
Seneca N; Gulyas B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2006;60(3):256-263
Measurement of serotonin transporter binding with PET and [¹¹C]MADAM:: A test-retest reproducibility study
Lundberg J; Halldin C; Farde L
Article: BRAIN. 2006;129(Pt 8):2017-2028
Support for dopaminergic hypoactivity in restless legs syndrome:: a PET study on D2-receptor binding
Cervenka S; Palhagen SE; Comley RA; Panagiotidis G; Cselenyi Z; Matthews JC; Lai RY; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33(6):657-668
Quantitative analyses of regional [¹¹C]PE2I binding to the dopamine transporter in the human brain:: a PET study
Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2006;59(5):260-269
Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain:: A comparison of the agonist radioligand [^11C]MNPA and antagonist [¹¹C]raclopride
Seneca N; Finnema SJ; Farde L; Gulyás B; Wikström HV; Halldin C; Innis RB
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2006;9(2):247-255
Support for limited brain availability of tyrosine in patients with schizophrenia
Bjerkenstedt L; Farde L; Terenius L; Edman G; Venizelos N; Wiesel FA
Article: PSYCHOPHARMACOLOGY. 2006;185(3):389-394
Search for correlations between serotonin 5-HT_1A receptor expression and cognitive functions -: a strategy in translational psychopharmacology
Borg J; Andrée B; Lundberg J; Halldin C; Farde L
Article: PSYCHOPHARMACOLOGY. 2006;185(1):29-35
Clozapine binds preferentially to cortical D₁-like dopamine receptors in the primate brain: a PET study
Chou YH; Halldin C; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2006;8(1):1-8
Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands:: [C-11]desipramine, [C-11]talopram and [C-11]talsupram
Schou M; Sóvágó J; Pike VW; Gulyás B; Bogeso KP; Farde L; Halldin C
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2005;58(3):173-183
[¹¹C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET
Halldin C; Lundberg J; Sóvágó J; Gulyás B; Guilloteau D; Vercouillie J; Emond P; Chalon S; Tarkiainen J; Hiltunen J; Farde L
Article: BRAIN RESEARCH BULLETIN. 2005;67(3):219-224
Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [¹¹C]RGH-1756
Sóvágó J; Farde L; Halldin C; Schukin E; Schou M; Laszlovszky I; Kiss B; Gulyás B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15(5):517-520
Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[¹⁸F]FMeNER-D₂
Schou M; Halldin C; Pike VW; Mozley PD; Dobson D; Innis RB; Farde L; Hall H
Article: JOURNAL OF NUCLEAR MEDICINE. 2005;46(9):1505-1515
Quantification of ¹¹C-MADAM binding to the serotonin transporter in the human brain
Lundberg J; Odano I; Olsson H; Halldin C; Farde L
Journal article: CEREBROVASCULAR AND BRAIN METABOLISM REVIEWS. 2005;25(1_suppl):s646
Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [11C]MNPA
Seneca N; Finnema S; Ichise M; Gulyas B; Wikstrom H; Innis RB; Farde L; Halldin C
Article: ARCHIVES OF NEUROLOGY. 2005;62(6):946-950
Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy
Meschaks A; Lindstrom P; Halldin C; Farde L; Savic I
Article: MOLECULAR IMAGING AND BIOLOGY. 2005;7(3):209-219
Two C-methyl derivatives of [¹¹C]WAY-100635 -: Effects of an amido α-methyl group on metabolism and brain 5-HT_1A receptor radioligand behavior in monkey
McCarron JA; Marchais-Oberwinkler S; Pike VW; Tarkiainen J; Halldin C; Sóvagó J; Gulyas BZ; Wikström HV; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2005;32(4):353-360
A preliminary PET evaluation of the new dopamine D₂ receptor agonist [¹¹C]MNPA in cynomolgus monkey
Finnema SJ; Seneca N; Farde L; Shchukin E; Sóvágó J; Gulyás B; Wikström HV; Innis RB; Neumeyer JL; Halldin C
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2005;13(3):883-893
N-Oxide analogs of WAY-100635: new high affinity 5-HT_1A receptor antagonists
Marchais-Oberwinkler S; Nowicki B; Pike VW; Halldin C; Sandell J; Chou YH; Gulyas B; Brennum LT; Farde L; Wikström HV
Article: PSYCHIATRY RESEARCH. 2005;138(1):1-12
The role of the striatal dopamine transporter in cognitive aging
Erixon-Lindroth N; Farde L; Wahlin TBR; Sovago J; Halldin C; Bäckman L
Article: NEUROCHEMISTRY INTERNATIONAL. 2004;45(5):773-781
Joint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor-transporter correlation using PET data
Cselényi Z; Lundberg J; Halldin C; Farde L; Gulyás B
Article: NEUROCHEMISTRY INTERNATIONAL. 2004;45(5):609-617
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [¹¹C]RGH-1756 in the monkey brain
Sóvágó J; Farde L; Halldin C; Langer O; Laszlovszky I; Kiss B; Gulyás B
Article: PSYCHOPHARMACOLOGY. 2004;175(2):148-153
A cross-validation study on the relationship between central D₂ receptor occupancy and serum perphenazine concentration
Talvik M; Nordström AL; Larsen NE; Jucaite A; Cervenka S; Halldin C; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2004;53(2):57-67
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain
Schou M; Halldin C; Sóvágó J; Pike VW; Hall H; Gulyás B; Mozley PD; Dobson D; Shchukin E; Innis RB; Farde L
Article: NEUROIMAGE. 2004;22(2):794-803
Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET
Olsson H; Halldin C; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2004;161(6):1016-1022
Low dopamine D₂ receptor binding in subregions of the thalamus in schizophrenia
Yasuno F; Suhara T; Okubo Y; Sudo Y; Inoue M; Ichimiya T; Takano A; Nakayama K; Haildin C; Farde L
Article: NEUROLOGY. 2004;62(8):1343-1351
Limbic reductions of 5-HT_1A receptor binding in human temporal lobe epilepsy
Savic I; Lindström P; Gulyás B; Halldin C; Andrée B; Farde L
Article: JOURNAL OF NEURAL TRANSMISSION. 2004;111(4):537-545
Transcription factor AP-2β genotype, striatal dopamine D2 receptor density and cerebrospinal fluid monoamine metabolite concentrations in humans
Damberg M; Berggård C; Farde L; Sedvall GC; Jönsson EG
Article: NUCLEAR MEDICINE AND BIOLOGY. 2004;31(3):327-336
New α₁-adrenoceptor antagonists derived from the antipsychotic sertindole-carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey
Balle T; Halldin C; Andersen L; Alifrangis LH; Badolo L; Jensen KG; Chou YW; Andersen K; Perregaard J; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2004;6(1):17-26
The pyridinyl-6 position of WAY-100635 as a site for radiofluorination-effect on 5-HT_1A receptor radioligand behavior in vivo
McCarron JA; Pike VW; Halldin C; Sandell J; Sóvagó J; Gulyas BS; Cselényi Z; Wikström HV; Marchais-Oberwinkler S; Nowicki B; Dollé F; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2003;6(4):361-370
Decreased thalamic D₂/D₃ receptor binding in drug-naive patients with schizophrenia:: a PET study with [¹¹C]FLB 457
Talvik M; Nordström AL; Olsson H; Halldin C; Farde L
Article: ORVOSI HETILAP. 2003;144(46):2271-2276
[Human positron emission tomography with oral 11C-vinpocetine].
Vas A; Christer H; Sóvágó J; Johan S; Cselényi Z; Kiss B; Kárpáti E; Lars F; Gulyás B
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(11):1520-1528
Radioiodinated SB 207710 as a radioligand in vivo:: imaging of brain 5-HT₄ receptors with SPET
Pike VW; Halldin C; Nobuhara K; Hiltunen J; Mulligan RS; Swahn CG; Karlsson P; Olsson H; Hume SP; Hirani E; Whalley J; Pilowsky LS; Larsson S; Schnell PO; Ell PJ; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2003;30(7):707-714
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[¹¹C]MeNER
Schou M; Halldin C; Sóvágó J; Pike VW; Gulyás B; Mozley PD; Johnson DP; Hall H; Innis RB; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(9):1220-1230
[¹¹C]PE2I:: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain
Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
Article: AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS. 2003;120B(1):51-57
NURR1 promoter polymorphisms:: Parkinson's disease, schizophrenia, and personality traits
Carmine A; Buervenich S; Galter D; Jönsson EG; Sedvall GC; Farde L; Gustavsson JP; Bergman H; Chowdari KV; Nimgaonkar VL; Anvret M; Sydow O; Olson L
Article: BIOLOGICAL PSYCHIATRY. 2003;53(7):577-584
Association between a promoter dopamine D₂ receptor gene variant and the personality trait detachment
Jönsson EG; Cichon S; Gustavsson JP; Grünhage F; Forslund K; Mattila-Evenden M; Rylander G; Åsberg M; Farde L; Propping P; Nöthen MM
Article: PSYCHOPHARMACOLOGY. 2003;167(1):37-45
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-lA receptors in the human brain
Andrée B; Hedman A; Thorberg SO; Nilsson D; Halldin C; Farde L
Article: PSYCHIATRIC GENETICS. 2003;13(1):23-28
Two NOTCH4 polymorphisms and their relation to schizophrenia susceptibility and different personality traits
Carmine A; Chheda MG; Jönsson EG; Sedvall GC; Farde L; Gustavsson JP; Bergman H; Anvret M; Buervenich S; Olson L
Article: PSYCHOPHARMACOLOGY. 2003;166(3):234-240
Occupancy of 5-HT_1A receptors by clozapine in the primate brain:: a PET study
Chou YH; Halldin C; Farde L
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2003;304(1):81-87
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity
Chalon S; Tarkiainen J; Garreau L; Hall H; Emond P; Vercouillie J; Farde L; Dasse P; Varnas K; Besnard JC; Halldin C; Guilloteau D
Article: ACTA NEUROLOGICA SCANDINAVICA. 2002;106(6):325-332
PET studies on the brain uptake and regional distribution of [¹¹C] vinpocetine in human subjects
Gulyás B; Halldin C; Sandell J; Karlsson P; Sóvágó J; Kárpáti E; Kiss B; Vas A; Cselényi Z; Farde L
Article: ORVOSI HETILAP. 2002;143(47):2631-2636
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study].
Vas A; Sóvágó J; Halldin C; Sandell J; Karlsson P; Kárpáti E; Kiss B; Cselényi Z; Farde L; Gulyás B
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(7):753-759
Cerebral uptake of [ethyl-¹¹C]vinpocetine and 1-[¹¹C]ethanol in cynomolgous monkeys:: a comparative preclinical PET study
Gulyás B; Vas A; Halldin C; Sóvágó J; Sandell J; Olsson H; Fredriksson A; Stone-Elander S; Farde L
Article: NEUROIMAGE. 2002;17(1):47-60
Wavelet-aided parametric mapping of cerebral dopamine D₂ receptors using the high affinity PET radioligand [¹¹C]FLB 457
Cselényi Z; Olsson H; Farde L; Gulyás B
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(6):651-656
PET examination of [¹¹C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter
Sandell J; Halldin C; Sovago J; Chou YH; Gulyás B; Yu MX; Emond P; Någren K; Guilloteau D; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2002;29(8):1031-1038
Drug distribution in man:: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine
Gulyás B; Halldin C; Sóvágó J; Sandell J; Cselényi Z; Vas A; Kiss B; Kárpáti E; Farde L
Article: PSYCHOPHARMACOLOGY. 2002;162(1):37-41
Low striatal and extra-striatal D₂ receptor occupancy during treatment with the atypical antipsychotic sertindole
Nyberg S; Olsson H; Nilsson U; Maehlum E; Halldin C; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2002;43(3):292-303
The PET radioligand [carbonyl-¹¹C]desmethyl-WAY-100635 binds to 5-HT_1A receptors and provides a higher radioactive signal than [carbonyl-¹¹C]WAY-100635 in the human brain
Andrée B; Halldin C; Pike VW; Gunn RN; Olsson H; Farde L
Journal article: AMERICAN JOURNAL OF PSYCHIATRY. 2002;159(2):325
Dr. Talvik and Colleagues Reply
TALVIK M; NORDSTRM A-L; NYBERG S; OLSSON H; HALLDIN C; FARDE L
Article: BIOLOGIA FUTURA. 2002;53(1-2):59-66
Autoradiographic evaluation of [¹¹C]vinpocetine binding in the human postmortem brain
Hall H; Varnäs K; Sandell J; Halldin C; Farde L; Vas A; Kárpáti E; Gulyás B
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(1):39-45
PET-examination and metabolite evaluation in monkey of [¹¹C]NAD-299, a radioligand for visualisation of the 5-HT_1A receptor
Sandell J; Halldin C; Chou YH; Swahn CG; Thorberg SO; Farde L
Article: ARCHIVES OF GENERAL PSYCHIATRY. 2002;59(1):25-30
Decreased dopamine D₂ receptor binding in the anterior cingulate cortex in schizophrenia
Suhara T; Okubo Y; Yasuno F; Sudo Y; Inoue M; Ichimiya T; Nakashima Y; Nakayama K; Tanada S; Suzuki K; Halldin C; Farde L
Journal article: NUCLEAR MEDICINE COMMUNICATIONS. 2001;22(11):1215-1221
Reproducibility of [11 C]FLB 457 binding in extrastriatal regions.
Sudo Y; Suhara T; Inoue M; Ito H; Suzuki K; Saijo T; Halldin C; Farde L
Article: NEUROIMAGE. 2001;14(4):936-945
Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - A simulation study based on experimental data
Olsson H; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2001;158(6):926-930
No support for regional selectivity in clozapine-treated patients: A PET study with [¹¹C]raclopride and [¹¹C]FLB 457
Talvik M; Nordström AL; Nyberg S; Olsson H; Halldin C; Farde L
Journal article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2001;44(S1):s170-s172
Radiolabeling, preliminary biological evaluation and pet examination in monkey of 5‐methyl‐6‐nitroquipazine — a potential serotonin transporter radioligand
Sandell J; Yu M; Emond P; Gulyas B; Cselenyi Z; Sovago J; Garreau L; Hall H; Chalon S; Guilloteau D; Någren K; Farde L; Halldin C
Journal article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2001;44(S1):s193-s195
Carbon‐11 labelling of madam in two different positions: A highly selective pet radioligand for the serotonin transporter
Tarkiainen J; Vercouillie J; Guilloteau D; Gulyás B; Sóvágó J; Cselényi Z; Emond P; Chalon S; Sandell J; Hiltunen J; Farde L; Halldin C
Journal article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2001;44(S1):s167-s169
[18F]6FPWAY — a prospective 5‐HT1A receptor radioligand — radiolabeling and pet examination in monkey — comparison with [11C]6FPWAY
Sandell J; Mccarron JA; Halldin C; Pike VW; Gulyas B; Cselenyi Z; Sovago J; Marchais S; Wikström HV; Farde L
Journal article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2001;44(S1):s472-s474
Radioactive metabolites of the 5‐HT1A receptor pet radioligand, [carbonyl‐11C]way‐100635, measured in human plasma samples
Någren K; Halldin C; Pike VW; Allonen T; Hietala J; Swahn C; Andrée B; Farde L; Osman S; Grasby P
Article: NEUROIMAGE. 2001;13(3):531-539
Error analysis for quantification of [¹¹C]FLB 457 binding to extrastriatal D₂ dopamine receptors in the human brain
Ito H; Sudo Y; Suhara T; Okubo Y; Halldin C; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2001;158(2):308-311
Sex differences in extrastriatal dopamine D₂-like receptors in the human brain
Kaasinen V; Någren K; Hietala J; Farde L; Rinne JO
Article: NUCLEAR MEDICINE AND BIOLOGY. 2001;28(2):177-185
New halogenated [¹¹C]WAY analogues, [¹¹C]6FPWAY and [¹¹C]6BPWAY -: Radiosynthesis and assessment as radioligands for the study of brain 5-HT_1A receptors in living monkey
Sandell J; Halldin C; Pike VW; Chou YH; Varnäs K; Hall H; Marchais S; Nowicki B; Wikström HV; Swahn CG; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(1):13-24
SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP
Nobuhara K; Farde L; Halldin C; Karlsson P; Swahn CG; Olsson H; Bergström KA; Larsson SA; Schnell PO; McPherson DW; Savonen A; Hiltunen J; Sedvall G
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2000;38(4):421-431
Autoradiographic localization of 5-HT_2A receptors in the human brain using L³H]M100907 and [¹¹C]M100907
Hall H; Farde L; Halldin C; Lundkvist C; Sedvall G
Article: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(8):707-714
Carbon-11 PB-12:: An attempt to visualize the dopamine D₄ receptor in the primate brain with positron emission tomography
Langer O; Halldin C; Chou YH; Sandell J; Swahn CG; Någren K; Perrone R; Berardi F; Leopoldo M; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2000;38(2):138-143
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study
Chou YH; Halldin C; Farde L
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2000;43(11):1069-1074
Radiochemical labelling of the dopamine D₃ receptor ligand RGH-1756
Langer O; Gulyás B; Sandell J; Laszlovszky I; Kiss B; Domány G; Acs T; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2000;3(3):203-214
A PET study of [¹¹C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain
Farde L; Ginovart N; Halldin C; Chou YH; Olsson H; Swahn CG
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2000;43(10):1033-1046
Synthesis of [¹¹C]2β-carbomethoxy-3β-(3′-iodo-4′-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography
Sandell J; Halldin C; Helfenbein J; Chou YH; Vercouillie J; Emond P; Swahn CG; Guilloteau D; Farde L
Article: NEUROBIOLOGY OF AGING. 2000;21(5):683-688
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain
Kaasinen V; Vilkman H; Hietala J; Någren K; Helenius H; Olsson H; Farde L; Rinne JO
Journal article: BEHAVIOURAL PHARMACOLOGY. 2000;11(3 & 4):345-346
PET STUDIES OF ATYPICAL ANTIPSYCHOTICS
Nordström A; TalvikLotfi M; Olsson H; Nyberg S; Farde L
Article: NEUROLOGY. 2000;54(7):1482-1487
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease
Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2000;157(4):635-637
Age-related cognitive deficits mediated by changes in the striatal dopamine system
Bäckman L; Ginovart N; Dixon RA; Wahlin TBR; Wahlin Å; Halldin C; Farde L
Article: NEUROPSYCHOPHARMACOLOGY. 2000;22(4):422-429
PET-determination of robalzotan (NAD-299) induced 5-HT_1A receptor occupancy in the monkey brain
Farde L; Andrée B; Ginovart N; Halldin C; Thorberg SO
Article: PSYCHOPHARMACOLOGY. 2000;149(1):45-55
Z-IQNP: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer's disease
Nobuhara K; Halldin C; Hall H; Karlsson P; Farde L; Hiltunen J; McPherson DW; Savonen A; Bergström KA; Pauli S; Swahn CG; Larsson SA; Schnell PO; Sedvall G
Article: PSYCHOPHARMACOLOGY. 2000;148(4):400-403
High 5HT_2A receptor occupancy in M100907-treated schizophrenic patients
Talvik-Lotfi M; Nyberg S; Nordström AL; Ito H; Halldin C; Brunner F; Farde L
Article: NEUROIMAGE. 1999;10(6):666-674
PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [¹¹C]FLB 457
Okubo Y; Olsson H; Ito H; Lofti M; Suhara T; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(11):1482-1485
Iodine-123 labelled Z-(R,R)-IQNP:: a potential radioligand for visualization of M₁ and M₂ muscarinic acetylcholine receptors in Alzheimer's disease
Bergström KA; Halldin C; Savonen A; Okubo Y; Hiltunen J; Nobuhara K; Swahn CG; Karlsson P; McPherson D; Knapp FF; Larsson S; Schnell PO; Farde L
Article: JOURNAL OF NEUROIMAGING. 1999;9(4):217-222
Brain uptake and plasma metabolism of [¹¹C]vinpocetine:: A preliminary PET study in a cynomolgus monkey
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöck P; Paróczai M; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 1999;19(10):1164-1173
Quantification of [¹¹C]FLB 457 binding to extrastriatal dopamine receptors in the human brain
Olsson H; Halldin C; Swahn CG; Farde L
Article: PSYCHOPHARMACOLOGY. 1999;146(2):220-227
A PET study of D₁-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain
Chou YH; Karlsson P; Halldin C; Olsson H; Farde L
Article: ORVOSI HETILAP. 1999;140(30):1687-1691
[Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies].
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöczk P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):509-518
Carbon-11 epidepride:: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D₂ receptors
Langer O; Halldin C; Dollé F; Swahn CG; Olsson H; Karlsson P; Hall H; Sandell J; Lundkvist C; Vaufrey F; Loc'h C; Crouzel C; Mazière B; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):501-507
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter
Lundkvist C; Loc'h C; Halldin C; Bottlaender M; Ottaviani M; Coulon C; Fuseau C; Mathis C; Farde L; Mazière B
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):491-499
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter
Helfenbein J; Sandell J; Halldin C; Chalon S; Emond P; Okubo Y; Chou YH; Frangin Y; Douziech L; Gareau L; Swahn CG; Besnard JC; Farde L; Guilloteau D
Article: PSYCHOPHARMACOLOGY. 1999;144(3):303-305
Pindolol binding to 5-HT_1A receptors in the human brain confirmed with positron emission tomography
Andrée B; Thorberg SO; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 1999;2(2):73-82
Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET
Suhara T; Sudo Y; Okauchi T; Maeda J; Kawabe K; Suzuki K; Okubo Y; Nakashima Y; Ito H; Tanada S; Halldin C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(4):343-350
Different brain radioactivity curves in a PET study with [¹¹C]β-CIT labelled in two different positions
Lundkvist C; Halldin C; Swahn CG; Ginovart N; Farde L
Article: MOLECULAR PSYCHIATRY. 1999;4(3):290-296
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers
Jönsson EG; Nöthen MM; Grünhage F; Farde L; Nakashima Y; Propping P; Sedvall GC
Article: NEUROIMAGE. 1999;9(2):235-242
Mapping of central D₂ dopamine receptors in man using [¹¹C]raclopride:: PET with anatomic standardization technique
Ito H; Okubo Y; Halldin C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(2):159-164
Radiosynthesis and autoradiographic evaluation of [¹¹C]NAD-299, a radioligand for visualization of the 5-HT_1A receptor
Sandell J; Halldin C; Hall H; Thorberg SO; Werner T; Sohn D; Sedvall G; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1999;31(2):154-162
Changes in striatal D₂-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates
Ginovart N; Farde L; Halldin C; Swahn CG
Article: JOURNAL OF NUCLEAR MEDICINE. 1999;40(1):102-109
Localization of 5-HT_1A receptors in the living human brain using [carbonyl-¹¹C]WAY-100635:: PET with anatomic standardization technique
Ito H; Halldin C; Farde L
Article: NEUROIMAGE. 1999;9(1):108-116
Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [¹²⁵I]PE2I
Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard JC; Farde L; Sedvall G
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 1998;1(2):95-101
D₂- and 5-HT₂ receptor occupancy in high-dose neuroleptic-treated patients
Nyberg S; Dencker SJ; Malm U; Dahl ML; Svenson JO; Halldin C; Naskashima Y; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(12):2061-2068
Carbon-11-NNC 112:: A radioligand for PET examination of striatal and neocortical D₁-dopamine receptors
Halldin C; Foged C; Chou YH; Karlsson P; Swahn CG; Sandell J; Sedvall G; Farde L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1998;8:s83
Striatai and extrastriatal D2-dopamine receptor occupancy during haloperidol and ciozapine treatment
Farde L; Olsson H; Talvik-Lotfi M; Halldin C
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1998;8:s168
PET determination of robalzotan occupancy of 5-HT1A receptors in the monkey brain
Farde L; Andrée B; Ginovart N; Halldin C; Thorberg S-O
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(11):1965-1971
Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man
Farde L; Ito H; Swahn CG; Pike VW; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 1998;18(9):941-950
Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [¹¹C]raclopride binding
Ito H; Hietala J; Blomqvist G; Halldin C; Farde L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1998;18(4):317-323
Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain
Andrée B; Nyberg S; Ito H; Ginovart N; Brunner F; Jaquet F; Halldin C; Farde L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1998;18(4):305-310
Plasma prolactin and central D₂ receptor occupancy in antipsychotic drug-treated patients
Nordström AL; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(5):503-508
[¹¹C]NNC 22-0215, a metabolically stable dopamine D₁ radioligand for PET
Foged C; Halldin C; Swahn CG; Ginovart N; Karlsson P; Lundkvist C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1998;25(5):531-534
Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu MX; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
Journal article: NEUROIMAGE. 1998;7(4):s291
Distribution of Serotonin Receptor Subtypes in the Post-Mortem Human Brain
Hall H; Halldin C; Farde L; Sedvall GC
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(4):405-409
Toxicity, mutagenicity, and behavioral effects of β-CIT, a ligand for dopamine transporter exploration by SPECT
Emond P; Farde L; Chalon S; Belzung C; Mauclaire V; Chiron JP; Halldin C; Besnard JC; Guilloteau D
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1998;25(4):338-346
[carbonyl-¹¹C]desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT_1A receptors in vitro and in vivo
Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(3):215-223
Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT_1A receptor radioligand, [carbonyl-¹¹C]WAY-100635 -: Explanation of high signal contrast in PET and an aid to biomathematical modelling
Osman S; Lundkvist C; Pike VW; Halldin C; McCarron JA; Swahn CG; Farde L; Ginovart N; Luthra SK; Gunn RN; Bench CJ; Sargent PA; Grasby PM
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(3):209-214
Evaluation and metabolite studies of ¹²⁵I- and ¹²³I-labelled E-(R,R)-IQNP:: Potential radioligands for visualization of M₁ muscarinic acetylcholine receptors in brain
Bergstrom KA; Halldin C; Hiltunen J; Swahn CG; Ito H; Ginovart N; Hall H; McPherson DW; Knapp FFR; Larsson S; Schnell PO; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(1):208-214
PET imaging of central 5-HT_2A receptors with carbon-11-MDL 100,907
Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;25(1):19-23
Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
Hiltunen J; Åkerman KK; Kuikka JT; Bergström KA; Halldin C; Nikula T; Räsänen P; Tiihonen J; Vauhkonen M; Karhu J; Kupila J; Länsimies E; Farde L
Article: BRAIN. 1997;120:2207-2217
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes
Bäckman L; Robins-Wahlin TB; Lundin A; Ginovart N; Farde L
Article: PSYCHOPHARMACOLOGY. 1997;133(4):396-404
A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(10):1261-1267
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET)
Foged C; Halldin C; Loch C; Maziere B; Pauli S; Maziere M; Hansen HC; Suhara T; Swahn CG; Karlsson P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(7):629-634
[I-125]beta-CIT-FE and [I-125]beta-CIT-FP are superior to [I-125]beta-CIT for dopamine transporter visualization: Autoradiographic evaluation in the human brain
Gunther I; Hall H; Halldin C; Swahn CG; Farde L; Sedvall G
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(7):621-627
[F-18]beta-CIT-FP is superior to [C-11]beta-CIT-FP for quantitation of the dopamine transporter
Lundkvist C; Halldin C; Ginovart N; Swahn CG; Farde L
Article: ARCHIVES OF GENERAL PSYCHIATRY. 1997;54(10):953-958
Delayed normalization of central D-2 dopamine receptor availability after discontinuation of haloperidol decanoate - Preliminary findings
Nyberg S; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 1997;133(2):196-202
PET-characterization of [carbonyl-C-11]WAY-100635 binding to 5-HT1A receptors in the primate brain
Farde L; Ginovart N; Ito H; Lundkvist C; Pike VW; McCarron JA; Halldin C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(5):389-393
Autoradiographic comparison of [I-125]epidepride and [I-125]NCQ 298 binding to human brain extrastriated dopamine receptors
Hall H; Halldin C; Jerning E; Osterlund M; Farde L; Sedvall G
Article: PSYCHOPHARMACOLOGY. 1997;131(4):339-345
Central 5-HT2A and D-2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men
Andree B; Halldin C; VrijmoeddeVries M; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(6):596-601
In vitro and in vive characterisation of nor-beta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain
Bergstrom KA; Halldin C; Hall H; Lundkvist C; Ginovart N; Swahn CG; Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1997;25(4):321-325
Effect of reserpine-induced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain
Ginovart N; Farde L; Halldin C; Swahn CG
Article: BRAIN. 1997;120:503-514
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease
Ginovart N; Lundin A; Farde L; Halldin C; Backman L; Swahn CG; Pauli S; Sedvall G
Journal article: DRUG DEVELOPMENT RESEARCH. 1997;40(2):158-170
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
Bymaster FP; Whitesitt CA; Shannon HE; DeLapp N; Ward JS; Calligaro DO; Shipley LA; Buelke‐Sam JL; Bodick NC; Farde L; Sheardown MJ; Olesen PH; Hansen KT; Suzdak PD; Swedberg MDB; Sauerberg P; Mitch CH
Article: DRUG DEVELOPMENT RESEARCH. 1997;40(2):158-170
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
Bymaster FP; Whitesitt CA; Shannon HE; DeLapp N; Ward JS; Calligaro DO; Shipley LA; BuelkeSam JL; Bodick NC; Farde L; Sheardown MJ; Olesen PH; Hansen KT; Suzdak PD; Swedberg MDB; Sauerberg P; Mitch CH
Article: BRAIN RESEARCH. 1997;745(1-2):96-108
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [H-3]WAY-100635 and [C-11]WAY-100635
Hall H; Lundkvist C; Halldin C; Farde L; Pike VW; McCarron JA; Fletcher A; Cliffe IA; Barf T; Wikstrom H; Sedvall G
Article: NEUROPSYCHOPHARMACOLOGY. 1997;16(1):1-7
A PET study of 5-HT2 and D-2 dopamine receptor occupancy induced by olanzapine in healthy subjects
Nyberg S; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 1996;128(3):240-247
Autoradiographic localisation of D-3-dopamine receptors in the human brain using the selective D-3-dopamine receptor agonist (+)-[H-3]PD 128907
Hall H; Halldin C; Dijkstra D; Wikstrom H; Wise LD; Pugsley TA; Sokoloff P; Pauli S; Farde L; Sedvall G
Article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1996;11(6):483-490
Characterization of C-11 or I-123 labelled beta-CIT-FP and beta-CIT-FE metabolism measured in monkey and human plasma. Identification of two labelled metabolites with HPLC
Bergstrom KA; Halldin C; Lundkvist C; Swahn CG; Akerman KK; Kuikka JT; Hiltunen J; Tiihonen J; Lansimies E; Neumeyer JL; Farde L
Article: PSYCHIATRY RESEARCH. 1996;67(3):163-171
Test-retest reliability of central [C-11]raclopride binding at high D-2 receptor occupancy. A PET study in haloperidol-treated patients
Nyberg S; Farde L; Halldin C
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:s4-s8
S.03.02 PET studies on the dopamine system in vivo
Farde L; Ginovart N; Halldin C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(6):837-844
C-11- and Br-76-labelled NNC 22-0010, selective dopamine D-1 receptor radioligands for PET
Foged C; Halldin C; Loch C; Maziere B; Karlsson P; Maziere M; Swahn CG; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(6):813-819
Preparation of [Br-76]FLB 457 and [Br-76]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET
Loch C; Halldin C; Bottlaender M; Swahn CG; Moresco RM; Maziere M; Farde L; Maziere B
Article: DEMENTIA. 1996;7(4):187-195
PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man
Farde L; Suhara T; Halldin C; Nyback H; Nakashima Y; Swahn CG; Karlsson P; Ginovart N; Bymaster FP; Shannon HE; Foged C; Suzdak PD; Sauerberg P
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(5):627-634
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-C-11]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET
Osman S; Lundkvist C; Pike VW; Halldin C; McCarron JA; Swahn CG; Ginovart N; Luthra SK; Bench CJ; Grasby PM; Wikstrom H; Barf T; Cliffe IA; Fletcher A; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1996;23(7):798-803
Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
Kuikka JT; Hiltunen J; Foged C; Bergstrom KA; Halldin C; Akerman K; Tiihonen J; Farde L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:157
S-45-2 Distribution of dopamine receptor subtypes in the post-mortem human brain
Hall H; Hurd YL; Suzuki M; Farde L; Halldin C; Sedvall G
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:130
P-13-2 In vivo examination of the Pre- and postsynaptic dopamine neurons in huntington's disease
Ginovart N; Lundin A; Farde L; Halldin C; Swahn CG; Pauli S; Sedvall G
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:212-213
O-27-9 Reduced D1-dopamine receptor binding in schizophrenia — Relation to psychopathology
Karlsson P; Farde L; Halldin C; Sedvall G
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:212
O-27-5 Autoradiographic localization of 5-HT1A-receptors in the human brain
Hall H; Lundkvist C; Halldin C; Pike VW; McCarron JA; Fletcher A; Cliffe IA; Farde L; Sedvall G
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6:165
S-52-1 Pet-studies on the dopamine system in vivo
Farde L; Ginovart N; Halldin C
Article: TRENDS IN NEUROSCIENCES. 1996;19(6):211-214
The advantage of using positron emission tomography in drug research
Farde L
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1996;23(2):115-123
Autoradiographic localization of extrastriatal D-2-dopamine receptors in the human brain using [I-125]epidepride
Hall H; Farde L; Halldin C; Hurd YL; Pauli S; Sedvall G
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1996;22(4):386-390
[C-11] beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography
Halldin C; Farde L; Lundkvist C; Ginovart N; Nakashima Y; Karlsson P; Swahn CG
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(3):221-227
[C-11]metaraminol, a false neurotransmitter: Preparation, metabolite studies and positron emission tomography examination in monkey
Nagren K; Halldin C; Swahn CG; Suhara T; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(3):201-209
Development of I-123-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding
Foged C; Halldin C; Hiltunen J; Braestrup C; Thomsen C; Hansen HC; Suhara T; Pauli S; Swahn CG; Karlsson P; Larsson S; Farde L
Journal article: SCHIZOPHRENIA RESEARCH. 1996;18(2-3):198
Decrease of D1-dopamine receptor binding in the frontal cortex of neuroleptic naive schizophrenic patients measured by PET
Karlsson P; Farde L; Halldin C; Sedvall G
Journal article: SCHIZOPHRENIA RESEARCH. 1996;18(2-3):199
D2- and 5-HT2 receptor occupancy in “mega-dose” treated schizophrenic patients
Nyberg S; Farde L; Dencker S-J; Malm U; Dahl M-L; Halldin C
Article: ANNALS OF NUCLEAR MEDICINE. 1996;10(1):85-88
Effects of cocaine on [11C]norepinephrine and [11C] beta-CIT uptake in the primate peripheral organs measured by PET.
Suhara T; Farde L; Halldin C; Någren K; Karlsson P
Journal article: EUROPEAN PSYCHIATRY. 1996;11:231s-232s
PET D1-receptor studies in schizophrenia
Karlsson P; Farde L; Halldin C; Sedvall G
Journal article: EUROPEAN PSYCHIATRY. 1996;11:202s
Dopamine and serotonin receptor occupancy in patients treated with antipsychotics
Nordström A-L; Nyberg S; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):1053-1056
PET EXAMINATION OF THE MONKEY HEART WITH HIGH SPECIFIC RADIOACTIVITY [C-11] NOREPINEPHRINE AND [C-11] METARAMINOL
FARDE L; HALLDIN C; NAGREN K; KARLSSON P; SWAHN CG; SUHARA T
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):1045-1048
AN HPLC-METHOD FOR DETERMINATION OF LIGAND METABOLISM DURING PET STUDIES WITH [C-11] METARAMINOL AND [C-11] NOREPINEPHRINE
SWAHN CG; HALLDIN C; NAGREN K; FARDE L
Article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1995;10(4):221-227
CENTRAL D-2 RECEPTOR OCCUPANCY AND EFFECTS OF ZUCLOPENTHIXOL ACETATE IN HUMANS
NYBERG S; FARDE L; BARTFAI A; HALLDIN C
Article: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(10):1444-1449
D-1, D-2, AND 5-HT2 RECEPTOR OCCUPANCY IN RELATION TO CLOZAPINE SERUM CONCENTRATION - A PET STUDY OF SCHIZOPHRENIC-PATIENTS
NORDSTROM AL; FARDE L; NYBERG S; KARLSSON P; HALLDIN C; SEDVALL G
Article: PSYCHOPHARMACOLOGY. 1995;121(3):309-316
LACK OF APPARENT ANTIPSYCHOTIC EFFECT OF THE D-1-DOPAMINE RECEPTOR ANTAGONIST SCH39166 IN ACUTELY ILL SCHIZOPHRENIC-PATIENTS
KARLSSON P; SMITH L; FARDE L; HARNRYD C; SEDVALL G; WIESEL FA
Article: PSYCHOPHARMACOLOGY. 1995;121(3):300-308
EVALUATION OF SCH-39166 AS PET LIGAND FOR CENTRAL D-1 DOPAMINE-RECEPTOR BINDING AND OCCUPANCY IN MAN
KARLSSON P; SEDVALL G; HALLDIN C; SWAHN CG; FARDE L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(7):905-913
[O-METHYL-C-11]BETA-CIT-FP, A POTENTIAL RADIOLIGAND FOR QUANTITATION OF THE DOPAMINE TRANSPORTER - PREPARATION, AUTORADIOGRAPHY, METABOLITE STUDIES, AND POSITRON EMISSION TOMOGRAPHY EXAMINATIONS
LUNDKVIST C; HALLDIN C; SWAHN CG; HALL H; KARLSSON P; NAKASHIMA Y; WANG SY; MILIUS RA; NEUMEYER JL; FARDE L
Article: LANCET. 1995;346(8977):743-749
CHEMICAL BRAIN ANATOMY IN SCHIZOPHRENIA
SEDVALL G; FARDE L
Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1995;10:81-86
Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man
Nyberg S; Nordström A-L; Halldin C; Farde L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5(3):346
P-4-61 Autoradiographic comparison of D2- and D3-dopamine receptor localization in the post mortem human brain using [125I]epidepride and [3H]PD 128907
Hall H; Halldin C; Suzuki M; Dijkstra D; Wikström H; Wise LD; Pugsley TA; Hurd Y; Farde L; Pauli S; Sedvall G
Article: PSYCHIATRY RESEARCH. 1995;61(2):67-83
NO ELEVATED D-2 DOPAMINE-RECEPTORS IN NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS REVEALED BY POSITRON EMISSION TOMOGRAPHY AND [C-11] N-METHYLSPIPERONE
NORDSTROM AL; FARDE L; ERIKSSON L; HALLDIN C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(6):711-717
SYNTHESIS AND BINDING-PROPERTIES OF [H-3]NNC-12-0781, A NEW RADIOLIGAND FOR THE DOPAMINE REUPTAKE SYSTEM
MULLER L; HALL H; HALLDIN C; FARDE L; HOHLWEG R; SUZDAK PD; NIELSEN EB; FOGED C
Article: JOURNAL OF NUCLEAR MEDICINE. 1995;36(7):1275-1281
CARBON-11-FLB-457 - A RADIOLIGAND FOR EXTRASTRIATAL D2 DOPAMINE-RECEPTORS
HALLDIN C; FARDE L; HOGBERG T; MOHELL N; HALL H; SUHARA T; KARLSSON P; NAKASHIMA Y; SWAHN CG
Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1995;20(3):200-208
VARIABILITY IN D-2-DOPAMINE RECEPTOR DENSITY AND AFFINITY - A PET STUDY WITH [C-11] RACLOPRIDE IN MAN
FARDE L; HALL H; PAULI S; HALLDIN C
Article: PSYCHOPHARMACOLOGY. 1995;119(1):1-8
ORAL-ADMINISTRATION OF NNC-756 - A PLACEBO-CONTROLLED PET STUDY OF D-1-DOPAMINE RECEPTOR OCCUPANCY AND PHARMACODYNAMICS IN MAN
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G; YNDDAL L; SLOTHNIELSEN M
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1995;36(4):385-392
SYNTHESIS OF 2-BETA-CARBOMETHOXY-3-BETA-(4-[BR-76]BROMOPHENYL)TROPANE ([BR-76]BETA-CBT), A PET TRACER FOR IN-VIVO IMAGING OF THE DOPAMINE UPTAKE SITES
LOCH C; MULLER L; OTTAVIANI M; HALLDIN C; FARDE L; MAZIERE B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5(1):19-25
EFFECT OF CLOZAPINE AND RISPERIDONE ON 5-HT2 AND D-2-DOPAMINE RECEPTOR-BINDING IN THE POSTMORTEM HUMAN BRAIN - AN AUTORADIOGRAPHIC STUDY
HALL H; HALLDIN C; NYBERG S; FARDE L; SEDVALL G
Journal article: PHARMACOLOGICAL RESEARCH. 1995;31:29
Extra-striatal dopamine receptors studied with [125I]epideprideIn VITRO and [[11C]FLB 457in vivo
Hall H; Farde L; Halldin C; Nyberg S; Mohell N; Jackson D; Sedvall G
Article: ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES. 1995;32(1):22-29
RECENT DEVELOPMENTS IN PET SCAN IMAGING OF NEURORECEPTORS IN SCHIZOPHRENIA
SEDVALL G; PAULI S; FARDE L; KARLSSON P; NYBERG S; NORDSTROM AL
Article: CLINICAL NEUROSCIENCE. 1995;3(2):112-121
UTILIZATION OF RADIOLIGANDS IN SCHIZOPHRENIA RESEARCH
SEDVALL G; FARDE L; HALL H; HALLDIN C; KARLSSON P; NORDSTROM AL; NYBERG S; PAULI S
Journal article: NEUROPSYCHOPHARMACOLOGY. 1994;11(4):245-256
DISTRIBUTION OF D-1-DOPAMINE AND D-2-DOPAMINE RECEPTORS, AND DOPAMINE AND ITS METABOLITES IN THE HUMAN BRAIN
HALL H; SEDVALL G; MAGNUSSON O; KOPP J; HALLDIN C; FARDE L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1994;4(3):221-223
D2 and 5-HT2 receptor occupancy in antipsychotic drug treated patients
Farde L; Nordström A; Nyberg S; Halldin C
Journal article: JOURNAL OF CLINICAL PSYCHIATRY. 1994;55(9):67-69
D1-RECEPTOR, D2-RECEPTOR AND 5-HT(2)-RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS
FARDE L; NORDSTROM AL; NYBERG S; HALLDIN C; SEDVALL G
Journal article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1994;21(7):695-696
[C-11] NNC-12-0722 OR [F-18] GBR-13119 - JUST WHAT IS BETTER - REPLY
MULLER L; HALLDIN C; FARDE L
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 1994;21(4):627-631
FLUORINE-18-LABELED NCQ-115, A SELECTIVE DOPAMINE D-2 RECEPTOR-LIGAND - PREPARATION AND POSITRON EMISSION TOMOGRAPHY
HALLDIN C; HOGBERG T; FARDE L
Journal article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1994;21(4):345-347
POSITRON EMISSION TOMOGRAPHY SHOWS HIGH SPECIFIC UPTAKE OF RACEMIC C-11 LABELED NOREPINEPHRINE IN THE PRIMATE HEART
FARDE L; HALLDIN C; NAGREN K; SUHARA T; KARLSSON P; SCHOEPS KO; SWAHN CG; BONE D
Journal article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1994;21(4):345-347
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart
Farde L; Halldin C; Någren K; Suhara T; Karlsson P; Schoeps K-O; Swahn C-G; Bone D
Journal article: APPLIED RADIATION AND ISOTOPES. 1994;45(4):515-521
SELECTIVE SYNTHESIS OF RACEMIC 1-C-11-LABELED NOREPINEPHRINE, OCTOPAMINE, NORPHENYLEPHRINE AND PHENYLETHANOLAMINE USING [C-11] NITROMETHANE
NAGREN K; SCHOEPS KO; HALLDIN C; SWAHN CG; FARDE L
Journal article: PSYCHOPHARMACOLOGY. 1994;114(2):248-256
INFLUENCE OF RATE OF ADMINISTRATION OF RACLOPRIDE ON AKATHISIA AND PROLACTIN RESPONSE
MOVINOSSWALD G; KARLSSON P; HAMMARLUNDUDENAES M; FARDE L
Journal article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1994;16(2):93-103
PET STUDY OF [C-11] BETA-CIT BINDING TO MONOAMINE TRANSPORTERS IN THE MONKEY AND HUMAN BRAIN
FARDE L; HALLDIN C; MULLER L; SUHARA T; KARLSSON P; HALL H
Journal article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1994;21(2):131-137
PREPARATION OF A POTENTIAL POSITRON EMISSION TOMOGRAPHIC RADIOLIGAND FOR THE DOPAMINE TRANSPORTER
MULLER L; HALLDIN C; FOGED C; KARLSSON P; HALL H; SWAHN CG; SUZDAK PD; HOHLWEG R; NIELSEN EB; FARDE L
Journal article: PSYCHOPHARMACOLOGY. 1994;114(1):31-38
AN OPEN CLINICAL AND BIOCHEMICAL-STUDY OF RITANSERIN IN ACUTE PATIENTS WITH SCHIZOPHRENIA
WIESEL FA; NORDSTROM AL; FARDE L; ERIKSSON B
Journal article: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. 1994;243(5):249-255
DOPAMINE D-1 RECEPTOR NUMBER - A SENSITIVE PET MARKER FOR EARLY BRAIN DEGENERATION IN HUNTINGTONS-DISEASE
SEDVALL G; KARLSSON P; LUNDIN A; ANVRET M; SUHARA T; HALLDIN C; FARDE L
Journal article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1994;9(1):25-31
METABOLISM OF THE PET LIGAND [C-11] SCH-23390 - IDENTIFICATION OF 2 RADIOLABELED METABOLITES WITH HPLC
SWAHN CG; HALLDIN C; FARDE L; SEDVALL G
Journal article: EXS. 1994;71:143-153
PET-DETERMINATION OF BENZODIAZEPINE RECEPTOR-BINDING IN STUDIES ON ALCOHOLISM
FARDE L; PAULI S; LITTON JE; HALLDIN C; NEIMAN J; SEDVALL G
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 1993;20(8):945-953
[C-11] NNC-687 AND [C-11] NNC-756, DOPAMINE D-1 RECEPTOR LIGANDS - PREPARATION, AUTORADIOGRAPHY AND PET INVESTIGATION IN MONKEY
HALLDIN C; FOGED C; FARDE L; KARLSSON P; HANSEN K; GRONVALD F; SWAHN CG; HALL H; SEDVALL G
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 1993;20(5):669-678
PREPARATION OF [1-C-11]DOPAMINE, [1-C-11]P-TYRAMINE AND [1-C-11]M-TYRAMINE - AUTORADIOGRAPHY AND PET EXAMINATION OF [1-C-11]DOPAMINE IN PRIMATES
SCHOEPS KO; HALLDIN C; NAGREN K; SWAHN CG; KARLSSON P; HALL H; FARDE L
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 1993;20(3):249-255
[C-11] BETA-CIT, A COCAINE ANALOG - PREPARATION, AUTORADIOGRAPHY AND PRELIMINARY PET INVESTIGATIONS
MULLER L; HALLDIN C; FARDE L; KARLSSON P; HALL H; SWAHN CG; NEUMEYER J; GAO YG; MILIUS R
Journal article: PSYCHIATRY RESEARCH. 1993;50(1):1-13
PET ANALYSIS OF [C-11] FLUMAZENIL BINDING TO BENZODIAZEPINE RECEPTORS IN CHRONIC ALCOHOL-DEPENDENT MEN AND HEALTHY CONTROLS
LITTON JE; NEIMAN J; PAULI S; FARDE L; HINDMARSH T; HALLDIN C; SEDVALL G
Journal article: BIOLOGICAL PSYCHIATRY. 1993;33(4):227-235
CENTRAL D2-DOPAMINE RECEPTOR OCCUPANCY IN RELATION TO ANTIPSYCHOTIC DRUG EFFECTS - A DOUBLE-BLIND PET STUDY OF SCHIZOPHRENIC-PATIENTS
NORDSTROM AL; FARDE L; WIESEL FA; FORSLUND K; PAULI S; HALLDIN C; UPPFELDT G
Journal article: PSYCHOPHARMACOLOGY. 1993;110(3):265-272
5-HT(2) AND D(2) DOPAMINE RECEPTOR OCCUPANCY IN THE LIVING HUMAN BRAIN - A PET STUDY WITH RISPERIDONE
NYBERG S; FARDE L; ERIKSSON L; HALLDIN C; ERIKSSON B
Journal article: PSYCHOPHARMACOLOGY. 1993;111(1):27-32
INTERACTION STUDY BETWEEN REMOXIPRIDE AND BIPERIDEN
YISAK W; FARDE L; VONBAHR C; NILSSON LB; FREDRIKSSON G; OGENSTAD S
Journal article: PSYCHOPHARMACOLOGY. 1993;113(2):149-156
PET EXAMINATION OF [C-11] NNC-687 AND [C-11] NNC-756 AS NEW RADIOLIGANDS FOR THE D-1-DOPAMINE RECEPTOR
KARLSSON P; FARDE L; HALLDIN C; SWAHN CG; SEDVALL G; FOGED C; HANSEN KT; SKRUMSAGER B
Journal article: PSYCHOPHARMACOLOGY. 1993;110(3):365-367
HIGH 5-HT(2) RECEPTOR OCCUPANCY IN CLOZAPINE TREATED PATIENTS DEMONSTRATED BY PET
NORDSTROM AL; FARDE L; HALLDIN C
Journal article: PSYCHOPHARMACOLOGY SERIES. 1993;10:94-100
PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs.
Farde L; Nordström AL
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1992;49(7):538-544
POSITRON EMISSION TOMOGRAPHIC ANALYSIS OF CENTRAL D1-DOPAMINE AND D2-DOPAMINE RECEPTOR OCCUPANCY IN PATIENTS TREATED WITH CLASSICAL NEUROLEPTICS AND CLOZAPINE - RELATION TO EXTRAPYRAMIDAL SIDE-EFFECTS
FARDE L; NORDSTROM AL; WIESEL FA; PAULI S; HALLDIN C; SEDVALL G
Journal article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1992;7(3):157-165
PET ANALYSIS OF CENTRAL [C-11] RACLOPRIDE BINDING IN HEALTHY-YOUNG ADULTS AND SCHIZOPHRENIC-PATIENTS - RELIABILITY AND AGE EFFECTS
NORDSTROM AL; FARDE L; PAULI S; LITTON JE; HALLDIN C
Journal article: BRITISH JOURNAL OF PSYCHIATRY. 1992;160(17):30-33
PET ANALYSIS INDICATES ATYPICAL CENTRAL DOPAMINE RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS
FARDE L; NORDSTROM AL
Journal article: BEHAVIOURAL PHARMACOLOGY. 1992;3(Supplement):21
PET SCANNING OF DOPAMINE RECEPTORS AND PSYCHOSIS
G S; L F; A-L N
Journal article: NEUROCHEMISTRY INTERNATIONAL. 1992;20:329S-333S
IMAGING OF DOPAMINE-RECEPTORS USING PET AND SPECT
HALL H; FARDE L; HALLDIN C; HOGBERG T; LARSSON S; SEDVALL G
Journal article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1992;7(2):97-103
LIGAND METABOLITES IN PLASMA DURING PET-STUDIES WITH THE C-11 LABELED DOPAMINE ANTAGONISTS, RACLOPRIDE, SCH 23390 AND N-METHYLSPIROPERIDOL
SWAHN CG; FARDE L; HALLDIN C; SEDVALL G
Journal article: CLINICAL PHARMACOKINETICS. 1992;22(2):152-161
Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.
Movin-Osswald G; Nordström AL; Hammarlund-Udenaes M; Wahlén A; Farde L
Journal article: ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH. 1992;42-1(2A):260-264
POSITRON EMISSION TOMOGRAPHY - EXAMINATION OF CHEMICAL TRANSMISSION IN THE LIVING HUMAN BRAIN - DEVELOPMENT OF RADIOLIGANDS
FARDE L; HALL H
Journal article: CLINICAL NEUROPHARMACOLOGY. 1992;15 Suppl 1 Pt A:466A-467A
Ligand selection for PET studies of D1 dopamine receptors. Relationship between distribution of binding sites and mRNA for DAARPP32 in the human brain.
Sedvall CG; Farde L; Hall H; Halldin C; Karlsson P; Brene S; Lindefors N; Persson H; Chipkin RE; Ehrlich M
Journal article: CLINICAL NEUROPHARMACOLOGY. 1992;15(Part B):29b
PET AND AUTORADIOGRAPHY OF BENZODIAZEPINE RECEPTOR BINDING WITH RADIOLABELLED FLUMAZENIL AND RO 15-4513.
Hall H; Farde L; Litton JE; Halldin C; Sedvall G
Journal article: PSYCHOPHARMACOLOGY. 1992;106(4):433-438
TIME COURSE OF D2-DOPAMINE RECEPTOR OCCUPANCY EXAMINED BY PET AFTER SINGLE ORAL DOSES OF HALOPERIDOL
NORDSTROM AL; FARDE L; HALLDIN C
Journal article: CLINICAL NEUROPHARMACOLOGY. 1992;15 Suppl 1 Pt A:468A-469A
PET studies of dopamine receptors in relation to antipsychotic drug treatment.
Farde L; Nordström AL; Halldin C; Wiesel FA; Sedvall G
Journal article: PSYCHOPHARMACOLOGY. 1992;108(1-2):16-22
[C-11] RO 15-4513, A LIGAND FOR VISUALIZATION OF BENZODIAZEPINE RECEPTOR-BINDING - PREPARATION, AUTORADIOGRAPHY AND POSITRON EMISSION TOMOGRAPHY
HALLDIN C; FARDE L; LITTON JE; HALL H; SEDVALL G
Journal article: PSYCHOPHARMACOLOGY. 1992;107(2-3):180-185
PET ANALYSIS OF ALCOHOL INTERACTION WITH THE BRAIN DISPOSITION OF [C-11] FLUMAZENIL
PAULI S; LILJEQUIST S; FARDE L; SWAHN CG; HALLDIN C; LITTON JE; SEDVALL G
Journal article: PSYCHOPHARMACOLOGY. 1992;107(1):23-29
SELECTIVE D1-DOPAMINE AND D2-DOPAMINE RECEPTOR BLOCKADE BOTH INDUCES AKATHISIA IN HUMANS - A PET STUDY WITH [C-11] SCH-23390 AND [C-11] RACLOPRIDE
FARDE L
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1991;1(3):221-223
PET studies of D1 and D2 dopamine receptors in drug naive schizophrenic patients
Sedval GC; Farde L; Karlsson P; Nordström A-L; Chipkin RE
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1991;1(3):229-231
Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET
Pauli S; Farde L; Halldin C; Sedvall G
Journal article: ACTA RADIOLOGICA, SUPPLEMENT. 1991;376:126-127
Kinetic analysis of receptor binding with positron emission tomography.
Eriksson L; Farde L; Rosenquist G
Journal article: PSYCHOPHARMACOLOGY. 1991;103(1):6-18
NCQ 298, A NEW SELECTIVE IODINATED SALICYLAMIDE LIGAND FOR THE LABELING OF DOPAMINE-D2 RECEPTORS
HALL H; HOGBERG T; HALLDIN C; KOHLER C; STROM P; ROSS SB; LARSSON SA; FARDE L
Journal article: INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION.. 1991;18(8):871-881
A COMPARATIVE PET-STUDY OF 5 C-11 OR F-18 LABELED SALICYLAMIDES - PREPARATION AND INVITRO DOPAMINE D-2 RECEPTOR-BINDING
HALLDIN C; FARDE L; HOGBERG T; HALL H; STROM P; OHLBERGER A; SOLIN O
Journal article: PSYCHOPHARMACOLOGY. 1991;103(2):150-153
C-11 SCH 39166, A SELECTIVE LIGAND FOR VISUALIZATION OF DOPAMINE-D1 RECEPTOR-BINDING IN THE MONKEY BRAIN USING PET
SEDVALL G; FARDE L; BARNETT A; HALL H; HALLDIN C
Journal article: ACTA RADIOLOGICA, SUPPLEMENT. 1991;376:121-122
Synthesis of five benzamide analogs. Comparison with positron emission tomography.
Halldin C; Farde L; Hall H; Högberg T; Printz G; Pulka W; Sedvall G; Solin O
Journal article: INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART A, APPLIED RADIATION AND ISOTOPES. 1991;42(5):451-455
SYNTHESIS OF C-11 LABELED SCH-39166, A NEW SELECTIVE DOPAMINE D-1 RECEPTOR LIGAND, AND PRELIMINARY PET INVESTIGATIONS
HALLDIN C; FARDE L; BARNETT A; SEDVALL G
Journal article: JOURNAL OF NEUROCHEMISTRY. 1990;55(6):2048-2057
COMPARISON OF THE INVITRO RECEPTOR-BINDING PROPERTIES OF N-[H-3]METHYLSPIPERONE AND [H-3] RACLOPRIDE TO RAT AND HUMAN BRAIN MEMBRANES
HALL H; WEDEL I; HALLDIN C; KOPP J; FARDE L
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1990;47(3):213-219
D2 DOPAMINE-RECEPTORS IN NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS - A POSITRON EMISSION TOMOGRAPHY STUDY WITH [C-11]RACLOPRIDE
FARDE L; WIESEL FA; STONEELANDER S; HALLDIN C; NORDSTROM AL; HALL H; SEDVALL G
Journal article: ACTA PHARMACEUTICA NORDICA. 1990;2(1):53-60
SYNTHESES OF [I-123]-(S)-3-IODO-5,6-DIMETHOXY-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]SALICYLAMIDE, [I-125]-(S)-3-IODO-5,6-DIMETHOXY-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]SALICYLAMIDE AND UNLABELED (S)-3-IODO-5,6-DIMETHOXY-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]SALICYLAMIDE (NCQ-298), SELECTIVE LIGANDS FOR THE STUDY OF DOPAMINE D-2 RECEPTORS
HOGBERG T; STROM P; HALL H; KOHLER C; HALLDIN C; FARDE L
Journal article: APPLIED RADIATION AND ISOTOPES. 1990;41(7):669-674
C-11 LABELING OF ETICLOPRIDE IN 2 DIFFERENT POSITIONS - A SELECTIVE HIGH-AFFINITY LIGAND FOR THE STUDY OF DOPAMINE D-2 RECEPTORS USING PET
HALLDIN C; FARDE L; HOGBERG T; HALL H; SEDVALL G
Journal article: SCHIZOPHRENIA RESEARCH. 1990;3(1):51-52
D1- and D2-dopamine receptor occupancy during treatment with classical and atypical neurpleptics
Farde L; Nordstrom A-L; Wiesel F-A; Halldin C; Sedvall G
Journal article: INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART A, APPLIED RADIATION AND ISOTOPES. 1990;41(7):669-674
Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET.
Halldin C; Farde L; Högberg T; Hall H; Sedvall G
Journal article: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 1990;14(5):759-767
CENTRAL D1-RECEPTOR AND D2-RECEPTOR OCCUPANCY DURING ANTIPSYCHOTIC DRUG-TREATMENT
WIESEL FA; FARDE L; NORDSTROM AL; SEDVALL G
Journal article: ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT. 1990;82:67-71
DISTRIBUTION OF REMOXIPRIDE TO THE HUMAN BRAIN AND CENTRAL D2-DOPAMINE RECEPTOR-BINDING EXAMINED INVIVO BY PET
FARDE L; VONBAHR C
Journal article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1990;16(4-6):257-265
MAPS OF RECEPTOR-BINDING PARAMETERS IN THE HUMAN BRAIN - A KINETIC-ANALYSIS OF PET MEASUREMENTS
BLOMQVIST G; PAULI S; FARDE L; ERIKSSON L; PERSSON A; HALLDIN C
Journal article: ACTA RADIOLOGICA, SUPPLEMENT. 1990;374:113-115
Recent advances in psychiatric brain imaging.
Sedvall G; Farde L; Nybäck H; Pauli S; Persson A; Savic I; Wiesel FA
Journal article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 1989;9(5):696-708
KINETIC-ANALYSIS OF CENTRAL [C-11] RACLOPRIDE BINDING TO D2-DOPAMINE RECEPTORS STUDIED BY PET - A COMPARISON TO THE EQUILIBRIUM-ANALYSIS
FARDE L; ERIKSSON L; BLOMQUIST G; HALLDIN C
Journal article: PSYCHIATRIC ANNALS. 1989;19(10):530-535
PET STUDIES OF PATIENTS TREATED WITH ANTIPSYCHOTIC-DRUGS
FARDE L
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1989;46(5):483-484
DOPAMINE RECEPTOR OCCUPANCY AND PLASMA HALOPERIDOL LEVELS - REPLY
FARDE L; WIESEL FA; HALLDIN C; SEDVALL G; NILSSON L
Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1989;4(2):115-126
THE NEW SELECTIVE D2-DOPAMINE RECEPTOR ANTAGONIST RACLOPRIDE - PHARMACOKINETICS, SAFETY AND TOLERABILITY IN HEALTHY-MALES
FARDE L; VONBAHR C; WAHLEN A; NILSSON L; WIDMAN M
Journal article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1989;4(1):21-31
Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography
Persson A; Pauli S; Halldin C; Stone‐Elander S; Farde L; Sjögren I; Sedvall G
Journal article: PSYCHOPHARMACOLOGY SERIES. 1989;7:32-39
The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.
Farde L; Wiesel FA; Nilsson L; Sedvall G
Journal article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1989;26(1‐12):338-339
Synthesis of [ethyl‐18F]fluororaclopride for the in vivo study of dopamine D2 receptors using PET
Halldin C; Högberg T; Stone‐Elander S; Farde L; Hall H; Printz G; Solin O; Sedvall G
Journal article: ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT. 1989;352:30-34
Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET.
Wiesel FA; Farde L; Halldin C
Journal article: PSYCHOPHARMACOLOGY. 1989;99:S28-S31
D1-DOPAMINE AND D2-DOPAMINE RECEPTOR OCCUPANCY DURING TREATMENT WITH CONVENTIONAL AND ATYPICAL NEUROLEPTICS
FARDE L; WIESEL FA; NORDSTROM AL; SEDVALL G
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1988;45(6):599-600
BRAIN DOPAMINE-RECEPTORS IN SCHIZOPHRENIA - PET PROBLEMS - REPLY
FARDE L; SEDVALL G; WIESEL FA; HALL H; HALLDIN C; STONEELANDER S
Journal article: PSYCHOPHARMACOLOGY. 1988;94(4):471-478
STEREOSELECTIVE BINDING OF 11C-RACLOPRIDE IN LIVING HUMAN-BRAIN - A SEARCH FOR EXTRASTRIATAL CENTRAL D2-DOPAMINE RECEPTORS BY PET
FARDE L; PAULI S; HALL H; ERIKSSON L; HALLDIN C; HOGBERG T; NILSSON L; SJOGREN I; STONEELANDER S
Journal article: NORDIC JOURNAL OF PSYCHIATRY. 1988;42(2):107-110
The application of positron emission tomography in psychiatry
Wiesel F-A; Farde L; Sedvall G; Wik G
Journal article: SCHIZOPHRENIA BULLETIN. 1988;14(3):471-484
WORKSHOP ON SCHIZOPHRENIA, PET, AND DOPAMINE D2 RECEPTORS IN THE HUMAN NEOSTRIATUM
ANDREASEN NC; CARSON R; DIKSIC M; EVANS A; FARDE L; GJEDDE A; HAKIM A; LAL S; NAIR N; SEDVALL G; TUNE L; WONG D
Journal article: JOURNAL OF NEURAL TRANSMISSION. 1988;73(1):7-21
HUMAN DOPAMINE RECEPTOR SUBTYPES - INVITRO BINDING ANALYSIS USING H-3 SCH 23390 AND H-3 RACLOPRIDE
HALL H; FARDE L; SEDVALL G
Journal article: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 1988;12(5):559-&
RACLOPRIDE, A NEW SELECTIVE LIGAND FOR THE DOPAMINE-D2 RECEPTORS
HALL H; KOHLER C; GAWELL L; FARDE L; SEDVALL G
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1988;45(1):71-76
CENTRAL D2-DOPAMINE RECEPTOR OCCUPANCY IN SCHIZOPHRENIC-PATIENTS TREATED WITH ANTIPSYCHOTIC-DRUGS
FARDE L; WIESEL FA; HALLDIN C; SEDVALL G
Journal article: PSYCHOPHARMACOLOGY. 1988;94(1):1-7
AN OPEN LABEL TRIAL OF RACLOPRIDE IN ACUTE SCHIZOPHRENIA - CONFIRMATION OF D2-DOPAMINE RECEPTOR OCCUPANCY BY PET
FARDE L; WIESEL FA; JANSSON P; UPPFELDT G; WAHLEN A; SEDVALL G
Journal article: PSYCHOPHARMACOLOGY. 1988;95(2):157-161
REMOXIPRIDE - A NEW POTENTIAL ANTIPSYCHOTIC DRUG - PHARMACOLOGICAL EFFECTS AND PHARMACOKINETICS FOLLOWING REPEATED ORAL-ADMINISTRATION IN MALE-VOLUNTEERS
FARDE L; GRIND M; NILSSON MI; OGENSTAD S; SEDVALL G
Journal article: PSYCHOPHARMACOLOGY SERIES. 1988;5:27-33
PET scanning--a new tool in clinical psychopharmacology.
Sedvall G; Farde L; Hall H; Pauli S; Persson A; Wiesel FA
Journal article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 1987;50(12):1655-1664
MUSCLE BIOPSY FINDINGS, CONDUCTION-VELOCITY AND REFRACTORY PERIOD OF SINGLE MOTOR-NERVE FIBERS IN SCHIZOPHRENIA
BORG J; EDSTROM L; BJERKENSTEDT L; WIESEL FA; FARDE L; HAGENFELDT L
Journal article: ANNALS OF NEUROLOGY. 1987;22(4):457-468
TRANSPLANTATION IN PARKINSONS-DISEASE - 2 CASES OF ADRENAL-MEDULLARY GRAFTS TO THE PUTAMEN
LINDVALL O; BACKLUND EO; FARDE L; SEDVALL G; FREEDMAN R; HOFFER B; NOBIN A; SEIGER A; OLSON L
Journal article: LIFE SCIENCES. 1987;41(7):813-816
QUANTITATIVE-DETERMINATION OF D2 DOPAMINE RECEPTOR CHARACTERISTICS IN HEALTHY-HUMAN SUBJECTS AND PSYCHIATRIC-PATIENTS
SEDVALL G; FARDE L; WIESEL FA
Journal article: JOURNAL OF MEDICAL SYSTEMS. 1987;11(4):277-286
Use of graphical techniques for error evaluation.
Maguire GQ; Jaeger J; Farde L; Noz ME
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1987;44(7):671-672
NO D2-RECEPTOR INCREASE IN PET STUDY OF SCHIZOPHRENIA
FARDE L; WIESEL FA; HALL H; HALLDIN C; STONEELANDER S; SEDVALL G
Journal article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1987;2(1):23-30
Stereoselective binding of 11C‐labelled piquindone (Ro 22–1319) to dopamine‐D2 receptors in the living human brain
Sedvall G; Ehrin E; Farde L
Journal article: PSYCHOPHARMACOLOGY. 1987;92(3):278-284
PET ANALYSIS OF HUMAN DOPAMINE RECEPTOR SUBTYPES USING C-11 SCH 23390 AND C-11 RACLOPRIDE
FARDE L; HALLDIN C; STONEELANDER S; SEDVALL G
Journal article: JOURNAL OF NEURAL TRANSMISSION, SUPPLEMENT. 1987;24:43-48
NEUROTRANSMITTER RECEPTOR IMAGING IN ALZHEIMERS-DISEASE
SEDVALL G; NYBACK H; FARDE L; PERSSON A
Journal article: ARCHIVES OF GENERAL PSYCHIATRY. 1986;43(10):995-1005
IMAGING OF NEUROTRANSMITTER RECEPTORS IN THE LIVING HUMAN-BRAIN
SEDVALL G; FARDE L; PERSSON A; WIESEL FA
Journal article: SCIENCE. 1986;231(4735):258-261
QUANTITATIVE-ANALYSIS OF D2 DOPAMINE RECEPTOR-BINDING IN THE LIVING HUMAN-BRAIN BY PET
FARDE L; HALL H; EHRIN E; SEDVALL G
Journal article: PHARMACOPSYCHIATRY. 1986;19(1):2-3
CENTRAL BENZODIAZEPINE RECEPTOR-BINDING STUDIED WITH 11-C LABELED RO-15-1788 AND POSITRON EMISSION TOMOGRAPHY
MINDUS P; EHRIN E; ERICSSON L; FARDE L; HEDSTROM CG; LITTON J; PERSSON A; SEDVALL G
Journal article: INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART A, APPLIED RADIATION AND ISOTOPES. 1986;37(10):1039-1043
PREPARATION OF C-11 LABELED SCH 23390 FOR THE INVIVO STUDY OF DOPAMINE-D-1 RECEPTORS USING POSITRON EMISSION TOMOGRAPHY
HALLDIN C; STONEELANDER S; FARDE L; EHRIN E; FASTH KJ; LANGSTROM B; SEDVALL G
Journal article: CLINICAL NEUROPHARMACOLOGY. 1986;9:137-139
IMAGING OF D1 AND D2 DOPAMINE RECEPTOR-BINDING IN THE LIVING HUMAN-BRAIN BY PET
SEDVALL G; FARDE L; STONEELANDER S
Journal article: ACTA RADIOLOGICA, SUPPLEMENT. 1986;369:449-452
Applications of a computerized adjustable brain atlas in positron emission tomography.
Bohm C; Greitz T; Blomqvist G; Farde L; Forsgren PO; Kingsley D; Sjögren I; Wiesel F; Wik G
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1985;82(11):3863-3867
SUBSTITUTED BENZAMIDES AS LIGANDS FOR VISUALIZATION OF DOPAMINE RECEPTOR-BINDING IN THE HUMAN-BRAIN BY POSITRON EMISSION TOMOGRAPHY
FARDE L; EHRIN E; ERIKSSON L; GREITZ T; HALL H; HEDSTROM CG; LITTON JE; SEDVALL G
Journal article: INTERNATIONAL JOURNAL OF APPLIED RADIATION AND ISOTOPES. 1985;36(4):269-273
PREPARATION OF C-11-LABELLED RACLOPRIDE, A NEW POTENT DOPAMINE RECEPTOR ANTAGONIST - PRELIMINARY PET STUDIES OF CEREBRAL DOPAMINE-RECEPTORS IN THE MONKEY
EHRIN E; FARDE L; DEPAULIS T; ERIKSSON L; GREITZ T; JOHNSTROM P; LITTON JE; NILSSON JLG; SEDVALL G; STONEELANDER S; OGREN SO
Journal article: JOURNAL OF PSYCHIATRIC RESEARCH. 1985;19(4):609-622
IMAGING OF [C-11]-LABELED RO 15-1788 BINDING TO BENZODIAZEPINE RECEPTORS IN THE HUMAN-BRAIN BY POSITRON EMISSION TOMOGRAPHY
PERSSON A; EHRIN E; ERIKSSON L; FARDE L; HEDSTROM CG; LITTON JE; MINDUS P; SEDVALL G
Journal article: CLINICAL NEUROPHARMACOLOGY. 1984;7:s295
STUDIES OF SCHIZOPHRENIA WITH POSITRON CT.
Widén L; Blomqvist G; DePaulis T; Ehrin E; Eriksson L; Farde L; Greitz T; Hedström CG; Ingvar DH; Litton JE; Nilsson JL; Ögren SO; Sedvall G; Stone-Slander S; Wiesel F-A; Wik G
Journal article: ACTA PHARMACEUTICA SUECICA. 1984;21(3):183-188
PREPARATION AND PRELIMINARY POSITRON EMISSION TOMOGRAPHY STUDIES OF C-11-RO 15-1788, A SELECTIVE BENZODIAZEPINE RECEPTOR ANTAGONIST
EHRIN E; JOHNSTROM P; STONEELANDER S; NILSSON JLG; PERSSON A; FARDE L; SEDVALL G; LITTON JE; ERIKSSON L; WIDEN L; GREITZ T
Visa fler

Alla övriga publikationer

Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2025;28:i35-i36
NO DIFFERENCES IN SYNAPTIC DENSITY IN TWINS WITH AUTISM AND THEIR NON-AUTISTIC CO-TWINS. HOWEVER, ARE DIFFERENCES IN SV2A BINDING POTENTIAL IN AUTISTIC BRAINS A MATTER OF WHITE MATTER?
Griffioen-Jarfalk G; Bolin M; Stephanov V; Cervenka S; Castelo-Branco M; Martins R; Lundberg J; Mehra C; Howes O; Murphy D; Bolte S; Farde L; Borg J
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2024;65
Evaluation of 3H/11C-labeled mGluR2 modulators based on isoindolone scaffold
Li Y; Dahl K; Johnstrom P; Varnas K; Halldin C; Farde L; Chen J; Yuan H; Haider A; Schou M; Liang S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2023;50(SUPPL 1):S257
In vivo quantification of [¹¹C]BIO-1819578, a novel radioligand for O-GlcNAcase, in non-human primates using Positron Emission Tomography
Bolin M; Nag S; Datta P; Arakawa R; Meynaq YK; Lin E; Genung N; Hering H; Guckian K; Martarello L; Kaliszczak M; Farde L; Stenkrona P; Halldin C; Moren AF
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2023;50(SUPPL 1):S254
First imaging of PARP1 in the living human brain - a translational PET study with [¹¹C]AZ3391
Schou M; Pike A; Jucaite A; Johnstrom P; Gonzalez MC; Hognasbacka A; Dahl K; Ghosh A; Johannes J; Staniszewska A; Leo E; Hamerlik P; Davies B; Cosulich S; Swales J; Lawrence R; Squatrito M; Mueller N; Sousa V; Bartek J; Stragliotto G; Stenkrona P; Farde L; Halldin C; Cselenyi Z
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:S55
Discovery, preclinical validation and early human imaging with [¹¹C]AZ14193391-the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand
Gonzalez MAC; Jucaite A; Cselenyi Z; Johnstrom P; Pike A; Hognasbacka A; Dahl K; Balazs A; Degorce S; Ghosh A; Hande S; Johannes J; Staniewska A; Leo E; Hammerlik P; Davies B; Cosulich S; Swales J; Lawrence R; Stenkrona P; Farde L; Halldin C; Schou M
Preprint: RESEARCH SQUARE. 2022
Lung muscarinic receptor occupancy by tiotropium: translational Positron Emission Tomography studies in non-human primates and humans
Cselényi Z; Jucaite A; Ewing P; Stenkrona P; Kristensson C; Johnström P; Schou M; Bolin M; Halldin C; Larsson B; Grime K; Eriksson UG; Farde L
Letter: MOVEMENT DISORDERS. 2022;37(8):1776-1778
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy
Rinne JO; Jucaite A; Cselenyi Z; Farde L
Preprint: RESEARCH SQUARE. 2022
Lung muscarinic receptor occupancy by tiotropium: translational PET studies in non-human primates and humans
Cselényi Z; Jucaite A; Ewing P; Stenkrona P; Kristensson C; Johnström P; Schou M; Bolin M; Halldin C; Larsson B; Grime K; Eriksson UG; Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(1_SUPPL):169-170
Centrum semiovale as reference region - An evaluation of methods to quantify [18F]FPEB PET binding data in man
Andersson M; Varnas K; Halldin C; Borg J; Farde L; Lundberg J
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(1_SUPPL):258-260
Validation of kinfitr: An open-source tool for reproducible PET kinetic modelling
Tjerkaski J; Cervenka S; Farde L; Matheson GJ
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(1_SUPPL):260-261
Lower thalamic dopamine D2-receptor binding and connectivity in drug-naive patients with psychosis - A combined [11C]FLB 457 PET and DTI study
Victorsson P; Plaven-Sigray P; Santillo A; Matheson GJ; Lee M; Collste K; Fatouros-Bergman H; Agartz I; Halldin C; Farde L; Cervenka S
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2021;16(3):S620
A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown A; Van der Aart J; Vishwanathan K; Farde L
Book chapter: PET AND SPECT IN PSYCHIATRY. 2021;p. 3-15
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets
Takano A; Halldin C; Farde L
Preprint: SSRN ELECTRONIC JOURNAL. 2021
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ ¹¹C ] PBR28 and Machine Learning Enhanced Analysis
Jucaite A; Cselényi Z; Kreisl WC; Rabiner EA; Varrone A; Carson RE; Rinne JO; Savage A; Schou M; Johnström P; Svenningsson P; Rascol O; Meissner WG; Barone P; Seppi K; Kaufmann H; Wenning GK; Poewe W; Farde L
Preprint: BIORXIV. 2020
Low convergent validity of [₁₁C]raclopride binding in extrastriatal brain regions: a PET study of within-subject correlations with [₁₁C]FLB 457
Freiburghaus T; Svensson J; Matheson G; Plavén-Sigray P; Lundberg J; Farde L; Cervenka S
Conference publication: SCHIZOPHRENIA BULLETIN. 2020;46:S135-S136
LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS - A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
Victorsson P; Plaven-Sigray P; Matheson G; Santillo A; Lee M; Collste K; Fatouros-Bergman H; Agartz I; Halldin C; Farde L; Cervenka S
Preprint: BIORXIV. 2020
Kinfitr – an open source tool for reproducible PET modelling: validation and evaluation of test-retest reliability
Tjerkaski J; Cervenka S; Farde L; Matheson GJ
Letter: NEUROIMAGE. 2020;207:116371
In response to the letter "[¹¹C]raclopride and extrastriatal binding to D2/3 receptors"
Svensson JE; Schain M; Plaven-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Book chapter: NEUROIMAGING IN SCHIZOPHRENIA. 2020;p. 145-159
Molecular Imaging
Cervenka S; Farde L
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S842
An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
Ekman S; Varrone A; Jucaite A; Vishwanathan K; Brown A; Cselenyi Z; Martin H; Lewensohn R; Schou M; Laus G; Van Der Aart J; Johnstrom P; Singh N; Farde L
Preprint: BIORXIV. 2019
Validity and reliability of extrastriatal [¹¹C]raclopride binding quantification in the living human brain
Svensson J; Schain M; Plavén-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Letter: BIOLOGICAL PSYCHIATRY. 2019;85(7):e35-e39
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
van Erp TGM; Walton E; Hibar DP; Schmaal L; Jiang W; Glahn DC; Pearlson GD; Yao N; Fukunaga M; Hashimoto R; Okada N; Yamamori H; Clark VP; Mueller BA; de Zwarte SMC; Ophoff RA; van Haren NEM; Andreassen OA; Gurholt TP; Gruber O; Kraemer B; Richter A; Calhoun VD; Crespo-Facorro B; Roiz-Santianez R; Tordesillas-Gutierrez D; Loughland C; Catts S; Fullerton JM; Green MJ; Henskens F; Jablensky A; Mowry BJ; Pantelis C; Quide Y; Schall U; Scott RJ; Cairns MJ; Seal M; Tooney PA; Rasser PE; Cooper G; Weickert CS; Weickert TW; Hong E; Kochunov P; Gur RE; Gur RC; Ford JM; Macciardi F; Mathalon DH; Potkin SG; Preda A; Fan F; Ehrlich S; King MD; De Haan L; Veltman DJ; Assogna F; Banaj N; de Rossi P; Iorio M; Piras F; Spalletta G; Pomarol-Clotet E; Kelly S; Ciufolini S; Radua J; Murray R; Marques TR; Simmons A; Borgwardt S; Schoenborn-Harrisberger F; Riecher-Roessler A; Smieskova R; Alpert KI; Bertolino A; Bonvino A; Di Giorgio A; Neilson E; Mayer AR; Yun J-Y; Cannon DM; Lebedeva I; Tomyshev AS; Akhadov T; Kaleda V; Fatouros-Bergman H; Flyckt L; Rosa PGP; Serpa MH; Zanetti MV; Hoschl C; Skoch A; Spaniel F; Tomecek D; McIntosh AM; Whalley HC; Knoechel C; Oertel-Knoechel V; Howells FM; Stein DJ; Temmingh HS; Uhlmann A; Lopez-Jaramillo C; Dima D; Faskowitz JI; Gutman BA; Jahanshad N; Thompson PM; Turner JA; Farde L; Flyckt L; Fatouros-Bergman H; Cervenka S; Collste K; Victorsson P; Engberg G; Erhardt S; Schwieler L; Malmqvist A; Hedberg M; Orhan F; Piehl F; Agartz I
Preprint: BIORXIV. 2019
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study
Tuisku J; Plavén-Sigray P; Gaiser EC; Airas L; Al-Abdulrasul H; Brück A; Carson RE; Chen M-K; Cosgrove KP; Ekblad L; Esterlis I; Farde L; Forsberg A; Halldin C; Helin S; Kosek E; Lekander M; Lindgren N; Marjamäki P; Rissanen E; Sucksdorff M; Varrone A; Rinne J; Matuskey D; Cervenka S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2018;45:S268-S269
Molecular Mapping of Serotoninergic and Dopaminergic Projections from Brainstem to Striatal Areas in Early Parkinson's disease Patients
Fazio P; Svenningsson P; Cselenyi Z; Halldin C; Farde L; Varrone A
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2018;45:S143-S144
Synthesis and biological evaluation of a novel mGluR5 radioligand: [¹⁸F]AZD9272
Nag S; Varnas K; Arakawa R; Takano A; Jahan M; Schou M; Halldin C; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2018;45:S648-S649
Brain exposure of ATM inhibitor AZD1390: positron emission tomography (PET) study in healthy human subjects
Varnas K; Jucaite A; Stenkrona P; De Vita S; Savage A; Varrone A; Johnstrom P; Cselenyi Z; Schou M; Davison C; Sykes A; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
Letter: SCHIZOPHRENIA RESEARCH. 2018;199:438-441
Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
Checa A; Malmqvist A; Flyckt L; Schwieler L; Samuelsson M; Skogh E; Cervenka S; Dahl M-L; Piehl F; Erhardt S; Wheelock CE
Conference publication: CANCER RESEARCH. 2018;78(13):ct013
Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with ¹¹C-labelled osimertinib
Vishwanathan K; Varrone A; Varnas K; Jucaite A; Cselenyi Z; Johnstrom P; Schou M; Vasquez-Romero A; Moein MM; Halldin C; Brown AP; Farde L
Preprint: BIORXIV. 2018
Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness
Matheson GJ; Plavén-Sigray P; Louzolo A; Borg J; Farde L; Petrovic P; Cervenka S
Review: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. 2018;373(1744):20170156
Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders
Farde L; Plaven-Sigray P; Borg J; Cervenka S
Preprint: BIORXIV. 2018
Test-retest reliability and convergent validity of (R)-[¹¹C]PK11195 outcome measures without arterial input function
Plavén-Sigray P; Matheson GJ; Cselényi Z; Jučaite A; Farde L; Cervenka S
Preprint: BIORXIV. 2017
Serotonin 5-HT_1A receptor binding and self-transcendence in healthy control subjects - a replication study using Bayesian hypothesis testing
Griffioen G; Matheson GJ; Cervenka S; Farde L; Borg J
Preprint: BIORXIV. 2017
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
Plavén-Sigray P; Matheson GJ; Gustavsson P; Stenkrona P; Halldin C; Farde L; Cervenka S
Conference publication: NEUROPSYCHOPHARMACOLOGY. 2017;42:S220-S221
First-Episode Psychosis Patients Display Increased Plasma IL-18 That Correlates With Cognitive Dysfunctions
Schwieler L; Orhan F; Fatouros-Bergman H; Cervenka S; Flyckt L; Farde L; Sellgren CM; Engberg G; Erhardt S
Conference publication: NEUROPSYCHOPHARMACOLOGY. 2017;42:S366-S367
Electroconvulsive Treatment of Patients With Major Depressive Episodes may Normalize Dopamine D2 Receptor Binding Potential in the Executive and Limbic Striatum: A Pilot PET Study
Svensson J; Tiger M; Liberg B; Halldin C; Schain M; Farde L; Lundberg J
Preprint: BIORXIV. 2017
Mapping Cortical Brain Asymmetry in 17,141 Healthy Individuals Worldwide via the ENIGMA Consortium
Kong X-Z; Mathias S; Guadalupe T; Abé C; Agartz I; Akudjedu T; Andre A; Saud A; Allen N; Ames D; Andreassen O; Arias Vasquez A; Armstrong N; Bergo F; Bastin M; Batalla A; Bauer J; Baune B; Baur R; Biederman J; Blaine S; Boedhoe P; Bøen E; Bose A; Bralten J; Brandeis D; Brem S; Brodaty H; Bröhl H; Brooks S; Buitelaar J; Bürger C; Bülow R; Calhoun V; Calvo A; Canales-Rodríguez EJ; Canive J; Cannon D; Caparelli E; Castellanos F; Cavalleri G; Cendes F; Chaim-Avancini TM; Chantiluke K; Chen Q-L; Chen X; Cheng Y; Christakou A; Clark V; Coghill D; Connolly C; Conzelmann A; Cόrdova-Palomera A; Cousijn J; Crow T; Cubillo A; Dannlowski U; de Bruttopilo SA; Zeeuw PD; Deary I; Delanty N; Demeter D; Martino AD; Dickie E; Dietsche B; Doan T; Doherty C; Doyle A; Durston S; Earl E; Ehrlich S; Ekman CJ; Elvsåshagen T; Epstein J; Fair D; Faraone S; Fatouros-Bergman H; Fernndez G; Busatto Filho G; Flyckt L; Forster K; Jean-Paul F; Foxe J; Fuentes-Claramonte P; Fullerton J; Garavan H; Garcia DDS; Gotlib I; Goudriaan A; Jorgen Grabe H; Groenewold N; Grotegerd D; Gruber O; Gurholt T; Haavik J; Hahn T; Hansell N; Harris M; Hartman C; Hernandez MDCV; Heslenfeld D; Hester R; Hibar DP; Ho B-C; Ho T; Hoekstra P; van Holst R; Hoogman M; Hovik M; Howells F; Hugdahl K; Huyser C; Ingvar M; Irwin L; Ishikawa A; James A; Jahanshad N; Jernigan T; Jonsson E; Kahler C; Kaleda V; Kelly C; Kerich M; Keshavan M; Khadka S; Kircher T; Kohls G; Konrad K; Korucuoglu O; Kramer B; Krug A; Kwon JS; Lambregts-Rommelse N; Landen M; Lazaro L; Lebedeva I; Lenroot R; Lesch K-P; Li Q; Lim K; Liu J; Lochner C; London E; Lonning V; Lorenzetti V; Luciano M; Luijten M; Lundervold A; Mackey S; MacMaster F; Maingault S; Malpas C; Malt U; Mataix-Cols D; Martin-Santos R; Mayer A; McCarthy H; Mitchell P; Mueller B; Maniega SM; Mazoyer B; McDonald C; McLellan Q; McMahon K; McPhilemy G; Momenan R; Morales A; Narayanaswamy J; Moreira JCV; Nerland S; Nestor L; Nigg J; Nordvik J-E; Novotny S; Oberwelland E; O'Gorman R; Oosterlaan J; Oranje B; Orr C; Overs B; Pauli P; Paulus M; Plessen K; von Polier G; Pomarol-Clotet E; Qiu J; Radua J; Ramos-Quiroga JA; Reddy YCJ; Reif A; Roberts G; Rosa P; Rubia K; Sacchet M; Sachdev P; Salvador R; Schmaal L; Schweren L; Seidman L; Seitz J; Serpa MH; Shaw P; Shumskaya E; Silk T; Simmons A; Simulionyte E; Sinha R; Sjoerds Z; Smelror RE; Soliva JC; Solowij N; Sponheim S; Stein D; Stein E; Stevens M; Strike L; Sudre G; Sui J; Tamm L; Temmingh H; Thoma R; Tomyshev A; Tronchin G; Turner J; Uhlmann A; van Erp TGM; van den Heuvel O; van der Meer D; van Eijk L; Vance A; Veer I; Dic
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27:S722
Associations between central chemokine levels and glial activation in first episode psychosis - a positron emission tomography study
Collste K; Orhan F; Erhardt S; Schwieler L; Flyckt L; Farde L; Engberg G; Cervenka S
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27:S741-S742
Social cognition in autism spectrum disorder is associated with brain serotonin transporter availability
Tangen A; Andersson M; Nystrom K; Bolte S; Halldin C; Farde L; Lundberg J; Borg J
Conference publication: MOVEMENT DISORDERS. 2017;32
In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson's disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.
Fazio P; Svenningsson P; Cselenyi Z; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2017;58
Pilot results of a brain PET insert tested on a 3T MRI
Gonzalez A; Aguilar A; Gonzalez-Montoro A; Sanchez S; Sanchez F; Correcher C; Catret J; Yakushev I; Schweiger IS; Schwaiger M; Farde L; Andersson M; Aussenhofer S
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:90-91
PET imaging of [¹¹C]PBR28 in patients with Parkinson's disease does not indicate increased binding to TSPO
Varnas K; Cselenyi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:234
Reduced TSPO levels in drug-naive first episode psychosis patients as measured using PET and [¹¹C]PBR28
Collste K; Plaven-Sigray P; Fatouros-Bergman H; Victorsson P; Schain M; Forsberg A; Amini N; Aeinehband S; Erhardt S; Halldin C; Flyckt L; Farde L; Cervenka S
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:165-166
Assessment of the reliability and validity of simplified ratio-based quantification approaches for [¹¹C]PBR28
Matheson GJ; Sigray PP; Forsberg A; Collste K; Varrone A; Halldin C; Farde L; Cervenka S
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:237
Serotonin 5HT_1A receptor binding and self-transcendence in healthy control subjects - a replication study using Bayesian inference
Griffioen G; Borg J; Matheson GJ; Cervenka S; Farde L
Conference publication: BRAIN BEHAVIOR AND IMMUNITY. 2016;57:E38
Cross-sectional and longitudinal associations between immune cells in blood and brain - A TSPO PET study in healthy control subjects
Kanegawa N; Collste K; Forsberg A; Schain M; Arakawa R; Jucaite A; Lekander M; Hoglund CO; Kosek E; Lampa J; Halldin C; Farde L; Varrone A; Cervenka S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2016;43:S615
Astrocyte Involvement in TSPO Signal After Microglia Depletion in mice
Toth M; Harald L; Haggkvist J; Forsberg A; Varrone A; Halldin C; Harris R; Farde L
Conference publication: INTERNATIONAL JOURNAL OF PSYCHOLOGY. 2016;51:879
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jonsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:674-675
ASSESSING THE DOPAMINERGIC BASIS OF DELUSIONAL IDEATION: THE RELATIONSHIP BETWEEN D1 AND D2 RECEPTOR AVAILABILITY AND DELUSIONAL BELIEFS IN HEALTHY SUBJECTS
Matheson GJ; Louzolo A; Plaven-Sigray P; Stenkrona P; Farde L; Ingvar M; Petrovic P; Cervenka S
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:662
PET EVALUATION OF GABA SENSITIVITY OF BENZODIAZEPINE (BZD) SITE AGONIST [11C]RO6899880 IN THE MONKEY BRAIN
Finnema SJ; Stepanov V; Amini N; Martinsson S; Borroni E; Honer M; Gobbi L; Grimwood S; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:618-619
CHARACTERIZATION OF [11C]LU AE92686 AS A PHOSPHODIESTERASE 10A PET RADIOLIGAND IN THE MONKEY BRAIN
Yang KC; Stepanov V; Amini N; Martinsson S; Takano A; Nielsen J; Bang-Andersen B; Grimwood S; Halldin C; Farde L; Finnema SJ
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:88-89
DETECTING DOPAMINERGIC MODULATION INDUCED CAMP CHANGES IN MONKEY BRAIN BY PDE10A PET IMAGING
Yang KC; Grimwood S; Nielsen J; Bang-Andersen B; Stepanov V; Amini N; Martinsson S; Takano A; Halldin C; Farde L; Finnema SJ
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:640-641
VALIDATION OF PARTIAL VOLUME EFFECT CORRECTION BASED ON FREESURFER AND AAL SEGMENTATION
Schain M; Cselenyi Z; Arakawa R; Rosenqvist G; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:676
PET STUDY OF THALAMIC DOPAMINE D2-RECEPTORS IN DRUG-NAIVE PATIENTS WITH SCHIZOPHRENIA
Ikonen P; Cervenka S; Collste K; Fatouros-Bergman H; Matheson G; Sigray PP; Varrone A; Halldin C; Flyckt L; Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:639-640
TOWARDS LESS-INVASIVE QUANTIFICATION OF [11C]PBR28: IMAGE-DERIVED AND POPULATION-BASED INPUT FUNCTIONS
Kanegawa N; Schain M; Collste K; Amini N; Takano A; Halldin C; Cervenka S; Farde L; Varrone A
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:675-676
DIURNAL AND SEASONAL VARIATION OF THE BRAIN SEROTONIN SYSTEM IN HEALTHY MALE SUBJECTS
Matheson GJ; Schain M; Almeida R; Lundberg J; Cselenyi Z; Borg J; Varrone A; Farde L; Cervenka S
Conference publication: AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY. 2016;50:46
GLUTAMATERGIC NEUROTRANSMISSION IN PSYCHIATRIC DISORDERS
Liberg B; Andersson M; Farde L; Lundberg J
Conference publication: NEUROPSYCHOPHARMACOLOGY. 2015;40:S142-S143
Low Serotonin 1B Receptor Binding Potential in the Anterior Cingulate Cortex in Drug-Free Patients with Recurrent Major Depressive Disorder
Tiger M; Farde L; Ruck C; Varrone A; Forsberg A; Lindefors N; Halldin C; Lundberg J
Review: PSYCHOPHARMACOLOGY. 2015;232(21-22):4129-4157
Application of cross-species PET imaging to assess neurotransmitter release in brain
Finnema SJ; Scheinin M; Shahid M; Lehto J; Borroni E; Bang-Andersen B; Sallinen J; Wong E; Farde L; Halldin C; Grimwood S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;42:S578-S579
Distribution of the Dopamine Transporter (DAT) in the nigro-striatal pathway examined in vivo with [18F] FE-PE2I and high-resolution PET
Fazio P; Cselenyi Z; Halldin C; Farde L; Varrone A
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;42:S235-S236
Simplified quantification of the dopamine transporter using [18F]FE-PE2I in PD patients and control subjects
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;42:S235
Maps of serotonin transporter distribution in the human brainstem obtained using high-resolution PET correlates with post-mortem autoradiography data (ARG)
Fazio P; Schain M; Varnas K; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2015;10(9):S300
Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases
Ballard P; Yang P; Cross D; Yates J; Finlay MRV; Grist M; Box M; Johnstrom P; Varnas K; Malmquist J; Halldin C; Farde L; Thress K
Conference publication: CHEMICAL SENSES. 2015;40(7):580
Decreased Dopamine Receptor D2 Binding Potential is Associated with Better Olfactory Function
Niman A; Cervenka S; Willander J; Backman L; Farde L; Larsson M
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2015;25:S274
Relationship between dose, plasma concentration and GABA-A receptor occupancy by partial GABA-A receptor modulators
Jucaite A; Lappalainen J; Cselenyi Z; Varnas K; Stenkrona P; Halldin C; Cross A; Farde L
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2015;58:S314
Estimation of the unbound brain to plasma ratio for CNS drug candidates - comparing results obtained with PET microdosing and microdialysis in non-human primates
Johnstrom P; Varnas K; Bergman L; Malmquist J; Halldin C; Farde L
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2015;58:S297
Synthesis of [¹¹CO]Raclopride and a Comparison with [¹¹CH₃]Raclopride in a Monkey PET Study
Rahman O; Dahl K; Takano A; Kanegawa N; Amini N; Langstrom B; Farde L; Halldin C
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2015;56(3)
Optimal acquisition time window for quantification of dopamine transporter availability with [¹⁸F]FE-PE2I in controls and PD patients
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
Meeting abstract: EUROPEAN PSYCHIATRY. 2015;30:277
Cognitive Performance in Drug-naive First Episode Schizophrenia (FES) Patients
Fatouros-Bergman H; Cervenka C; Flyckt L; Edman G; Schwieler L; Ikonen P; Collste K; Piehl F; Agartz I; Engberg G; Erhardt S; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41:S275-S276
Quantification of Dopamine Transporter Availability in Striatum and Substantia Nigra of Parkinson's Disease Patients with [18F]FE-PE2I and High-Resolution PET
Fazio P; Svenningsson P; Forsberg A; Jonsson EG; Amini N; Nakao R; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: A template-based analysis
Fazio P; Schain M; Varnas K; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
Quantitative analysis of [¹⁸F]FE-PE2I binding to the dopamine transporter in Parkinson's disease
Fazio P; Svenningsson P; Forsberg A; Jonsson E; Amini N; Nakao R; Halldin C; Farde L; Varrone A
Conference publication: MOVEMENT DISORDERS. 2014;29:S246
Effect of the myeloperoxidase inhibitor AZD3241 on translocator protein binding in brain - A positron emission tomography study in patients with Parkinson's disease
Jucaite A; Svennigsson P; Rinne J; Cselenyi Z; Varrone A; Karlsson P; Varnas K; Johnstrom P; McLoughlin MJ; Halldin C; Posener J; Salter H; Kugler A; Budd S; Farde L
Conference publication: MOVEMENT DISORDERS. 2014;29:S71-S72
Examination of the dopamine transporter in striatum and substantia nigra in Parkinson's disease with [¹⁸F]FE-PE2I and high-resolution PET
Fazio P; Svenningsson P; Forsberg A; Jonsson EG; Amini N; Halldin C; Farde L; Varrone A
Book chapter: PET AND SPECT IN PSYCHIATRY. 2014;p. 3-14
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets
Takano A; Halldin C; Farde L
Book chapter: DRUG DELIVERY APPLICATIONS OF NONINVASIVE IMAGING. 2013;p. 432-448
IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES
Lee C; Varnäs K; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40:S302
Evaluation of Two Automated Methods for PET Region of Interest Analysis
Schain M; Varnas K; Cselenyi Z; Halldin C; Farde L; Varrone A
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40:S208
Effects of ECT against depression on [11C]raclopride binding
Tiger M; Halldin C; Farde L; Lundberg J
Review: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2013;40(3):267-279
Modeling of PET data in CNS drug discovery and development
Varnas K; Varrone A; Farde L
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2013;56:S79
Development of [¹¹C]AZ13198083, a novel histamine type-3 radioligand with rapid kinetics.
Schou M; Varnas K; Dahl K; Johnstrom P; Nakao R; Amini N; Finnema S; Malmquist J; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2013;54
Effect of ligand mass dose on binding of the β-amyloid specific radioligand [18F]AZD4694 (NAV4694)
Cselenyi Z; Andreasen N; Halldin C; Schou M; Johnstrom P; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2012;39:S220
β-Amyloid Binding in Elderly Subjects with Stable or Declining Episodic Memory Function Measured with PET and [11C]AZD2184
Mattsson P; Forsberg A; Persson J; Halldin C; Nilsson L; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2012;39:S181-S182
Quantification and Whole-Body Distribution of a Novel Dopamine D₂/D₃ Receptor Agonist, [¹⁸F]MCL-524, in Monkeys: A Prediction for Application in Human Subjects
Finnema SJ; Stepanov V; Nakao R; Amini N; Sromek AW; Neumeyer JL; Seeman P; Stabin MG; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2012;39:S361
Test-retest of [11C]raclopride in rat: a PET/MRI study
Haggkvist J; Toth M; Doorduin J; Nagy K; Mathe D; Varrone A; Farde L; Halldin C; Gulyas B
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2012;39:S182
Initial Evaluation of the Novel Dopamine Transporter Radioligand [18F]FE-PE2I in Healthy Controls and Parkinson's Disease Patients
Varrone A; Forsberg A; Nakao R; Amini N; Nag S; Svenningsson P; Halldin C; Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S61
The novel dopamine D₂/D₃ receptor agonist radioligand [¹⁸F]MCL-524 is sensitive to dopamine levels
Finnema S; Stepanov V; Nakao R; Amini N; Sromek A; Neumeyer J; Seeman P; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S62-S63
Further validation of the serotonin sensitivity of [¹¹C]AZ10419389 receptor binding in non-human primates
Finnema S; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S149-S151
Image derived input function using a multivariate analysis method based on pair-wise correlation between PET-image voxels
Schain M; Benjaminsson S; Varnas K; Forsberg A; Halldin C; Lansner A; Farde L; Varrone A
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S135-S136
Evaluation of two methods for automated PET region of interest analysis
Varnas K; Schain M; Cselenyi Z; Halldin C; Farde L; Varrone A
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S65
Tiagabine does not modify [¹¹C]Ro 15-4513 and [¹¹C]flumazenil binding to a major extent in anesthetized non-human primates
Finnema S; Borroni E; Nakao R; Amini N; Takano A; Gobbi L; Honer M; Grimwood S; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S63-S64
Visualizing the central 5-HT1B receptor with PET in rats: effects of cyclosporin A on [¹¹C]AZ10419369 uptake
Toth M; Haggkvist J; Doorduin J; Nagy K; Varrone A; Mathe D; Farde L; Gulyas B; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S61-S62
Test-retest variability of [¹¹C]raclopride in rat using PET/MRI
Haggkvist J; Toth M; Doorduin J; Nagy K; Mathe D; Varrone A; Farde L; Halldin C; Gulyas B
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S70-S71
Preliminary evaluation of the quantification and metabolism in human subjects of the dopamine transporter redioligand [¹⁸F]FE-PE21
Vantone A; Nakao R; Amini N; Forberg A; Nag S; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S114-S115
Sensitive and specific amyloid-β PET imaging using the three novel radioligands [¹⁸F]AZD4694, [¹¹C]AZD2184 and [¹¹C]AZD2995 in Alzheimer's disease patients
Forsberg A; Mattsson P; Cselenyi Z; Jonhagen ME; Jureus A; Jeppsson F; Halldin C; Svensson S; Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32:S151
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT
Schain M; Toth M; Cselenyi Z; Arakawa R; Halldin C; Farde L; Varrone A
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:216
Relationship between dose, plasma concentration and a4β2 nicotinic receptor occupancy for AZD1446 (TC-6683)
Jucaite A; Nyberg S; Takano A; Kagedahl M; Johnstrom P; Halldin C; Jostell K-G; Rohnson E; Farde L
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:155
SERT and NET occupancy by serotonin and norepinephrine reuptake inhibitors in non-human primates in vivo
Takano A; Halldin C; Farde L
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:152
Effect of a single dose SSRI on serotonin levels in the non-human and human primate brain
Nord M; Finnema S; Halldin C; Farde L
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:34-35
Central D2-occupancy and optimal dosing does it apply for atypical antipsychotics?
Farde L
Meeting abstract: NEUROBIOLOGY OF AGING. 2012;33:S5-S6
EARLY CLINICAL DEVELOPMENT OF AMYLOID-BETA SPECIFIC PET RADIOLIGAND [18F]AZD4694
Cselenyi Z; Forsberg A; Halldin C; Schou M; Johnstrom P; Varnas K; Svensson S; Andreasen N; Reiman EM; Eriksdotter-Jonhagen M; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53
[¹⁸F] MCL-524, an 18 F-labeled dopamine D2/D3 receptors agonist radioligand with higher binding signal than [¹¹C] MNPA
Finnema S; Stepanov V; Nakao R; Sromek A; Neumeyer J; Seeman P; Farde L; Halldin C
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53
5-HT_1B receptor imaging in Parkinson's disease with ¹¹C-AZ10419369 and positron emission tomography
Varrone A; Svenningsson P; Forsberg A; Tiger M; Varnas K; Nilsson L-G; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53
Microdosing of radiolabeled CNS drugs in non-human primates. Assessment of brain exposure and dose dependent effects on brain exposure using positron emission tomography
Schou M; Varnas K; Lundquist S; Nakao R; Amini N; Gulyas B; Takano A; Finnema S; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53
Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy studied by [11C] PE2I and PET using parent and metabolite combined arterial plasma input - A new approach
Odano I; Varrone A; Nakao R; Karlsson P; Savic I; Ciumas C; Halldin C; Farde L
Conference publication: ACS NATIONAL MEETING BOOK OF ABSTRACTS. 2012;243
Development of high affinity, highly selective agonist ligands for positron emission tomography imaging of the dopamine D₂ receptor
Sromek AW; Neumeyer JL; Si Y-G; Zhang T; Seeman P; George SR; Farde L; Halldin C; Stepanov V; Finnema S
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2012;22:S55
Amphetamine-opioid interactions in the human brain reward system - a PET study using [¹¹C]carfentanil
Guterstam J; Jayaram-Lindstrom N; Cervenka S; Halldin C; Farde L; Frost J; Franck J
Conference publication: INTERNATIONAL JOURNAL OF PSYCHOLOGY. 2012;47:582
The serotonin transporter in the human brain has a role in attentional processes: PET study with [11C]MADAM
Borg J; Lundberg J; Nordstrom A-L; Kizling I; Jovanovic H; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38:S147
D-Amphetamine decreases [¹¹C]ORM-13070 receptor binding in the monkey brain using a bolus-infusion protocol
Finnema SJ; Stepanov V; Varrone A; Nakao R; Haaparanta-Solin M; Solin O; Ingman K; Sallinen J; Scheinin M; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38:S188
The First PET Evaluation of the Fluorine-18 Labeled Dopamine D₂/D₃ Receptors Agonist, [¹⁸F]MCL-524
Finnema SJ; Stepanov V; Nakao R; Sromek AW; Zhang TZ; Neumeyer JL; George SR; Seeman P; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38:S148
PET investigation of in vivo SERT and NET occupancy by venlafaxine and milnacipran in non-human primates
Takano A; Nag S; Halldin C; Farde L
Conference publication: CURRENT NEUROPHARMACOLOGY. 2011;9:55-56
Fenobam Binds to sites not Recognized by ABP688 and other mGluR5 NAMs, but by AZ11696415 in the Primate brain
Raboisson P; Johnson A; Jureus A; Pierrou S; Wensbo D; Strom P; Malmquist J; Sandell J; Andersson JD; Varnas K; Halldin C; Farde L
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21:S320-S321
In vivo monoamine transporter occupancy by venlafaxine and milnacipran in non-human primates
Takano A; Nag S; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2011;52
D-Amphetamine decreases 5-HT_1Breceptor binding of [¹¹C]AZ10419369 in the monkey brain
Finnema S; Varrone A; Farde L; Halldin C
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2011;52
A new quantitative approach for dopamine transporter binding using [11C]PE2I and PET allowing BBB-penetrating radiolabeled metabolite
Odano I; Varrone A; Nakao R; Karlsson P; Savic I; Ciumas C; Jucaite A; Halldin C; Farde L
Review: CNS NEUROSCIENCE & THERAPEUTICS. 2011;17(2):97-103
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia
Nord M; Farde L
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2011;54:S308
Quantitative measurement of [¹¹C]ORM-13070 receptor binding in the monkey brain using a bolus-infusion protocol
Finnema SJ; Nakao R; Haaparanta-Solin M; Varrone A; Stepanov V; Solin O; Ingman K; Sallinen J; Scheinin M; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2011;54:S9
Radiolabeling and monkey PET evaluation of the dopamine D₂ and D₃ receptor agonist radioligand [¹⁸F]MCL-524
Stepanov V; Finnema SJ; Nakao R; Sromek AW; Zhang T-Z; Neumeyer JL; Susan GR; Seeman P; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2011;54:S311
D-Amphetamine decreases [¹¹C]AZ10419369 receptor binding in the monkey brain
Finnema SJ; Varrone A; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2011;54:S41
[¹⁸F]AZD4694-a new ¹⁸F-labeled β-amyloid probe with rapid brain wash-out
Schou M; Peter J; Varnas K; Anders J; Sandell J; Cselenyi Z; Swahn B-M; Svensson S; Lindstrom-Boo E; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2010;37:S249
Improved methodology for measurement of serotonin release using [¹¹C]AZ10419369 and PET
Finnema SJ; Varrone A; Hwang T; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2010;37:S206
[11C]AZ11696415: Characterization of a novel PET radioligand for in-vivo visualization of the mGlu5 receptor in the cynomolgus monkey brain
Andersson JD; Farde L; Seneca N; Truong P; Wensbo D; McLeod D; Raboisson P; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2010;37:S293-S294
A Comparison Between the ECAT HRRT and HR Systems in the Quantification of Serotonin Transporter Availability with [11C]MADAM
Schain M; Toth M; Cselenyi Z; Karlsson P; Halldin C; Farde L; Varrone A
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S299-S300
In vivo assessment of changes in serotonin release in the non-human primate brain using PET and [11C]AZ10419369
Finnema SJ; Varrone A; Hwang TJ; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S164-S165
Quantification of serotonin transporter availability with [11C]MADAM - A comparison between the ECAT HRRT and HR systems
Nilsson MS; Toth M; Cseleny Z; Karlsson P; Halldin C; Farde L; Varrone A
Meeting abstract: NEUROIMAGE. 2010;52:S142
Quantification and wavelet-aided parametric imaging of cerebral amyloid using the HRRT PET-system and [18F]AZD4694
Cselenyi Z; Jonhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnstroem P; Varnas K; Svensson S; Farde L
Meeting abstract: NEUROIMAGE. 2010;52:S126
[¹⁸F]AZD4694-A new PET radioligand for sensitive detection of β-amyloid deposits
Jureus A; Swahn B-M; Sandell J; Jeppsson F; Neelissen JAM; Halldin C; Johnstrom P; Schou M; Cselenyi Z; Farde L; Svensson SPS
Meeting abstract: NEUROIMAGE. 2010;52:S122
The novel mGluR5 radioligand [¹¹C]AZ11696415: Palladium mediated ¹¹C-cyanation and initial in vivo characterization in the cynomolgus monkey brain using positron emission tomography (PET)
Andersson J; Seneca N; Truong P; Wensbo D; McLeod D; Raboisson P; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S95
Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Fujie S; Sasaki T; Nakayama K; Halldin C; Farde L; Suhara T
Meeting abstract: NEUROIMAGE. 2010;52:S61-S62
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain
Finnema SJ; Varnas K; Stepanov V; Varrone A; Gulyas B; Arponen E; Helin S; Solin O; Haaparanta M; Sallinen J; Ingman K; Scheinin M; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S55
Confirmation of fenfluramine effect on 5-HT1B binding of [11C]AZ10419369 using an equilibrium approach
Finnema SJ; Varrone A; Hwang TJ; Farde L; Halldin C
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2010;51
Dopamine transporter binding in patients with juvenile myoclonic epilepsy using [11C]PE2I and PET
Odano I; Varrone A; Ciumas C; Jucaite A; Halldin C; Farde L; Savic I
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2010;51
Confirmation of fenfluramine effect on 5-HT_1B binding of [¹¹C]AZ10419369 using an equilibrium approach
Finnema S; Varrone A; Hwang T-J; Farde L; Halldin C
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2010;13:38-39
New methodology for PET-measurements of in vivo drug effects on endogenous serotonin levels
Farde L
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2009;29:S66
Fenfluramine decreases 5-HT_1B binding OF [¹¹C]AZ10419369 in the primate
Finnema SJ; Varrone A; Hwang TJ; Gulyas B; Pierson E; Farde L; Halldin C
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2009;29:S575-S576
A comparison of grey matter density in restless legs syndrome patients and matched controls, using FSL-VBM
Comley R; Cervenka S; Palhagen S; Panagiotidis G; Matthews J; Lai R; Halldin C; Farde L; Nichols T; Whitcher B
Published conference paper: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(10):1639-1650
Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT
Varrone A; Sjoholm N; Eriksson L; Gulyas B; Halldin C; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36:S235-S236
Development of an improved amyloid probe, [¹¹C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients
Andersson J; Varnas K; Cselenyi Z; Gulyas B; Swahn B; Finnema S; Nyberg S; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36:S222
The 5-HT_1B radioligand [¹¹C]AZ10419369 is sensitive to endogenous serotonin levels in vivo
Finnema SJ; Varrone A; Hwang T; Gulyas B; Pierson E; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(SUPPL 2):235-236
Development of an improved amyloid probe, [¹¹C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients
Andersson J; Varnas K; Cselenyi Z; Gulyas B; Swahn B; Finnema S; Nyberg S; Farde L; Halldin C
Published conference paper: NEUROPSYCHOLOGIA. 2009;47(11):2299-2304
Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning
MacDonald SWS; Cervenka S; Farde L; Nyberg L; Backman L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2009;50
Automated receptor imaging system (ARIS) in neuroreceptor binding studies with PET
Odano I; Sakaguchi K; Hosoya T; Varrone A; Savic I; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2009;50
Effect of fenfluramine on 5-HT1B binding of [11C]AZ10419369 in the primate brain
Finnema S; Varrone A; Hwang T-J; Gulyas B; Pierson E; Farde L; Halldin C
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S7-S8
Limbic dopamine D2-receptor binding and social desirability
Cervenka S; Halldin C; Farde L
Conference publication: SCHIZOPHRENIA BULLETIN. 2009;35:152-153
THE CONCEPT OF ATYPICALITY-NEUROPHARMACOLOGICAL UNDERPINNINGS AS REVEALED BY MOLECULAR IMAGING
Farde L
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2009;52:S87
RADIOSYNTHESIS OF AN IMPROVED AMYLOID PROBE, [11C]AZD2184: PET CHARACTERIZATION IN THE CYNOMOLGUS MONKEY AND HUMAN BRAIN
Andersson J; Varnas K; Cselenyi Z; Gulyas B; Finnema SJ; Swahn B; Nyberg S; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2009;52:S76
EFFECT OF FENFLURAMINE ON 5-HT1B BINDING OF [11C]AZ10419369 IN THE PRIMATE BRAIN
Finnema SJ; Varrone A; Hwang TJ; Gulyas B; Pierson E; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2009;52:S74
DEVELOPMENT OF A PET RADIOLIGAND FOR THE 5-HT1B RECEPTOR FROM A COMPOUND LIBRARY: RADIOSYNTHESIS, CHARACTERIZATION IN THE PRIMATE BRAIN AND METABOLITE ANALYSIS
Andersson J; Pierson ME; Finnema SJ; Gulyas B; Seneca N; Heys JR; Elmore C; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35:S145
Point Spread Function Reconstruction of High-Resolution Research Tomograph - HRRT - PET-Images Improves In Vivo Neuroreceptor Quantification
Varrone A; Sjoholm N; Gulyas B; Halldin C; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35:S172
[¹¹C] AZ10419369: A selective 5-HT_1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the cynomolgus macaque and the human brain.
Andersson J; Pierson EM; Nyberg S; McCarthy DJ; Finnema SJ; Varnas K; Takano A; Karlsson P; Gulyas B; Medd AM; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
Conference publication: ACS NATIONAL MEETING BOOK OF ABSTRACTS. 2008;236
MEDI 223-AZ10419369 a translational tool for 5-HT1B receptors
Pierson ME; Andersson J; Nyberg S; Soderstrom J; McCarthy DJ; Finnema SJ; Varnas K; Takano A; Karlsson P; Gulyas B; Powell ME; Heys JR; Potts W; Maier D; Medd A; Sobotka-Briner CD; Seneca N; Farde L; Halldin C
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2008;18:S270
PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
Nyberg S; Takano A; Jucaite A; Karlsson P; McCarthy D; Kagedal M; Eriksson H; Lee CM; Halldin C; Farde L
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11:222-223
Evidence of functional compartmentalization of the human striatum: subregional dopamine D2-receptor binding in relation to cognition
Cervenka S; Backman L; Cselenyi Z; Halldin C; Farde L
Conference publication: BIOLOGICAL PSYCHIATRY. 2008;63(7):105S-106S
PET-measured D2,5HT2A, and NET occupancy by quetiapine and norquetiapine in non-human primates
Nyberg S; Takano A; Grimm S; Gulyas B; McCarthy D; Lee C-M; Goldstein JM; Halldin C; Farde LF
Conference publication: BIOLOGICAL PSYCHIATRY. 2008;63(7):106S
PET-measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate (Quetiapine XR) in brains of healthy subjects
Nyberg S; Takano A; Jucaite A; Karlsson P; McCarthy D; Kagedal M; Eriksson H; Lee C-M; Halldin C; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2008;18:S82-S83
Lower 5-HT1A receptor binding in patients with borderline personality disorder:: a PET study using [¹¹C]WAY100635
Jovanovic H; Andersson EE; Karlsson P; Halldin C; Nordstroem AL; Asberg M; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2008;18:S64
Molecular imaging of the 5-HTIA receptor and 5-HTT in relation to cognitive functions in man
Borg J; Lundberg J; Andree B; Kizling I; Halldin C; Fardel L
Meeting abstract: NEUROIMAGE. 2008;41:T38
Dopamine D_2/3 receptor occupancy of apomorphine in the non-human primate brain does not support the existence of two affinity states in vivo
Finnema SJ; Bang-Andersen B; Gulyas B; Bundgaard C; Wikstroem HV; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T19
[¹¹C]AZ10419369:: A selective 5-HT_1B receptor radioligand suitable for positron emission tomography (PET); Characterization in cynomolgus monkey brain
Andersson J; Pierson ME; Finnema S; Gulyas B; Medd AM; Powell ME; McCarthy DJ; Nyberg S; Heys R; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2008;41:T134
Quantitative analysis of dopamine D2 receptor binding in human brain using PET with an agonist radioligand [¹¹C]MNPA
Otsuka T; Ito H; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Suhara T; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T104
Quantitative analyses of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in the human brain
Varnaes K; Nyberg S; Halldin C; Varrone A; Takano A; Karlsson P; McCarthy D; Smith M; Pierson ME; Soederstroem J; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T102
Radiosynthesis of [¹¹C]MNPA from the precursor (R)-(-)-2-hydroxy-10,11-acetonide-NPA and a preliminary test-retest PET analysis in monkey brain
Steiger C; Finnema SJ; Wikstroem HV; Gulyas B; Nakao R; Suzuki K; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2008;41:T91
COMT inhibition prevents the formation of lipophilic radiometabolites of catechols, -: An example with (S)-[¹¹C]N-methyl-NNC 01-0259
Finnema SJ; Bang-Andersen B; Jorgensen M; Gulyas B; Farde L; Wikstrom HV; Halldin C
Meeting abstract: NEUROIMAGE. 2008;41:T85
Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT
Varrone A; Sjoholm N; Gulyas B; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T77
Automated system for parametric image analysis in neuroreceptor binding studies with PET
Odano I; Sakaguchi K; Hosoya T; Varrone A; Savic I; Halldin C; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S254-S255
PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates
Nyberg S; Takano A; Grimm S; Gulyas B; McCarthy D; Lee C; Goldstein J; Halldin C; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007;34:S205-S206
COMT inhibition is a method for avoidance of lipophilic radiometabolites of catechols, exemplified with (S)-[¹¹C]N-methyl-NNC 01-0259
Finnema SJ; Bang-Andersen B; Jorgensen M; Jogolev G; Gulyas B; Farde L; Wikstrom HV; Halldin C
Conference publication: PHARMACOPSYCHIATRY. 2007;40(5):227
Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115)
Karlsson P; Hargarter L; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Conference publication: INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2007;11(4):322
PET-measured D2, 5HT2A, and NET occupancy by quetiapine and n-desalkyl-quetiapine (norquetiapine) in non-human primates
Goldstein J; Nyberg S; Takano A; Grimm S; Gulyas B; McCarthy D; Lee C; Halldin C; Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2007;61(6):489
Utility of imaging techniques in drug development for schizophrenia
Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S212
Investigation of the metabolites of (S, S)-[11C] MeNER in humans, monkeys and rats
Schou M; Zoghbi SS; Shetty H; Shchukin E; Liow J; Hong J; Andree A; Gulyas B; Farde L; Innis RB; Pike VW; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S174
Radiosynthesis and evaluation of new α₁-adrenoceptor antagonists as potential PET radioligands for brain imaging
Airaksinen AJ; Finnema S; Balle T; Bang-Andersen B; Gulyas B; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S211
Low effect of amphetamine on the binding of the partial dopamine D₁ receptor agonist radioligand [¹¹C] N-methyl-NNC 01-0259
Finnema SJ; Bang-Andersen B; Farde L; Jorgensen M; Gulyas B; Foged C; Wikstrom H; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S211
No "ceiling effect" observed with the exogenous dopamine agonist apomorphine -: A PET study with the dopamine D₂ receptor agonist radioligand [¹¹C]MNPA and antagonist radioligand [¹¹C]Raclopride
Finnema SJ; Bang-Andersen B; Farde L; Gulyas B; Wikstrom HV; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S212
Advantage of [18F]flumazenil for central benzodiazepine receptor mapping compared to [11C]flumazenil.
Odano I; Karlsson P; Farde L; Krasikova R; Airaksinen A; Pauli S; Savic I; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33:S211
[¹¹C] Cyclopropyl-FLB 457:: PET examination of a more D2 selective high affinity radioligand for extrastriatal D2 dopamine receptors
Airaksinen AJ; Finnema S; Nag S; Mukherjee J; Farde L; Halldin C
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2006;9:S131-S132
Pet-comparison of regional expression levels of the serotonin transporter and the 5ht_1A-receptor in the human brain
Lundberg J; Halldin C; Farde L
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2006;9:S26
Integration of tracer development into CNS drug discovery and development programs
Farde L
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2006;27(6):310-316
Using positron emission tomography to facilitate CNS drug development
Lee C-M; Farde L
Meeting abstract: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(2):P74
Pharmacokinetics and dopamine D₂ and serotonin 5-HT_2A receptor occupancy of paliperidone in healthy subjects:: Two open-label, single-dose studies.
Karlsson P; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T120
Dopamine D2/D3 receptor occupancy of apomorphine evaluated with the agonist radioligand [11C]MNPA and the antagonist radioligand [11C]Raclopride.: A PET evaluation in the non-human primate brain
Finnema S; Bang-Andersen B; Farde L; Gulyas B; Wikstrom HV; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T114
PET evaluation of the partial dopamine D1 receptor agonist radioligands R- and S-[11C]N-methyl-NNC 01-0259
Finnema S; Bang-Andersen B; Farde L; Jorgensen M; Gulyas B; Foged C; Wikstrom HV; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T88
Comparisons of central benzodiazepine receptor mapping tracers, [18F]Flumazenil and [11C]Flumazenil presentation
Odano I; Farde L; Savic I; Ciumas C; Krasikova R; Airaksinen A; Karlsson P; Pauli S; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T87
Dopamine transporter binding corrected for tissue heterogeneity and partial volume effect using [11C]PE2I and PET
Odano I; Jucaite A; Olsson H; Karlsson P; Pauli S; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T86
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635
Cselenyi Z; Olsson H; Halldin C; Gulyas B; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T85
Increasing the accuracy of in vivo quantification of dopamine-D2/D3 receptor binding in the human brain by partial volume effect correction
Sovago J; Farde L; Cervenka S; Halldin C; Gulyas B
Meeting abstract: NEUROIMAGE. 2006;31:T48
Synthesis of ¹¹C-labeled (S,S)-CFMME and (R)-OHDMI and their evaluation as candidate radioligands for imaging norepinephrine transporters with PET
Schou M; Pike VW; Sovago J; Gulyas B; Gallagher P; Dobson D; Walter MW; Rudyk H; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T28
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion:: A PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2
Seneca N; Gulyas B; Varrone A; Schou M; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
Conference publication: SCHIZOPHRENIA RESEARCH. 2006;81:85-86
Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects
Karlsson P; Dencker E; Nyberg S; Cselenyi Z; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Conference publication: SCHIZOPHRENIA RESEARCH. 2006;81:225
Evidence of schizophrenia as a hypodopaminergic condition
Wiesel FA; Farde L; Terenius L; Edman G; Venizelos N; Bjerkenstedt L
Conference publication: SCHIZOPHRENIA RESEARCH. 2006;81:107
A PET study of ACP-103, a novel 5HT 2A receptor inverse agonist, in the human brain
Van Kammen D; Mansson M; Jovanovic H; Borg J; Karlsson P; Halldin C; Farde L; Vanover K; Hacksell U; Brann M; Davis R; Weiner D; Nordstrom A
Review: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2006;30(6):791-807
The correlative triad among aging, dopamine, and cognition: Current status and future prospects
Backman L; Nyberg L; Lindenberger U; Li S-C; Farde L
Review: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(4):615-629
QTc interval prolongation and antipsychotic drug treatments: focus on sertindole
Lindström E; Farde L; Eberhard J; Haverkamp W
Conference publication: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2005;238:S47
Increased dopamine D2-receptor availability in patients with Restless Legs Syndrome as measured with Positron Emission Tomography
Cervenka S; Pålhagen SE; Comley RA; Panagiotidis G; Matthews JC; Lai RY; Halldin C; Farde L
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15:S386
Pharmacokinetics and dopamine D₂ and serotonin 5-HT_2A receptor occupancy of paliperidone in healthy subjects
Karlsson P; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Conference publication: AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS. 2005;138B(1):128-129
Exclusion of amino acid transporter A2 (ATA2) gene in relation to the attenuated tyrosine transport in schizophrenia
Ming Y; Venizelos N; Bjerkenstedt L; Farde L; Wiesel FA; Terenius L
Conference publication: AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS. 2005;138B(1):124
Brain-derived neurotrophic factor gene (BDNF) variants, schizophrenia, and related traits: An association study
Jönsson EG; Gunnar A; Edman-Ahlbom B; Sillén A; Kulle B; Frigessi A; Vares M; Ekholm B; Tamagaki C; Okugawa G; Bergman H; Farde L; Hall H; Agartz I; Sedvall GC; Terenius L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):398
Altered pattern of midbrain dopamine markers in adolescents with AD/HD
Forssberg H; Jucaite A; Fernell E; Halldin C; Waters S; Tedroff J; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S44
(S,S)-[¹⁸F]FMeNER-D₂ is Superior to (S,S)-[¹¹C]MeNER as a Positron-Emitting Radioligand for Imaging Norepinephrine Transporters in the Post Mortem Human Brain
Schou M; Halldin C; Pike VW; Mozley P; Dobson D; Innis RB; Farde L; Hall H
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S82
A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain
Seneca N; Finnema S; Ichise M; Gulyas B; Wikstrom H; Innis R; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S82
Scatchard Analysis of the D2 Receptor Agonist [¹¹C]MNPA in the Monkey Brain Using PET
Finnema SJ; Seneca N; Farde L; Gulyas B; Bang-Andersen B; Wikstrom HV; Innis RB; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S53
Synthesis and PET Evaluation of (R)-[¹¹C] OHDMI - A Candidate Radioligand for the Brain Norepinephrine Transporter
Schou M; Pike VW; Sovago J; Gulyas B; Farde L; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S44
Test-retest evaluation of central [¹¹C]MeNER binding to the norepinephrine transporter in healthy subjects using PET
Andree B; Schou M; Mozley PD; Vandenhende F; Farde L; Gulyas B; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005;32:S22
Central 5-HT_1A Receptor Binding in Patients with Alzheimer's Disease and Healthy Controls Examined with PET and [carbonyl-¹¹C]WAY-100635
Andree B; Mattsson P; Farde L; Halldin C
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2005;48:S272
POST MORTEM AUTORADIOGRAPHY OF THE HUMAN BRAIN NOREPINEPHRINE TRANSPORTER WITH (S,S)-[¹⁸F]FMeNER-D₂
Schou M; Halldin C; Pike VW; Mozley PD; Dobson D; Innis RB; Farde L; Hall H
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2005;48:S273
THE NET RADIOLIGAND (S,S)-[¹¹C]MeNER PRODUCES A LIPOPHILIC LABELED METABOLITE MEASURED IN HUMAN PLASMA
Schou M; Pike VW; Andree B; Gulyas B; Shchukin E; Farde L; Halldin C
Published conference paper: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2005;229:219-223
[¹¹C]Vinpocetine:: a prospective peripheral benzodiazepine receptor ligand for primate PET studies
Gulyás B; Halldin C; Vas A; Banati RB; Shchukin E; Finnema S; Tarkainen J; Tihanyi K; Szilágyi G; Farde L
Letter: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(1):141-142
Half-life of receptor occupancy - a meaningless concept
Olsson H; Farde L
Published conference paper: BIOLOGICAL PSYCHIATRY. 2005;57(3):229-238
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity
Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
Letter: AMERICAN JOURNAL OF PSYCHIATRY. 2004;161(9):1721
Religion, spirituality, and mysticism -: Dr Borg and colleagues reply
Borg J; Andrée B; Söderström H; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2004;31:S208
Quantitative analysis of [¹¹C]PE2I binding to dopamine transporter in human brain
Odano I; Jucaite A; Olsson H; Halldin C; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2004;31:S208
Demonstration of selective norepinephrine transporter binding in human brain using PET and [¹¹C]MeNER
Andrée B; Seneca N; Schou M; Mozley PD; Potter WZ; Farde L; Gulyas B; Halldin C
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2004;31:S208
Effect of amphetamine on dopamine D2 receptors binding in the primate brain with the new agonist ligand [¹¹C]MNPA
Seneca N; Finnema S; Sovago J; Shchukin E; Gulyas B; Farde L; Innis R; Wikstrom H; Halldin C
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2004;7:S67
The dopamine hypothesis of schizophrenia: The role of pet
Farde L; Seneca N; Finnema SJ; Wikstrom HV; Halldin C
Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2004;7:S472-S473
Binding potential of [¹¹C]WAY100635 to serotonin 5-HTlA receptor and cognitive functions
Borg J; Andrée B; Lundberg J; Halldin C; Farde L
Conference publication: BIOLOGICAL PSYCHIATRY. 2004;55:72S
D2 receptor binding in drug-naive patients examined with FLB457 and raclopride
Nordstrom AL; Talvik M; Halldin C; Farde L
Conference publication: BIOLOGICAL PSYCHIATRY. 2004;55:145S-146S
Extrastriatal D2 imaging with PET
Suhara T; Yasuno F; Okubo Y; Sudo Y; Inoue M; Ichimiya T; Takano A; Nakayama K; Halldin C; Farde L
Conference publication: BIOLOGICAL PSYCHIATRY. 2004;55:11S
Measurement of extra-striatal dopamine release after methylphenidate in man: An [11C]FLB 457 PET study
Montgomery A; Asselin MC; Farde L; Grasby P
Conference publication: NEUROIMAGE. 2004;22:T175
PET evaluation of the dopamine D2 receptor agonist
Finnem SJ; Seneca N; Gulyas B; Sovago J; Farde L; Innis RB; Wikstrom HV; Halldin C
Conference publication: NEUROIMAGE. 2004;22:T58-T59
Regional central norepinephrine transporter occupancy induced by reboxetine determined in man using [11C]MeNER
Andree B; Seneca N; Schou M; Mozley PD; Potter WZ; Farde L; Gulyás B; Halldin C
Conference publication: NEUROIMAGE. 2004;22:T32
A PET comparison of the NET tracers (S,S)-[11C]MeNER and (S,S)[18F]FMeNER-D2 in monkeys
Schou M; Halldin C; Sovago J; Pike VW; Hall H; Gulyas B; Mozley PD; Dobson D; Innis RB; Shchukin E; Farde L
Conference publication: INTERNATIONAL JOURNAL OF PSYCHOLOGY. 2004;39(5-6):145
Decreased thalamic D2 dopamine receptor binding in drug-naive patients with schizophrenia
Talvik M; Nordstrom AL; Farde L
Conference publication: INTERNATIONAL JOURNAL OF PSYCHOLOGY. 2004;39(5-6):146
The serotonin system and spiritual experiences
Borg J; Andrée B; Henrik S; Farde L
Review: ERNST SCHERING RESEARCH FOUNDATION WORKSHOP. 2004;48(48):95-109
PET for drug development
Halldin C; Gulyás B; Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 2003;160(11):1965-1969
The serotonin system and spiritual experiences
Borg J; Andrée B; Soderstrom H; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:S330
PET examinations or thalamic D2 receptors in schizophrenic patients
Talvik M; Nordström AL; Olsson H; Halldin C; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:S109-S110
Is dopamine a variable in PET-studies on drug induced receptor occupancy?
Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2003;44(5):68P
A PET-examination of [¹¹C]DADAM in human brain -: A PET radioligand for the serotonin transporter with a fast equilibrium.
Halldin C; Lundberg J; Tarkiainen J; Hiltunen J; Sovago J; Gulyas B; Guilloteau D; Emond P; Chalon S; Vercouillie J; Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2003;57(2):91
Serotonin transporter occupancy during antidepressant drug treatment
Lundberg J; Olsson H; Halldin C; Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2003;57(2):97
Relationship between plasma concentrations, D₂-receptor occupancy and efficacy of Risperdal CONSTA™
Farde L; Eerdekens M; Eerdekens E; Eriksson B; Mannaert E
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2003;57(2):92
On the pathophysiology of schizophrenia
Bjerkenstedt L; Farde L; Terenius L; Edman G; Venizelos N; Wiesel FA
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2003;57(2):88-89
Typical and atypical antipsychotics. Information from PET studies
Farde L
Conference publication: NEUROIMAGE. 2002;16(3):S56
Detailed multi-receptor mapping in the human brain
Cselenyi Z; Farde L; Olsson H; Halldin C; Gulyas B
Conference publication: NEUROIMAGE. 2002;16(3):S18
N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine or MADAM is a serotonin transporter ligand with high affinity and specificity:: in vitro characterization
Chalon S; Tarkiainen J; Garreau L; Hall H; Emond P; Vercouillie J; Farde L; Besnard JC; Halldin C; Guilloteau D
Conference publication: NEUROIMAGE. 2002;16(3):S45
Investigation of dopamine D2/D3 receptors in the monkey brain: a PET study with two radioligands of different selectivity profiles
Sovago J; Gulyas B; Halldin C; Farde L
Conference publication: NEUROIMAGE. 2002;16(3):S19
Two new C-methyl analogues of WAY-100635-preparation, labeling with carbon-11 and evaluation as PET radioligands for brain 5-HT_1A receptors in monkey
Pike VW; Tarkiainen J; Marchais S; McCarron JA; Halldin C; Sovago J; Gulyas B; Truong P; Wikstrom HV; Farde L
Conference publication: NEUROIMAGE. 2002;16(3):S17
A pet examination of [11C]MADAM in monkey and human brain-a selective radioligand for the serotonin transporter
Lundberg J; Halldin C; Tarkiainen J; Sovago J; Vercouillie J; Gulyas B; Guilloteau D; Emond P; Chalon S; Hiltunen J; Farde L
Conference publication: NEUROIMAGE. 2002;16(3):S3
[11C]DADAM - A fast equilibrium pet radioligand for the serotonin transporter
Halldin C; Tarkiainen J; Sovago J; Vercouillie J; Gulyas B; Guilloteau D; Emond P; Chalon S; Hiltunen J; Lundberg J; Farde L
Conference publication: NEUROIMAGE. 2002;16(3):S43
Displaceability of [¹¹C]FLB-457 from extra-striatal D2 receptors
Montgomery A; Asselin MC; Farde L; Grasby P
Conference publication: EUROPEAN PSYCHIATRY. 2002;17:7S-8S
PET and antipsychotic drugs -: background
Nordström AL; Talvik M; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2002;43(5):359P-360P
Evaluation of two C-methyl derivatives of ¹¹C-WAY-100635 as potential radioligands for 5-HT_1A receptors.
Pike V; Tarkiainen J; Marchais S; McCarron J; Halldin C; Sovago J; Gulyas B; Truong P; Wikström H; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2002;43(5):164P
A PET-comparison in monkey brain of ¹¹C-MADAM labeled in two different positions -: Selective for the serotonin transporter.
Halldin C; Tarkiainen J; Sovago J; Vercouillie J; Gulyas B; Guilloteau D; Emond P; Chalon S; Hiltunen J; Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 2002;159(5):761-767
PET study of D₁ dopamine receptor binding in neuroleptic-naive patients with schizophrenia
Karlsson P; Farde L; Halldin C; Sedvall G
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2002;12:S4-S5
Antipsychotic pharmacokinetics and receptor binding in schizophrenia
Farde L
Conference publication: SCHIZOPHRENIA RESEARCH. 2002;53(3):79
A new perspective on the pathophysiology of schizophrenia
Bjerkenstedt L; Edman G; Farde L; Flyckt L; Sillén A; Terenius L; Venizelos N; Wiesel FA
Review: CURRENT PHARMACEUTICAL DESIGN. 2001;7(18):1907-1929
PET studies with carbon-11 radioligands in neuropsychopharmacological drug development
Halldin C; Gulyás B; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(8):973
Radioactive metabolites of the 5-HT1A receptor PET radioligand, [carbonyl-11C]WAY-100635, in human plasma samples:: A multi-centre study
Någren K; Halldin C; Pike VW; Allonen T; Hietala J; Swahn CG; Andrée B; Farde L; Osman S; Grasby P
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(8):996
Biological evaluation and PET examination in monkey of [3H]- and [11C]-5-methyl-6-nitroquipazine -: A potential serotonin transporter radioligand for use both in vitro and in vivo
Halldin C; Sandell J; Sóvágó J; Chou YH; Gulyás B; Chalon S; Yu M; Emond P; Guilloteau D; Någren K; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(8):973
[11C]MADAM -: A highly suitable radioligand for examination of the serotonin transporter with PET
Halldin C; Guilloteau D; Tarklainen J; Sóvágó J; Gulyás B; Sandell J; Emond P; Vercouillie J; Chalon S; Hiltunen J; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(8):972
A PET and SPECT comparison of the new selective serotonin transporter radioligand ADAM in the cynomolgus monkey brain
Halldin C; Tarkiainen J; Karlsson P; Emond P; Cselényi ZS; Gulyás B; Guilloteau D; Hiltunen J; Jonsson C; Larsson S; Farde L
Review: SCANDINAVIAN JOURNAL OF PSYCHOLOGY. 2001;42(3):287-296
Dopamine and cognitive functioning:: Brain imaging findings in Huntington's disease and normal aging
Bäckman L; Farde L
Conference publication: NEUROIMAGE. 2001;13(6):S1299
Detailed mapping of dopamine D2 receptors in the human limbic system using FLB 457 binding analysis in wavelet space
Cselényi Z; Olsson H; Gulyás B; Halldin C; Farde L
Conference publication: NEUROIMAGE. 2001;13(6):S833
Mesial temporal lobe epilepsy is associated with limbic reductions in serotonin 5HT1A receptor binding
Savic I; Gulyas B; Lindström P; Halldin C; Farde L
Conference publication: NEUROIMAGE. 2001;13(6):S12
A novel principle of radiotracer administration in human brain mapping:: PET studies on brain uptake and distribution of orally and intravenously administered [11C]vinpocetine.
Gulyás B; Halldin C; Sóvágó J; Sandell J; Cselényi Z; Karlsson P; Kárpáti E; Kiss B; Vas A; Farde L
Review: QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;45(2):139-152
Brain radioligands - State of the art and new trends
Halldin C; Gulyás B; Langer O; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2001;42(5):251P
¹⁸F6FPWAY-synthesis and initial investigation as a prospective 5-HT_1A receptor radioligand in vivo.
McCarron JA; Sandell J; Pike VW; Halldin C; Gulyas B; Cselényi ZS; Sovago J; Wikström HV; Marchais S; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2001;42(5):112P
¹¹CMADAM -: A selective radioligand for PET-examination of the serotonin transporter in the monkey brain.
Halldin C; Guilloteau D; Tarkiainen J; Vercouille J; Gulyás B; Sóvágó J; Cseléyi ZS; Sandell J; Emond P; Chalon S; Hiltunen J; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2001;42(5):212P-213P
PET studies on brain uptake and distribution of orally and intravenously administered ¹¹Cvinpocetine.: A novel principle of radiotracer administration.
Gulyás BZ; Halldin C; Sandell J; Sóvágó J; Cselényi ZS; Karlsson P; Vas A; Kárpáti E; Kiss B; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2001;42(5):211P
PET studies on brain uptake and distribution of the dopamine D3 radioligand ¹¹CRGH-1756.
Gulvás B; Halldin C; Langer O; Karlsson P; Sóvágó J; Cselényi ZS; Laszlovszky I; Kiss B; Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2001;55(2):82-83
Dopamine receptors, schizophrenia, and personality traits
Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(5):515-521
Use of PET and the radioligand [Carbonyl-¹¹C]WAY-100635 in psychotropic drug development
Andrée B; Halldin C; Thorberg SO; Sandell J; Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(5):449-455
Radioligands for the study of brain 5-HT_1A receptors in vivo - Development of some new analogues of WAY
Pike VW; Halldin C; Wikström H; Marchais S; McCarron JA; Sandell J; Nowicki B; Swahn CG; Osman S; Hume SP; Constantinou M; Andrée B; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2000;41(5):139P
Quantification of [¹¹C]FLB457 binding to extrastriatal D2 dopamine receptors in the human brain.
Ito H; Sudo Y; Suhara T; Okubo Y; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2000;41(5):39P
Two new halogenated analogues of WAY-100635 as potential PET radioligands for the study of 5-HT1A receptors.
Sandell J; Halldin C; Pike V; Chou Y; Marchais S; Nowicki B; Wikström H; Swahn C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2000;41(5):121P
[¹²³I]SB 207710 exhibits 5-HT₄ receptor-selective binding in monkey brain in vivo.
Pike VW; Mulligan RS; Halldin C; Nobuhara K; Hiltunen J; Swahn CG; Karlsson P; Pilowsky LS; Ell P; Larsson S; Schnell PO; Farde L
Editorial comment: PSYCHOPHARMACOLOGY. 2000;148(1):22-23
Non-equipotent doses partly explain differences among antipsychotics - implications of PET studies
Nyberg S; Farde L
Conference publication: INTERNATIONAL JOURNAL OF PSYCHOLOGY. 2000;35(3-4):23
Brain imaging and personality traits
Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2000;54:25-26
Efficacy, side-effects and dopamine D₂- and serotonin 5-HT_2A-receptor occupancy
Nyberg S; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(9):990
DWAY is a selective PET radioligand for human brain 5-HT_1A receptors in vivo
Halldin C; Pike V; Andrée B; Swahn CH; Sandell J; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(9):973
Z-IQNP:: A potential radioligand for the SPECT study of muscarinic acetylcholine receptors in Alzheimer's disease
Nobuhara K; Halldin C; Hall H; Karlsson P; Hiltunen J; McPherson D; Savonen A; Bergström KA; Swahn CG; Larsson S; Schnell PO; Farde L; Sedvall G
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(9):981
Evaluation of binding characteristics of the dopamine transporter radioligand PE2I in both PET and SPECT using the same monkey
Nobuhara K; Halldin C; Karlsson P; Guilloteau D; Pauli S; Emond P; Swahn CG; Hiltunen J; Larsson S; Schnell PO; Hall H; Sedvall G; Farde L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(9):991
[1231]SB 207710 -: Preparation and investigation as a potential radioligand for brain 5-HT₄ receptors in vivo
Pike VW; Mulligan RS; Halldin C; Nobuhara K; Hiltunen J; Swahn CG; Hall H; Karlsson P; Pilowsky LS; Ell P; Larsson S; Schnell PO; Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 1999;156(6):869-875
Suggested minimal effective dose of risperidone based on PET-measured D₂ and 5-HT_2A receptor occupancy in schizophrenic patients
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1999;40(5):38P
PET examination of [C-11]NAD-299, a new radioligand for visualization of the 5-HT1A receptor.
Halldin C; Sandell J; Chou YH; Hall H; Thornberg SO; Werner T; Swahn CG; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1999;40(5):306P
2β-carbomethoxy-3β(3′-IODO-4′- isopropylphenyl)nortropane as a radioligand for exploration of the serotonin transporter by PET and SPET:: In vitro and in vivo evaluation.
Helfenbein J; Sandell J; Halldin C; Chalon S; Chou YH; Karlsson P; Garreau L; Emond P; Besnard JC; Farde L; Guilloteau D
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1999;40(5):30P
Dopamine D1-receptor binding in neuroleptic naive schizophrenic patients examined by PET.
Karlsson P; Farde L; Halldin C; Swahn CG; Sedvall G
Conference publication: SCHIZOPHRENIA RESEARCH. 1999;36(1-3):109-110
A high central 5HT_2A a receptor occupancy in M100907-treated schizophrenic patients demonstrated with pet and [¹¹C]M100907
Talvik-Lotfi M; Nyberg S; Nordström AL; Ito H; Halldin C; Brunner F; Farde L
Conference publication: SCHIZOPHRENIA RESEARCH. 1999;36(1-3):245
PET-measured striatal and extrastriatal, D₂-receptor occupancy in sertindole-treated patients
Nyberg S; Nilsson U; Halldin C; Farde L
Conference publication: AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 1998;81(6):497
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density in vivo of healthy volunteers.
Jönsson EG; Nöthen MM; Neidt H; Farde L; Propping P; Sedvall GC
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(8):715-719
Whole hemisphere autoradiography of the postmortem human brain
Hall H; Halldin C; Farde L; Sedvall G
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1998;39(5):118P
PET-characterization of [C-11]PE2I binding to dopamine transporter in the monkey brain.
Halldin C; Guilloteau D; Okubo Y; Lundkvist C; Olsson H; Karlsson P; Chalon S; Emond P; Swahn CG; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1998;39(5):237P
Radiosynthesis and human post-mortem autoradiography of [C-11]NAD-299, a new radioligand for visualization of the 5-HT1A receptor.
Sandell J; Halldin C; Thorberg SO; Werner T; Sohn D; Sedvall G; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1998;39(5):136P
Localization of central 5-HT1A receptors in man using [carbonyl-C-11]WAY-100635: PET with anatomic standardization technique.
Ito H; Halldin C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1998;39(5):120P
Precursor synthesis, radiolabeling and PET examination in monkey of three potent serotonin transporter radioligands.
Sandell J; Helfenbein J; Halldin C; Okubo Y; Chalon S; Frangin Y; Galinier E; Swahn CG; Guilloteau D; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1998;39(5):72P
Quantitative analysis of extrastriatal dopamine D2 receptors in the human brain by 3D PET.
Suhara T; Sudo Y; Suzuki K; Okauchi T; Farde L; Halldin C; Tanada S; Sasaki Y
Letter: ARCHIVES OF GENERAL PSYCHIATRY. 1998;55(3):283-284
Positron emission tomography finding of a high striatal D₂ receptor occupancy in olanzapine-treated patients
Nordström AL; Nyberg S; Olsson H; Farde L
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1998;13:S15-S20
Implications of brain imaging for the management of schizophrenia
Nyberg S; Nilsson U; Okubo Y; Halldin C; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1998;29(1-2):165
D2-density, personality traits, and negative symptoms of schizophrenia
Farde L
Book chapter: POSITRON EMISSION TOMOGRAPHY: CRITICAL ASSESSMENT OF RECENT TRENDS. 1998;p. 91-98
Development of PET radioligands for the quantitation of serotonin receptors in the human brain
Halldin C; Farde L; Lundkvist C; Ito H; Ginovart N; Hall H; Nyberg S; Swahn CG; Sedvall G; McCarron JA; Pike VW
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 1998;52(2):100-101
D₂ density, personality traits, and cognitive functions
Farde L
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 1998;52:70
Neuroimaging in psychiatry
Farde L
Published conference paper: SCHIZOPHRENIA RESEARCH. 1997;28(2-3):157-162
Brain imaging of schizophrenia - the dopamine hypothesis
Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1997;38(5):1202
5-HT1A receptor imaging in the human brain using [C-11]WAY-100635 and PET.
Ito H; Halldin C; Lundkvist C; Swahn CG; Pike V; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1997;38(5):547
Neuroleptic interactions on the in vivo dopamine D2 extrastriatal binding of Br-76 FLB 457 studied by PET in human.
Loch C; Guillem E; Martinot JL; Halldin C; Syrota A; Farde L; Maziere B
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1997;38(5):297
5-HT2A receptor imaging in the human brain using [C-11]MDL 100,907 and PET.
Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1997;38(5):277
[C-11]NNC 22-0215, a metabolically stable benzazepine developed as dopamine D-1 receptor radioligand for PET.
Halldin C; Foged C; Swahn CG; Ginovart N; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1997;38(5):204
Characterization of bromine-76 labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter.
Lundkvist C; Loch C; Halldin C; Bottlaender M; Ottaviani M; Coulon C; Mathis C; Farde L; Maziere B
Editorial comment: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1997;94(7):2787-2788
Imaging the living human brain: Magnetic resonance imaging and positron emission tomography
Volkow ND; Rosen B; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1997;24(1-2):178-179
D-1-dopamine receptors in schizophrenia examined by PET
Karlsson P; Farde L; Halldin C; Sedvall G
Letter: NATURE. 1997;385(6617):590
D2 dopamine receptors and personality traits
Farde L; Gustavsson JP; Jonsson E
Editorial comment: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1997;12:S47-S48
How can we improve compliance in schizophrenia? Papers from a satellite symposium to the XXth congress of the Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia, 24 June 1996 - Conclusions
Farde L
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1997;12:S3-S7
D-2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: A pilot study with sertindole in healthy subjects
Farde L; Mack RJ; Nyberg S; Halldin C
Book chapter: ALZHEIMER DISEASE: ADVANCES IN ALZHEIMER DISEASE THERAPY. 1997;p. 435-438
Pet-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain
Nybäck H; Halldin C; Karlsson P; Nakashima Y; Farde L; Sauerberg P; Shannon HE; Bymaster FP
Editorial comment: JOURNAL OF PSYCHOPHARMACOLOGY. 1997;11(1):13-14
The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed
Nyberg S; Farde L
Letter: AMERICAN JOURNAL OF PSYCHIATRY. 1996;153(9):1240
Unique receptor-blockading profile of clozapine - Reply
Nordstrom AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G
Letter: PSYCHIATRY RESEARCH-NEUROIMAGING. 1996;67(2):161-162
In schizophrenia, some dopamine D-2-like receptors are still elevated - Reply
Nordstrom AL; Farde L
Published conference paper: JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY. 1996;206(1):133-144
Development of radioligands for the dopamine transporter
Muller L; Halldin C; Lundkvist C; Swahn CG; Foged C; Hall H; Karlsson P; Ginovart N; Nakashima Y; Suhara T; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1996;37(5):879
Development of a fluorine-18 labelled PET radioligand for the dopamine transporter: [N-fluoropropyl-F-18]beta-CIT-FP.
Lundkvist C; Halldin C; Ginovart N; Swahn CG; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1996;37(5):424
[C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with PET.
Halldin C; Lundkvist C; Ginovart N; Nyberg S; Hall H; Swahn CG; Carr AA; Brunner F; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1996;37(5):437
Binding studies of 5-HT1A receptors in human brain by autoradiography and in the monkey brain by PET.
Halldin C; Hall H; Pike VW; Lundkvist C; Ginovart N; McCarron JA; Swahn CG; Osman S; Cliffe IA; Fletcher A; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1996;37(5):296
Initial human studies with SPECT using [I-123]NNC 13-8241 for visualization of benzodiazepine receptors.
Kuikka JT; Bergstrom KA; Halldin C; Hiltunen J; Foged C; Akerman KK; Tiihonen J; Farde L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1996;37(5):1271
Examination of [C-11]beta-CIT-FP and [C-11]beta-CIT-FE uptake in the human brain by PET.
Farde L; Halldin C; Lundkvist C; Ginovart N; Hall H; Karlsson P; Swahn CG; Neumeyer JL
Published conference paper: BRITISH JOURNAL OF PSYCHIATRY. 1996;168(29):40-44
Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs - Review of D-2 and 5-HT2 receptor occupancy studies and clinical response
Nyberg S; Nakashima Y; Nordstrom AL; Halldin C; Farde L
Letter: LIFE SCIENCES. 1996;58(10):PL 187-92-192
[C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography
Lundkvist C; Halldin C; Ginovart N; Nyberg S; Swahn CG; Carr AA; Brunner F; Farde L
Conference publication: SCHIZOPHRENIA RESEARCH. 1996;18(2-3):XIID6
Long-time persistence of D-2 dopamine receptor occupancy after discontinuation of haloperidol decanoate
Nyberg S; Farde L; Halldin C
Conference publication: SCHIZOPHRENIA RESEARCH. 1996;18(2-3):XIID5
D2- and 5-HT2 receptor occupancy in ''mega-dose'' treated schizophrenic patients
Nyberg S; Farde L; Dencker SJ; Malm U; Dahl ML; Halldin C
Conference publication: SCHIZOPHRENIA RESEARCH. 1996;18(2-3):XIID2
Decrease of D1-dopamine receptor binding in the frontal cortex of neuroleptic naive schizophrenic patients measured by PET
Karlsson P; Farde L; Halldin C; Sedvall G
Letter: LANCET. 1996;347(8996):264
Dopamine receptors in schizophrenia
Sedvall G; Farde L
Conference publication: PRECLINICAL AND CLINICAL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE, CEREBROVASCULAR AND MENTAL DISORDERS. 1996;11:198-207
Neuroreceptor imaging by PET: Implications for clinical psychiatry and psychopharmacology
Sedvall CG; Brene S; Farde L; Karlsson P; Nordstrom AL; Nyberg S; Pauli S; Halldin C
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):971-976
THE METABOLITE PATTERN OF [I-123] BETA-CIT DETERMINED WITH A GRADIENT HPLC METHOD
BERGSTROM KA; HALLDIN C; KUIKKA JT; SWAHN CG; TIIHONEN J; HILTUNEN J; LANSIMIES E; FARDE L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):959-964
SYNTHESIS OF NOR-BETA-CIT, BETA-CIT AND TRIMETHYLSTANNYL-BETA-CT
AMETAMEY SM; HALLDIN C; SWAHN CG; HALL H; SCHUBIGER PA; FARDE L
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1995;10:81-85
Positron emission tomography studies on D-2 dopamine receptor occupancy and plasma antipsychotic drug levels in man
Nyberg S; Nordstrom AL; Halldin C; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1995;15(1-2):86
DECREASED D-1-DOPAMINE RECEPTOR-BINDING IN DRUG-NAIVE SCHIZOPHRENIC-PATIENTS EXAMINED BY PET
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G
Other: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 1995;19(4):297-300
LIPOPHILIC METABOLITE OF [I-123] BETA-CIT IN HUMAN PLASMA MAY OBSTRUCT QUANTITATION OF THE DOPAMINE TRANSPORTER
BERGSTROM KA; HALLDIN C; KUIKKA JT; SWAHN CG; TIIHONEN J; HILTUNEN J; LANSIMIES E; FARDE L
Conference publication: PSYCHOPHARMACOLOGY. 1995;118(2):B8
D-2 RECEPTOR OCCUPANCY IN RELATION TO CLOZAPINE SERUM CONCENTRATION - A PET STUDY IN SCHIZOPHRENIC-PATIENTS
NORDSTROM AL; FARDE L; NYBERG S; KARLSSON P; HALLDIN C; SEDVALL G
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(2):173-178
D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE
NYBERG S; FARDE L; HALLDIN C; DAHL ML; BERTILSSON L
Published conference paper: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1995;15(1):19S-23S
POSITRON EMISSION TOMOGRAPHY STUDIES ON D-2 AND 5-HT2 RECEPTOR-BINDING IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS
FARDE L; NYBERG S; OXENSTIERNA G; NAKASHIMA Y; HALLDIN C; ERICSSON B
Published conference paper: CLINICAL NEUROPHARMACOLOGY. 1995;18:S121-S129
POSITRON EMISSION TOMOGRAPHY STUDIES ON DOPAMINE-RECEPTORS IN SCHIZOPHRENIA
FARDE L; NORDSTROM AL; KARLSSON P; HALLDIN C; SEDVALL G
Book chapter: ALZHEIMER'S AND PARKINSON'S DISEASES. 1995;p. 245-249
Positron emission tomography (PET) studies with ligands for cholinergic receptors in the human brain
NYBACK H; HALLDIN C; KARLSSON P; ERIKSSON L; AHLIN A; MULLER L; FARDE L
Book chapter: PET FOR DRUG DEVELOPMENT AND EVALUATION: DEVELOPMENTS IN NUCLEAR MEDICINE. 1995;p. 73-81
PET in the Development of Dopamine D1 Antagonists as New Potential Antipsychotic Drugs
Foged C; Karlsson P; Skrumsager BK; Ynddal L; Nielsen EB; Halldin C; Farde L
Book chapter: ALZHEIMER'S AND PARKINSON'S DISEASES. 1995;p. 499-505
New radioligands for PET-examination of central muscarinic receptors
FARDE L; SUHARA T; HALLDIN C; KARLSSON P; NYBACK H; MULLER L; FOGED C; SAUERBERG P; LUCAS R
Book chapter: PET FOR DRUG DEVELOPMENT AND EVALUATION: DEVELOPMENTS IN NUCLEAR MEDICINE. 1995;p. 67-71
PET Studies in the Early Clinical Development of a New Antipsychotic
Sitsen JMA; Farde L
Book chapter: PET FOR DRUG DEVELOPMENT AND EVALUATION: DEVELOPMENTS IN NUCLEAR MEDICINE. 1995;p. 51-53
PET in Neuropsychiatric Drug Development
Farde L
Book chapter: PET FOR DRUG DEVELOPMENT AND EVALUATION: DEVELOPMENTS IN NUCLEAR MEDICINE. 1995;p. 83-92
Is the 5-HT2-Receptor a Target for Antipsychotic Drug Action? PET Studies on Dopamine (D2 and Serotonin (5-HT2) Receptor Occupancy in Patients and Healthy Subjects
Nyberg S; Nordström A-L; Halldin C; Farde L
Book chapter: PET FOR DRUG DEVELOPMENT AND EVALUATION: DEVELOPMENTS IN NUCLEAR MEDICINE. 1995;p. 55-65
Radioligand Disposition and Metabolism — Key Information in Early Drug Development
Halldin C; Swahn C-G; Farde L; Sedvall G
Book chapter: CHEMISTS' VIEWS OF IMAGING CENTERS. 1995;p. 497-511
Preparation and examination of labelled stereoisomers in vivo by PET
HALLDIN C; SUHARA T; FARDE L; SEDVALL G
Conference publication: SCHIZOPHRENIA. 1995;38:190-199
D2-DOPAMINE RECEPTORS IN SCHIZOPHRENIA
FARDE L; HALLDIN C
Published conference paper: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5:25-30
PET imaging of neuroreceptors in schizophrenia
Sedvall G; Pauli S; Karlsson P; Farde L; Nordstrom AL; Nyberg S; Halldin C
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1994;35(5):P253
BR-76 BETA-CBT, A NEW PET LIGAND FOR IN-VIVO IMAGING OF THE DOPAMINE UPTAKE SITES
LOCH C; MULLER L; STRIJCKMANS V; HALLDIN C; FOGED C; FARDE L; MAZIERE B
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1994;35(5):P122
EVALUATION IN BABOON AND IN HUMAN OF I-123 NCQ-298, A HIGH-AFFINITY SPECT LIGAND FOR STUDYING DOPAMINE D-2 RECEPTORS
MAZIERE B; LOCH C; HALLDIN C; BOURGUIGNON M; SYROTA A; MAZIERE M; FARDE L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1994;35(5):P84-P85
[C-11] FLB-457, A SELECTIVE PET RADIOLIGAND FOR EXAMINATION OF EXTRASTRIATAL DOPAMINE D2 RECEPTORS
FARDE L; HALLDIN C; SUHARA T; NYBERG S; KARLSSON P; HOGBERG T; HALL H; SWAHN CG
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1994;35(5):P122
[C-11] NNC-112, A SELECTIVE PET RADIOLIGAND FOR EXAMINATION OF EXTRASTRIATAL DOPAMINE D1 RECEPTORS
HALLDIN C; FOGED C; KARLSSON P; SWAHN CG; ANDERSON PH; FARDE L
Conference publication: JOURNAL OF NEUROCHEMISTRY. 1994;63:S28
3-DIMENSIONAL NEURORECEPTOR IMAGING IN THE HUMAN BRAIN BY PET
SEDVALL G; PAULI S; FARDE L; HALLDIN C
Conference publication: SCHIZOPHRENIA RESEARCH. 1994;11(2):112-113
D2 OCCUPANCY IN SCHIZOPHRENIC-PATIENTS ON DEPOT NEUROLEPTICS
NYBERG S; HALLDIN C; BERTILSSON L; FARDE L
Book chapter: ALZHEIMER DISEASE: ADVANCES IN ALZHEIMER DISEASE THERAPY. 1994;p. 234-238
Xanomeline, A Specific M1 Agonist: Early Clinical Studies
Bodick NC; DeLong AF; Bonate PL; Gillespie T; Henry DP; Satterwhite JH; Lucas RA; Heaton J; Carter GV; Farde L; Cutler NR; Sramek JJ; Seifert RD; Conrad JJ; Wardle TS
Conference publication: NEUROBIOLOGY OF AGING. 1994;15:S105
NEW RADIOLIGANDS FOR PET-EXAMINATION OF CENTRAL MUSCARINIC RECEPTORS
FARDE L; SUHARA T; HALLDIN C; KARLSSON P; NYBACK H; MULLER L; FOGED C; SAUERBERG P; LUCAS R
Conference publication: RECENT ADVANCES IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND COGNITIVE DYSFUNCTION. 1994;7:11-16
BRAIN IMAGING INNEURODEGENERATIVE AND COGNITIVE DISORDERS
SEDVALL G; KARLSSON P; NYBACK H; LUNDIN A; FARDE L; PAULI S; HALLDIN C
Conference publication: ACS NATIONAL MEETING BOOK OF ABSTRACTS. 1993;206:170-NUCL
PREPARATION AND EXAMINATION OF LABELED STEREOISOMERS IN-VIVO BY PET
HALLDIN C; FARDE L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1993;34(5):P102
EVALUATION IN BABOON AND HUMAN OF BR-76 FLB-457, A HIGH-AFFINITY PET LIGAND FOR STUDYING DOPAMINE D-2 RECEPTORS
MAZIERE B; HALLDIN C; LOCH C; MORESCO RM; DELFORGE J; BOTTLAENDER M; FUSEAU C; SYROTA A; FARDE L; MAZIERE M
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1993;34(5):P89
[I-123] NNC 13-8241 AND [I-125] NNC 13-8241 - NEW SELECTIVE RADIOLIGANDS FOR EXAMINATION OF BENZODIAZEPINE RECEPTORS
FOGED C; HALLDIN C; PAULI S; SUHARA T; KARLSSON P; HANSEN H; SWAHN CG; LARSSON S; SCHNELL PO; FARDE L
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1993;34(5):P7
PREPARATION OF 3 C-11 LABELED NOVEL FUNCTIONAL M1 SELECTIVE MUSCARINIC AGONISTS
HALLDIN C; MULLER L; FOGED C; SAUERBERG P; KARLSSON P; SWAHN CG; HALL H; FARDE L
Conference publication: NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3. 1993;:1713-1716 vol.3-1716
ATTENUATION CORRECTION IN PET - TRANSMISSION VS CONTOUR FINDING IN THE STUDY OF [C-11] RACLOPRIDE BINDING
LITTON JE; NORDSTROM AL; HALLDIN C; FARDE L
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1992;19(8):592
PREPARATION OF (11C)BETA-CIT, A NEW LIGAND FOR IMAGING COCAINE BINDING-SITES INVIVO BY PET
HALLDIN C; FARDE L; MULLER L; KARLSSON P; NEUMEYER JL; GAO Y; MILIUS R; HALL H; SWAHN CG
Other: BRITISH JOURNAL OF PSYCHIATRY. 1992;160:60-64
CLOZAPINE - THE ATYPICAL ANTIPSYCHOTIC - DISCUSSION
KRUPP F; HIPPIUS H; MELTZER HP; KANE JM; GERLACH J; NABER D; COWARD DM; BALDESSARINI RJ; BUNNEY BS; FARDE L
Book chapter: SEARCH FOR THE CAUSES OF SCHIZOPHRENIA. 1990;p. 285-300
Positron Emission Tomography in Schizophrenia
Wiesel F-A; Farde L; Nordström A-L; Sedvall G; Wik G
Conference publication: ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT. 1990;82:58-62
DRUG-INTERACTION STUDIES WITH REMOXIPRIDE
YISAK W; VONBAHR C; FARDE L; GRIND M; MATTILA M; OGENSTAD S
Book chapter: NEUROPSYCHOPHARMACOLOGY. 1990;p. 40-54
The Future of Psychopharmacology and Positron Emission Tomography
Sedvall G; Farde L; Kopp J; Pauli S; Persson A; Savic I; Wiesel F-A
Book chapter: THIOXANTHENE. 1990;p. 13-24
Die Bedeutung der D1- und D2-Dopaminrezeptor-Blockade für die antipsychotische Wirkung von Neuroleptika. Eine PET-Studie an schizophrenen Patienten
Wiesel F-A; Farde L; Nordström A-L; Sedvall G
Book chapter: VISUALIZATION OF BRAIN FUNCTIONS. 1989;p. 159-165
Visualization of Neuroreceptor Functions in the Living Human Brain
Sedvall G; Farde L; Kopp J; Nybäck H; Pauli S; Persson A; Savic I; Wiesel FA
Conference publication: ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY. 1988;70(2):P35
REDUCTION IN SPECIFIC RO-15-1788 BINDING AFTER ORAL DIAZEPAM TREATMENT IN HEALTHY-MEN VISUALIZED BY POSITRON EMISSION TOMOGRAPHY (PET)
PAULI S; PERSSON A; ANDERSSON P; PERSSON H; FARDE L; ROSENQVIST G; SEDVALL G
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1988;14(5-6):255
DETERMINATION OF RECEPTOR DENSITY, ASSOCIATION-RATE, AND DISSOCIATION-RATE CONSTANTS FOR RADIOLIGANDS WITH PET - A COMPARISON BETWEEN THE EQUILIBRIUM AND THE KINETIC APPROACHES
BLOMQVIST G; ERIKSSON L; FARDE L; PAULI S; PERSSON A
Conference publication: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1988;43(2):178
PHARMACODYNAMICS AND PHARMACOKINETICS OF RACLOPRIDE AFTER SINGLE ORAL DOSES IN MALE-VOLUNTEERS
WAHLEN A; FARDE L; VONBAHR C; SEDVALL G
Conference publication: INTERNATIONAL JOURNAL OF NEUROSCIENCE. 1987;32(1-2):688
PHARMACOKINETICS AND EFFECTS ON PLASMA PROLACTIN LEVELS OF REMOXIPRIDE - A NEW POTENTIAL NEUROLEPTIC DRUG
NILSSON MI; FARDE L; GRIND M; NILSSON L; OXENSTIERNA G; SEDVALL G; WAHLEN A; WIDMAN M
Book chapter: CLINICAL EFFICACY OF POSITRON EMISSION TOMOGRAPHY: DEVELOPMENTS IN NUCLEAR MEDICINE. 1987;p. 213-219
PET-Determination of Central D1- and D2-Dopamine Receptor Occupancy in Neuroleptic Treated Schizophrenics
Farde L; Wiesel FA; Halldin C; Sedvall G
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 1986;27(6):879
DOPAMINE D-1 AND D-2 RECEPTORS IN THE LIVING HUMAN-BRAIN STUDIED WITH THE SELECTIVE LIGANDS C-11 SCH 23390 AND C-11 RACLOPRIDE
FARDE L; STONEELANDER S; HALLDIN C; SEDVALL G
Conference publication: ACTA PHARMACOLOGICA ET TOXICOLOGICA. 1986;59:106
PHARMACOKINETIC PROPERTIES AND EFFECT ON PLASMA PROLACTIN CONCENTRATIONS OF REMOXIPRIDE - A NEW POTENTIAL NEUROLEPTIC AGENT IN HEALTHY-VOLUNTEERS
NILSSON MI; FARDE L; GRIND M; NILSSON L; OXENSTIERNA G; WAHLEN A; SEDVALL G
Conference publication: ACTA PHARMACOLOGICA ET TOXICOLOGICA. 1986;59:105
PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTENTIAL NEUROLEPTIC DRUG RACLOPRIDE IN HUMAN VOLUNTEERS
FARDE L; WAHLEN A; VONBAHR C; NILSSON L; SEDVALL G
Conference publication: INTERNATIONAL JOURNAL OF NEUROSCIENCE. 1986;31(1-4):223-224
QUANTITATIVE PET-SCAN STUDIES OF BENZODIAZEPINE RECEPTORS IN THE BRAIN OF HEALTHY-HUMAN SUBJECTS AND PSYCHIATRIC-PATIENTS USING [C-11] RO 15-1788
PERSSON A; EHRIN E; FARDE L; MINDUS P; SEDVALL G
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1986;23(10-12):1405-1406
SYNTHESIS OF C-11 SCH 23390, A DOPAMINE D-1 RECEPTOR ANTAGONIST, FOR USE IN INVIVO RECEPTOR-BINDING STUDIES WITH PET
HALLDIN C; STONEELANDER S; FARDE L; EHRIN E; FASTH KJ; LANGSTROM B; SEDVALL G
Book chapter: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 1986;p. 119-124
Dopamine D1-receptor binding in the living human brain.
Sedvall G; Farde L; Stone-Elander S; Halldin C
Conference publication: INTERNATIONAL JOURNAL OF NEUROSCIENCE. 1986;31(1-4):4
QUANTITATIVE PET-SCAN STUDIES ON HUMAN DOPAMINE-D2 RECEPTORS USING C-11 RACLOPRIDE, A SUBSTITUTED BENZAMIDE
FARDE L; EHRIN E; HALL H; SEDVALL G
Book chapter: BIOLOGICAL PSYCHIATRY, HIGHER NERVOUS ACTIVITY. 1985;p. 305-311
PET Studies on Brain Energy Metabolism and Dopamine Receptors in Schizophrenic Patients and Monkeys
Sedvall G; Blomqvist G; DePaulis T; Ehrin E; Eriksson L; Farde L; Greitz T; Hedström CG; Ingvar DH; Litton J-E; Nilsson JLG; Stone-Elander S; Widén L; Wiesel F-A; Wik G
Conference publication: ACTA NEUROLOGICA SCANDINAVICA. 1985;72(2):234
DOPAMINE-D2 RECEPTOR DENSITY DETERMINED IN THE LIVING HUMAN-BRAIN BY SATURATION CURVES
FARDE L; HALL H; EHRIN E; SEDVALL G
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1984;21(11-1):1161-1162
C-11-LABELING OF LIGANDS FOR PET STUDIES OF DOPAMINE AND BENZODIAZEPINE RECEPTORS
EHRIN E; JOHNSTROM P; STONEELANDER S; NILSSON JLG; DEPAULIS T; FARDE L; GREITZ T; LITTON JE; PERSSON A; SEDVALL G; WIDEN L
Conference publication: ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY. 1984;58(5):P110
C-11 LABELED BENZAMIDES AS LIGANDS FOR IMAGING OF DOPAMINE-RECEPTORS IN THE HUMAN-BRAIN
SEDVALL G; BLOMQVIST G; DEPAULIS T; EHRIN E; ERIKSSON L; FARDE L; GREITZ T; HEDSTROM CG; INGVAR DH; LITTON JE; NILSSON JLG; STONEELANDER S; WIDEN L; WIESEL FA; WIK G; OGREN SO
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1984;9(7):A27
PREPARATION OF A C-11-LABELLED BENZAMIDE, A POTENTIAL DOPAMINE RECEPTOR ANTAGONIST FOR PET-VISUALIZATION OF CEREBRAL DOPAMINE-RECEPTORS
EHRIN E; JOHNSTROM P; STONEELANDER S; NILSSON JLG; DEPAULIS T; FARDE L; GREITZ T; LITTON JE; SEDVALL G; WIDEN L
Visa fler

Forskningsbidrag

MRI brain morphology and connectivity in schizophrenia; translational studies of four cohorts; importance of genetic and non-genetic risk factors for brain development and clinical outcome
Swedish Research Council
1 January 2018 - 31 December 2020
Longterm brain dysfunction after surgery and trauma
Swedish Research Council
1 January 2017 - 31 December 2020
PET-study of the time course for dopaminergic degeneration in Parkinson´s disease
Swedish Research Council
1 January 2017 - 31 December 2019
PET studies of the glutamate system in schizophrenia
Swedish Research Council
1 January 2016 - 31 December 2019
Respiratory control and cognitive function in anesthesia and surgery
Swedish Research Council
1 January 2014 - 31 December 2016
PET studies of brain biomarkers in schizophrenia
Swedish Research Council
1 January 2012 - 31 December 2015
Brain immune activation in schizophrenia - functional investigations of a novel antipsychotic drug target
Swedish Research Council
1 January 2012 - 31 December 2013
PET studies of neurotransmission systems in major psychiatric disorders
Swedish Research Council
1 January 2009 - 31 December 2011
PET ANALYSIS OF DOPAMINE D2 RECEPTORS IN SCHIZOPHRENIA
National Institute of Mental Health
1 May 1986 - 31 August 2000

Anställningar

Professor Emeritus/Emerita, Klinisk neurovetenskap, Karolinska Institutet, 2025-2027
Professor, Klinisk neurovetenskap, Karolinska Institutet, 2021-2024
Professor/Överläkare, Klinisk neurovetenskap, Karolinska Institutet, 1999-2021

Examina och utbildning

Docent, Allmän psykiatri, Karolinska Institutet, 1989

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI